EP4061932A1 - Protein purification using a split intein system - Google Patents
Protein purification using a split intein systemInfo
- Publication number
- EP4061932A1 EP4061932A1 EP20820794.4A EP20820794A EP4061932A1 EP 4061932 A1 EP4061932 A1 EP 4061932A1 EP 20820794 A EP20820794 A EP 20820794A EP 4061932 A1 EP4061932 A1 EP 4061932A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- intein
- taxon
- solid phase
- protein
- poi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000017730 intein-mediated protein splicing Effects 0.000 title claims abstract description 142
- 238000001742 protein purification Methods 0.000 title abstract description 13
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 166
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 150
- 239000003446 ligand Substances 0.000 claims abstract description 46
- 235000018102 proteins Nutrition 0.000 claims description 137
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 58
- 235000001014 amino acid Nutrition 0.000 claims description 44
- 239000007790 solid phase Substances 0.000 claims description 41
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 40
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 39
- 229940024606 amino acid Drugs 0.000 claims description 36
- 150000001413 amino acids Chemical group 0.000 claims description 36
- 238000009739 binding Methods 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 30
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 29
- 229920005989 resin Polymers 0.000 claims description 27
- 239000011347 resin Substances 0.000 claims description 25
- 238000003776 cleavage reaction Methods 0.000 claims description 24
- 238000000746 purification Methods 0.000 claims description 24
- 210000004899 c-terminal region Anatomy 0.000 claims description 23
- 230000007935 neutral effect Effects 0.000 claims description 20
- 230000007017 scission Effects 0.000 claims description 19
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 14
- 235000009582 asparagine Nutrition 0.000 claims description 14
- 229960001230 asparagine Drugs 0.000 claims description 14
- 230000001965 increasing effect Effects 0.000 claims description 14
- 239000012539 chromatography resin Substances 0.000 claims description 13
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 12
- 125000000539 amino acid group Chemical group 0.000 claims description 12
- 235000018417 cysteine Nutrition 0.000 claims description 12
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 12
- 239000007787 solid Substances 0.000 claims description 11
- 239000013598 vector Substances 0.000 claims description 11
- 229920000936 Agarose Polymers 0.000 claims description 9
- 238000005406 washing Methods 0.000 claims description 9
- 238000001261 affinity purification Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 6
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 6
- 230000035772 mutation Effects 0.000 claims description 6
- 230000003068 static effect Effects 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 5
- -1 antibody mimetics Proteins 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 150000001768 cations Chemical class 0.000 claims description 4
- 108020001507 fusion proteins Proteins 0.000 claims description 4
- 102000037865 fusion proteins Human genes 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 239000011324 bead Substances 0.000 claims description 3
- 239000002738 chelating agent Substances 0.000 claims description 3
- 238000004587 chromatography analysis Methods 0.000 claims description 3
- 230000002269 spontaneous effect Effects 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 claims description 3
- 108010001857 Cell Surface Receptors Proteins 0.000 claims description 2
- 102000019034 Chemokines Human genes 0.000 claims description 2
- 108010012236 Chemokines Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000009792 diffusion process Methods 0.000 claims description 2
- 239000000835 fiber Substances 0.000 claims description 2
- 239000002657 fibrous material Substances 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 230000003993 interaction Effects 0.000 claims description 2
- 239000006249 magnetic particle Substances 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 102000006240 membrane receptors Human genes 0.000 claims description 2
- 239000000025 natural resin Substances 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 239000012260 resinous material Substances 0.000 claims description 2
- 229920003002 synthetic resin Polymers 0.000 claims description 2
- 239000000057 synthetic resin Substances 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 238000005342 ion exchange Methods 0.000 claims 1
- 239000013308 plastic optical fiber Substances 0.000 claims 1
- 239000013309 porous organic framework Substances 0.000 claims 1
- 238000001042 affinity chromatography Methods 0.000 abstract description 6
- 239000007795 chemical reaction product Substances 0.000 abstract description 3
- 241001464430 Cyanobacterium Species 0.000 description 63
- 101150093191 RIR1 gene Proteins 0.000 description 45
- 101100302210 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RNR1 gene Proteins 0.000 description 45
- 101001105683 Homo sapiens Pre-mRNA-processing-splicing factor 8 Proteins 0.000 description 44
- 102100021231 Pre-mRNA-processing-splicing factor 8 Human genes 0.000 description 44
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 39
- 241000203407 Methanocaldococcus jannaschii Species 0.000 description 38
- 108010054814 DNA Gyrase Proteins 0.000 description 25
- 241000233866 Fungi Species 0.000 description 23
- 102000001218 Rec A Recombinases Human genes 0.000 description 20
- 108010055016 Rec A Recombinases Proteins 0.000 description 20
- 108020004414 DNA Proteins 0.000 description 19
- 239000012634 fragment Substances 0.000 description 19
- 229920001184 polypeptide Polymers 0.000 description 18
- 125000003275 alpha amino acid group Chemical group 0.000 description 17
- 239000000872 buffer Substances 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 17
- 241000700605 Viruses Species 0.000 description 16
- 244000052637 human pathogen Species 0.000 description 16
- 241001152403 Haloquadratum walsbyi Species 0.000 description 15
- 241000192117 Trichodesmium erythraeum Species 0.000 description 15
- 239000000499 gel Substances 0.000 description 15
- 241001148023 Pyrococcus abyssi Species 0.000 description 14
- 241001222730 Pyrococcus horikoshii OT3 Species 0.000 description 14
- 150000007523 nucleic acids Chemical class 0.000 description 14
- 241000205160 Pyrococcus Species 0.000 description 13
- 241001235254 Thermococcus kodakarensis Species 0.000 description 13
- 239000000306 component Substances 0.000 description 13
- 238000010828 elution Methods 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 102000039446 nucleic acids Human genes 0.000 description 13
- 108020004707 nucleic acids Proteins 0.000 description 13
- 125000003729 nucleotide group Chemical group 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 241001515965 unidentified phage Species 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 102000053602 DNA Human genes 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 241000159506 Cyanothece Species 0.000 description 11
- 238000007792 addition Methods 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 230000004048 modification Effects 0.000 description 11
- 238000012986 modification Methods 0.000 description 11
- 239000002773 nucleotide Substances 0.000 description 11
- 229920000642 polymer Polymers 0.000 description 11
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 10
- 241000383377 Crocosphaera watsonii WH 8501 Species 0.000 description 10
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 10
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000000356 contaminant Substances 0.000 description 10
- 238000006467 substitution reaction Methods 0.000 description 10
- 108091035707 Consensus sequence Proteins 0.000 description 9
- 108060004795 Methyltransferase Proteins 0.000 description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 101710177611 DNA polymerase II large subunit Proteins 0.000 description 8
- 101710184669 DNA polymerase II small subunit Proteins 0.000 description 8
- 102100039303 DNA-directed RNA polymerase II subunit RPB2 Human genes 0.000 description 8
- 101000669831 Homo sapiens DNA-directed RNA polymerase II subunit RPB2 Proteins 0.000 description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
- 101100388071 Thermococcus sp. (strain GE8) pol gene Proteins 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 241000186359 Mycobacterium Species 0.000 description 7
- 241000192707 Synechococcus Species 0.000 description 7
- 241000192584 Synechocystis Species 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 7
- 238000011068 loading method Methods 0.000 description 7
- 101150033305 rtcB gene Proteins 0.000 description 7
- 239000002002 slurry Substances 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 241000907165 Coleofasciculus chthonoplastes Species 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 241000228404 Histoplasma capsulatum Species 0.000 description 6
- 241001048922 Methanococcus aeolicus Nankai-3 Species 0.000 description 6
- 241001478892 Nostoc sp. PCC 7120 Species 0.000 description 6
- 241000205188 Thermococcus Species 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000005855 radiation Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- 241000351920 Aspergillus nidulans Species 0.000 description 5
- 241001561026 Batrachochytrium dendrobatidis Species 0.000 description 5
- 241000221204 Cryptococcus neoformans Species 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 102100031562 Excitatory amino acid transporter 2 Human genes 0.000 description 5
- 101150116572 GLT-1 gene Proteins 0.000 description 5
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 241001287670 Methanocaldococcus vulcanius M7 Species 0.000 description 5
- 241000204641 Methanopyrus kandleri Species 0.000 description 5
- 241000424623 Nostoc punctiforme Species 0.000 description 5
- 241000589516 Pseudomonas Species 0.000 description 5
- 101150041420 Slc1a2 gene Proteins 0.000 description 5
- 241001453296 Synechococcus elongatus Species 0.000 description 5
- 241001495444 Thermococcus sp. Species 0.000 description 5
- 108700019146 Transgenes Proteins 0.000 description 5
- 239000003513 alkali Substances 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000439487 Cafeteria roenbergensis virus Species 0.000 description 4
- 241001671277 Cafeteria roenbergensis virus BV-PW1 Species 0.000 description 4
- 108700031407 Chloroplast Genes Proteins 0.000 description 4
- 108010092681 DNA Primase Proteins 0.000 description 4
- 102000016559 DNA Primase Human genes 0.000 description 4
- 102100021389 DNA replication licensing factor MCM4 Human genes 0.000 description 4
- 241000192091 Deinococcus radiodurans Species 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- 241000205063 Haloarcula marismortui Species 0.000 description 4
- 101000615280 Homo sapiens DNA replication licensing factor MCM4 Proteins 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- 241000246099 Legionellales Species 0.000 description 4
- 241001486996 Methanocaldococcus Species 0.000 description 4
- 241000186366 Mycobacterium bovis Species 0.000 description 4
- 241000187486 Mycobacterium flavescens Species 0.000 description 4
- 241000204971 Natronomonas pharaonis Species 0.000 description 4
- 241000192656 Nostoc Species 0.000 description 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 4
- 241000047166 Thermococcus sibiricus MM 739 Species 0.000 description 4
- 241000051160 Thermus thermophilus HB27 Species 0.000 description 4
- 241000868182 Thermus thermophilus HB8 Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 108010013829 alpha subunit DNA polymerase III Proteins 0.000 description 4
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 4
- 210000003763 chloroplast Anatomy 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- 239000002121 nanofiber Substances 0.000 description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 239000011534 wash buffer Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000253994 Acyrthosiphon pisum Species 0.000 description 3
- 241001116450 Alkalilimnicola ehrlichii MLHE-1 Species 0.000 description 3
- 241001225321 Aspergillus fumigatus Species 0.000 description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 description 3
- 244000206911 Candida holmii Species 0.000 description 3
- 235000002965 Candida holmii Nutrition 0.000 description 3
- 241000978694 Candidatus Hamiltonella defensa Species 0.000 description 3
- 241000195598 Chlamydomonas moewusii Species 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 201000007336 Cryptococcosis Diseases 0.000 description 3
- 241000482582 Cryptococcus gattii VGIII Species 0.000 description 3
- 241001299747 Cylindrospermopsis raciborskii Species 0.000 description 3
- 230000005778 DNA damage Effects 0.000 description 3
- 231100000277 DNA damage Toxicity 0.000 description 3
- 102100030960 DNA replication licensing factor MCM2 Human genes 0.000 description 3
- 239000004593 Epoxy Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000393058 Ferroplasma acidarmanus Species 0.000 description 3
- 241001464795 Gloeobacter violaceus Species 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
- 101000583807 Homo sapiens DNA replication licensing factor MCM2 Proteins 0.000 description 3
- 101001018431 Homo sapiens DNA replication licensing factor MCM7 Proteins 0.000 description 3
- 241001138401 Kluyveromyces lactis Species 0.000 description 3
- 241000488294 Microcystis aeruginosa NIES-843 Species 0.000 description 3
- 241000187485 Mycobacterium gastri Species 0.000 description 3
- 241000186362 Mycobacterium leprae Species 0.000 description 3
- 241000172870 Natrialba magadii ATCC 43099 Species 0.000 description 3
- 241001037736 Nocardia farcinica IFM 10152 Species 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 241000981395 Salinibacter ruber DSM 13855 Species 0.000 description 3
- 241000192560 Synechococcus sp. Species 0.000 description 3
- 241000135044 Thermobifida fusca YX Species 0.000 description 3
- 241000144615 Thermococcus aggregans Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229940091771 aspergillus fumigatus Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 244000000008 fungal human pathogen Species 0.000 description 3
- 244000053095 fungal pathogen Species 0.000 description 3
- 239000005090 green fluorescent protein Substances 0.000 description 3
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 210000003000 inclusion body Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 101150005648 polB gene Proteins 0.000 description 3
- 230000001323 posttranslational effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 241000202362 uncultured archaeon Species 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 241000470638 'Nostoc azollae' 0708 Species 0.000 description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 241001600126 Acidovorax citrulli Species 0.000 description 2
- 241000192542 Anabaena Species 0.000 description 2
- 241001247255 Aphanothece halophytica Species 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 240000002900 Arthrospira platensis Species 0.000 description 2
- 235000016425 Arthrospira platensis Nutrition 0.000 description 2
- 241000131350 Aspergillus neoglaber Species 0.000 description 2
- 241000123650 Botrytis cinerea Species 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- 241000222178 Candida tropicalis Species 0.000 description 2
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 2
- 241001277507 Chrysosporum ovalisporum Species 0.000 description 2
- 241000193155 Clostridium botulinum Species 0.000 description 2
- 241000724200 Clostridium phage c-st Species 0.000 description 2
- 102100034588 DNA-directed RNA polymerase III subunit RPC2 Human genes 0.000 description 2
- 241000798860 Debaryomyces hansenii CBS767 Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241001022534 Ellipticus Species 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 241001583753 Gemmata obscuriglobus UQM 2246 Species 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000585155 Haemophilus phage Aaphi23 Species 0.000 description 2
- 241000580511 Halomicrobium mukohataei Species 0.000 description 2
- 241000756831 Halorhabdus utahensis DSM 12940 Species 0.000 description 2
- 101000848675 Homo sapiens DNA-directed RNA polymerase III subunit RPC2 Proteins 0.000 description 2
- 241000748655 Invertebrate iridescent virus 6 Species 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 239000006137 Luria-Bertani broth Substances 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241001206747 Methanocaldococcus fervens AG86 Species 0.000 description 2
- 241001206745 Methanocaldococcus infernus ME Species 0.000 description 2
- 241001491087 Methanoculleus marisnigri JR1 Species 0.000 description 2
- 241000589308 Methylobacterium extorquens Species 0.000 description 2
- 241001003008 Methylococcus capsulatus str. Bath Species 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 241000186367 Mycobacterium avium Species 0.000 description 2
- 241001031905 Mycobacterium gilvum PYR-GCK Species 0.000 description 2
- 241000186363 Mycobacterium kansasii Species 0.000 description 2
- 241001025881 Mycobacterium smegmatis str. MC2 155 Species 0.000 description 2
- 241001463753 Mycobacterium tuberculosis T17 Species 0.000 description 2
- 241001031911 Mycobacterium vanbaalenii PYR-1 Species 0.000 description 2
- 241000023298 Mycobacterium virus Bethlehem Species 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 241000329495 Nanoarchaeum equitans Kin4-M Species 0.000 description 2
- 241001123225 Naumovozyma castellii Species 0.000 description 2
- 241000187580 Nocardioides Species 0.000 description 2
- 241000894763 Nostoc punctiforme PCC 73102 Species 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 241001279233 Paramecium bursaria Species 0.000 description 2
- 241000201398 Paramecium bursaria Chlorella virus NY2A Species 0.000 description 2
- 241001617999 Parastagonospora nodorum SN15 Species 0.000 description 2
- 241001149509 Penicillium vulpinum Species 0.000 description 2
- 102000010562 Peptide Elongation Factor G Human genes 0.000 description 2
- 108010077742 Peptide Elongation Factor G Proteins 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 241000981393 Persephonella marina Species 0.000 description 2
- 241000701253 Phycodnaviridae Species 0.000 description 2
- 241000235401 Phycomyces blakesleeanus Species 0.000 description 2
- 241000235648 Pichia Species 0.000 description 2
- 241000221946 Podospora anserina Species 0.000 description 2
- 241000512220 Polaromonas Species 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 241000192142 Proteobacteria Species 0.000 description 2
- 241000530613 Pseudanabaena limnetica Species 0.000 description 2
- 101150002896 RNR2 gene Proteins 0.000 description 2
- 101001109694 Rattus norvegicus Nuclear receptor subfamily 4 group A member 2 Proteins 0.000 description 2
- 241000741609 Rhodothermus marinus DSM 4252 Species 0.000 description 2
- 108700043532 RpoB Proteins 0.000 description 2
- 241000193448 Ruminiclostridium thermocellum Species 0.000 description 2
- 241001350119 Salmonella phage SETP3 Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 101710145752 Serine recombinase gin Proteins 0.000 description 2
- 241000946160 Staphylothermus marinus F1 Species 0.000 description 2
- 241000204103 Thermococcus fumicolans Species 0.000 description 2
- 241000204074 Thermococcus hydrothermalis Species 0.000 description 2
- 241000205180 Thermococcus litoralis Species 0.000 description 2
- 241001054881 Thermococcus onnurineus NA1 Species 0.000 description 2
- 241001135697 Thermodesulfovibrio yellowstonii Species 0.000 description 2
- 241000204673 Thermoplasma acidophilum Species 0.000 description 2
- 241001313699 Thermosynechococcus elongatus Species 0.000 description 2
- 241001453191 Thermosynechococcus vulcanus Species 0.000 description 2
- 241000643381 Thermus aquaticus Y51MC23 Species 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 108010029287 Threonine-tRNA ligase Proteins 0.000 description 2
- 102100034997 Threonine-tRNA ligase, mitochondrial Human genes 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 241000970911 Trichormus variabilis ATCC 29413 Species 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 241001489220 Vanderwaltozyma polyspora Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 239000008366 buffered solution Substances 0.000 description 2
- 230000034303 cell budding Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000006240 deamidation Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 229960004198 guanidine Drugs 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000003100 immobilizing effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 108091005601 modified peptides Proteins 0.000 description 2
- 108091005573 modified proteins Proteins 0.000 description 2
- 102000035118 modified proteins Human genes 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 210000002706 plastid Anatomy 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CVOFKRWYWCSDMA-UHFFFAOYSA-N 2-chloro-n-(2,6-diethylphenyl)-n-(methoxymethyl)acetamide;2,6-dinitro-n,n-dipropyl-4-(trifluoromethyl)aniline Chemical compound CCC1=CC=CC(CC)=C1N(COC)C(=O)CCl.CCCN(CCC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O CVOFKRWYWCSDMA-UHFFFAOYSA-N 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 101000818089 Acholeplasma phage L2 Uncharacterized 25.6 kDa protein Proteins 0.000 description 1
- 241001134630 Acidothermus cellulolyticus Species 0.000 description 1
- 241001600124 Acidovorax avenae Species 0.000 description 1
- 241000637385 Acinetobacter baumannii ACICU Species 0.000 description 1
- 241000606750 Actinobacillus Species 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 241000423335 Aeropyrum pernix K1 Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241001024600 Aggregatibacter Species 0.000 description 1
- 241001203470 Allochromatium vinosum DSM 180 Species 0.000 description 1
- 241001135315 Alteromonas macleodii Species 0.000 description 1
- 241000224489 Amoeba Species 0.000 description 1
- 244000105975 Antidesma platyphyllum Species 0.000 description 1
- 241000724287 Apple mosaic virus Species 0.000 description 1
- 241000893512 Aquifex aeolicus Species 0.000 description 1
- 101100473585 Arabidopsis thaliana RPP4 gene Proteins 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 241000186063 Arthrobacter Species 0.000 description 1
- 241000495005 Arthroderma otae CBS 113480 Species 0.000 description 1
- 241000690777 Arthrospira maxima CS-328 Species 0.000 description 1
- 241000235349 Ascomycota Species 0.000 description 1
- 241000131376 Aspergillus auratus Species 0.000 description 1
- 241001277109 Aspergillus brevipes Species 0.000 description 1
- 241000131363 Aspergillus fennelliae Species 0.000 description 1
- 241001507865 Aspergillus fischeri Species 0.000 description 1
- 241000228243 Aspergillus giganteus Species 0.000 description 1
- 241000131370 Aspergillus quadricinctus Species 0.000 description 1
- 241001507862 Aspergillus spinosus Species 0.000 description 1
- 241001277111 Aspergillus viridinutans Species 0.000 description 1
- 101000770875 Autographa californica nuclear polyhedrosis virus Uncharacterized 14.2 kDa protein in PK1-LEF1 intergenic region Proteins 0.000 description 1
- 241000589149 Azotobacter vinelandii Species 0.000 description 1
- 241000670671 Bacteriophage APSE-2 Species 0.000 description 1
- 241000918611 Bacteriophage APSE-5 Species 0.000 description 1
- 241000221198 Basidiomycota Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000551460 Blastomyces dermatitidis ER-3 Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000327164 Botrytis cinerea B05.10 Species 0.000 description 1
- 241000371430 Burkholderia cenocepacia Species 0.000 description 1
- 241001040392 Burkholderia cenocepacia PC184 Species 0.000 description 1
- 241000132899 Burkholderia vietnamiensis G4 Species 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 101150085479 CHS2 gene Proteins 0.000 description 1
- 101100456282 Caenorhabditis elegans mcm-4 gene Proteins 0.000 description 1
- 241000253373 Caldanaerobacter subterraneus subsp. tengcongensis Species 0.000 description 1
- 101000909256 Caldicellulosiruptor bescii (strain ATCC BAA-1888 / DSM 6725 / Z-1320) DNA polymerase I Proteins 0.000 description 1
- 101000736909 Campylobacter jejuni Probable nucleotidyltransferase Proteins 0.000 description 1
- 241000222173 Candida parapsilosis Species 0.000 description 1
- 241001161418 Candida tropicalis MYA-3404 Species 0.000 description 1
- 241001496650 Candidatus Desulforudis Species 0.000 description 1
- 241000620141 Carboxydothermus Species 0.000 description 1
- 241000186220 Cellulomonas flavigena Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000195597 Chlamydomonas reinhardtii Species 0.000 description 1
- 241000671028 Chlorobium chlorochromatii CaD3 Species 0.000 description 1
- 241001333725 Chlorobium luteolum DSM 273 Species 0.000 description 1
- 241000309104 Chlorochromatium aggregatum Species 0.000 description 1
- 241001665089 Chloroflexus aurantiacus J-10-fl Species 0.000 description 1
- 241000023502 Clostridium kluyveri DSM 555 Species 0.000 description 1
- 241001279782 Coelomomyces stegomyiae Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000186226 Corynebacterium glutamicum Species 0.000 description 1
- 241000500845 Costelytra zealandica Species 0.000 description 1
- 241000606678 Coxiella burnetii Species 0.000 description 1
- 241000068896 Coxiella burnetii Dugway 5J108-111 Species 0.000 description 1
- 241001398415 Coxiella burnetii Q321 Species 0.000 description 1
- 241000317051 Coxiella burnetii RSA 493 Species 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 241001522864 Cryptococcus gattii VGI Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 102100027700 DNA-directed RNA polymerase I subunit RPA2 Human genes 0.000 description 1
- 241000235036 Debaryomyces hansenii Species 0.000 description 1
- 241000959949 Deinococcus geothermalis Species 0.000 description 1
- 241000228124 Desulfitobacterium hafniense Species 0.000 description 1
- 241000981919 Desulfitobacterium hafniense Y51 Species 0.000 description 1
- 241000605762 Desulfovibrio vulgaris Species 0.000 description 1
- 241000981531 Dictyoglomus thermophilum H-6-12 Species 0.000 description 1
- 241000168726 Dictyostelium discoideum Species 0.000 description 1
- 101100167214 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) chsA gene Proteins 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 101000686824 Enterobacteria phage N4 Virion DNA-directed RNA polymerase Proteins 0.000 description 1
- 101000984570 Enterobacteria phage T4 Baseplate wedge protein gp53 Proteins 0.000 description 1
- 241000286074 Escherichia phage Min27 Species 0.000 description 1
- 101000997743 Escherichia phage Mu Serine recombinase gin Proteins 0.000 description 1
- 101000644628 Escherichia phage Mu Tail fiber assembly protein U Proteins 0.000 description 1
- 102100039466 Eukaryotic translation initiation factor 5B Human genes 0.000 description 1
- 101710092084 Eukaryotic translation initiation factor 5B Proteins 0.000 description 1
- 241000037564 Ferroplasma acidarmanus Type I Species 0.000 description 1
- 241000499462 Floydiella terrestris Species 0.000 description 1
- 241000187809 Frankia Species 0.000 description 1
- 241000003115 Frankia alni ACN14a Species 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- 102100031885 General transcription and DNA repair factor IIH helicase subunit XPB Human genes 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 101100377543 Gerbera hybrida 2PS gene Proteins 0.000 description 1
- 241000257328 Glossina austeni Species 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 241000543540 Guillardia theta Species 0.000 description 1
- 101000748060 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 8.3 kDa protein in rep-hol intergenic region Proteins 0.000 description 1
- 241001074968 Halobacteria Species 0.000 description 1
- 241000205062 Halobacterium Species 0.000 description 1
- 241000204946 Halobacterium salinarum Species 0.000 description 1
- 241000906459 Halobacterium salinarum NRC-1 Species 0.000 description 1
- 241000204933 Haloferax volcanii Species 0.000 description 1
- 241000769894 Halorhodospira halophila SL1 Species 0.000 description 1
- 101000623276 Herpetosiphon aurantiacus Uncharacterized 10.2 kDa protein in HgiBIM 5'region Proteins 0.000 description 1
- 101000623175 Herpetosiphon aurantiacus Uncharacterized 10.2 kDa protein in HgiCIIM 5'region Proteins 0.000 description 1
- 101000626850 Herpetosiphon aurantiacus Uncharacterized 10.2 kDa protein in HgiEIM 5'region Proteins 0.000 description 1
- 241000393105 Heterosigma akashiwo virus 01 Species 0.000 description 1
- 241000466583 Histoplasma capsulatum G186AR Species 0.000 description 1
- 101000650600 Homo sapiens DNA-directed RNA polymerase I subunit RPA2 Proteins 0.000 description 1
- 101000920748 Homo sapiens General transcription and DNA repair factor IIH helicase subunit XPB Proteins 0.000 description 1
- 101001092206 Homo sapiens Replication protein A 32 kDa subunit Proteins 0.000 description 1
- 101100283436 Human herpesvirus 8 type P (isolate GK18) gM gene Proteins 0.000 description 1
- 108010058683 Immobilized Proteins Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241001123232 Kazachstania unispora Species 0.000 description 1
- 241000902907 Kineococcus radiotolerans Species 0.000 description 1
- 101000768313 Klebsiella pneumoniae Uncharacterized membrane protein in cps region Proteins 0.000 description 1
- 241001596092 Kribbella flavida DSM 17836 Species 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000724188 Lactococcus phage Species 0.000 description 1
- 241001217879 Listonella phage phiHSIC Species 0.000 description 1
- 241001508814 Lodderomyces elongisporus Species 0.000 description 1
- 241000227653 Lycopersicon Species 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 241001134698 Lyngbya Species 0.000 description 1
- 239000007987 MES buffer Substances 0.000 description 1
- 241000589945 Magnetospirillum magnetotacticum Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 241001118708 Methanoregula boonei Species 0.000 description 1
- 241000205263 Methanospirillum hungatei Species 0.000 description 1
- 241001302035 Methanothermobacter Species 0.000 description 1
- 241001302042 Methanothermobacter thermautotrophicus Species 0.000 description 1
- 101000804418 Methanothermobacter thermautotrophicus (strain ATCC 29096 / DSM 1053 / JCM 10044 / NBRC 100330 / Delta H) Uncharacterized protein MTH_1463 Proteins 0.000 description 1
- 241000218953 Micromonospora aurantiaca Species 0.000 description 1
- 241001291091 Mimivirus Species 0.000 description 1
- 241001263448 Mycetozoa Species 0.000 description 1
- 241001002976 Mycobacterium avium 104 Species 0.000 description 1
- 241000180044 Mycobacterium avium subsp. avium Species 0.000 description 1
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 1
- 241000187472 Mycobacterium chitae Species 0.000 description 1
- 241000187471 Mycobacterium fallax Species 0.000 description 1
- 241000187484 Mycobacterium gordonae Species 0.000 description 1
- 241000823612 Mycobacterium leprae Br4923 Species 0.000 description 1
- 241000432069 Mycobacterium leprae TN Species 0.000 description 1
- 241000187493 Mycobacterium malmoense Species 0.000 description 1
- 241000141164 Mycobacterium phage Catera Species 0.000 description 1
- 241000023297 Mycobacterium phage U2 Species 0.000 description 1
- 241000817847 Mycobacterium thermoresistibile ATCC 19527 Species 0.000 description 1
- 241000765897 Mycobacterium tuberculosis C Species 0.000 description 1
- 241001049988 Mycobacterium tuberculosis H37Ra Species 0.000 description 1
- 241001646725 Mycobacterium tuberculosis H37Rv Species 0.000 description 1
- 108700035964 Mycobacterium tuberculosis HsaD Proteins 0.000 description 1
- 241000567066 Mycobacterium tuberculosis K85 Species 0.000 description 1
- 241000385315 Mycobacterium tuberculosis T46 Species 0.000 description 1
- 241001024169 Mycobacterium tuberculosis T85 Species 0.000 description 1
- 241000714908 Mycobacterium tuberculosis T92 Species 0.000 description 1
- 241000091781 Mycobacterium virus KBG Species 0.000 description 1
- 241001208555 Mycobacterium virus Omega Species 0.000 description 1
- 241000187494 Mycobacterium xenopi Species 0.000 description 1
- 241001025880 Myxococcus xanthus DK 1622 Species 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 241001123224 Naumovozyma dairenensis Species 0.000 description 1
- 241001268000 Nodularia spumigena CCY9414 Species 0.000 description 1
- 102100022932 Nuclear receptor coactivator 5 Human genes 0.000 description 1
- 108091005461 Nucleic proteins Chemical group 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 101150016564 ORF39 gene Proteins 0.000 description 1
- 101150075249 ORF40 gene Proteins 0.000 description 1
- 101710087110 ORF6 protein Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 101000770870 Orgyia pseudotsugata multicapsid polyhedrosis virus Uncharacterized 37.2 kDa protein Proteins 0.000 description 1
- 101100378791 Paenarthrobacter nicotinovorans aldh gene Proteins 0.000 description 1
- 101100156835 Paenarthrobacter nicotinovorans xdh gene Proteins 0.000 description 1
- 241000222051 Papiliotrema laurentii Species 0.000 description 1
- 241000526686 Paracoccidioides brasiliensis Species 0.000 description 1
- 241000205833 Paracoccidioides brasiliensis Pb03 Species 0.000 description 1
- 241000314260 Paracoccidioides brasiliensis Pb18 Species 0.000 description 1
- 208000026681 Paratuberculosis Diseases 0.000 description 1
- 241000228150 Penicillium chrysogenum Species 0.000 description 1
- 241001123663 Penicillium expansum Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 241001632455 Picrophilus torridus Species 0.000 description 1
- 241001599925 Polaromonas naphthalenivorans Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920012266 Poly(ether sulfone) PES Polymers 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 241001660519 Polynucleobacter sp. Species 0.000 description 1
- 241001427555 Polyphaga <Blattaria> Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000206614 Porphyra purpurea Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241001358835 Pseudomonas fluorescens PF5 Species 0.000 description 1
- 241000589626 Pseudomonas syringae pv. tomato Species 0.000 description 1
- 241000190117 Pyrenophora tritici-repentis Species 0.000 description 1
- 241000517244 Pyrobaculum arsenaticum Species 0.000 description 1
- 101000902592 Pyrococcus furiosus (strain ATCC 43587 / DSM 3638 / JCM 8422 / Vc1) DNA polymerase Proteins 0.000 description 1
- 241000206613 Pyropia yezoensis Species 0.000 description 1
- 101150030723 RIR2 gene Proteins 0.000 description 1
- 241001418202 Raphidiopsis brookii D9 Species 0.000 description 1
- 101710182657 Reduced folate transporter Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000327096 Rhodococcus erythropolis SK121 Species 0.000 description 1
- 241001004346 Rhodospirillum centenum SW Species 0.000 description 1
- 241001148570 Rhodothermus marinus Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241001260013 Roseovarius Species 0.000 description 1
- 241001170740 Ruminiclostridium thermocellum ATCC 27405 Species 0.000 description 1
- 241000198071 Saccharomyces cariocanus Species 0.000 description 1
- 240000005862 Saccharomyces cerevisiae JAY291 Species 0.000 description 1
- 235000006717 Saccharomyces cerevisiae JAY291 Nutrition 0.000 description 1
- 241001123227 Saccharomyces pastorianus Species 0.000 description 1
- 241000838182 Salinispora arenicola CNS-205 Species 0.000 description 1
- 241001350113 Salmonella phage SETP12 Species 0.000 description 1
- 241001350112 Salmonella phage SETP5 Species 0.000 description 1
- 241001633332 Scheffersomyces stipitis CBS 6054 Species 0.000 description 1
- 241000235348 Schizosaccharomyces japonicus Species 0.000 description 1
- 241001518902 Shigella flexneri 2a str. 2457T Species 0.000 description 1
- 241001518905 Shigella flexneri 2a str. 301 Species 0.000 description 1
- 241000140514 Shigella flexneri 5 str. 8401 Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 241000894536 Sodalis glossinidius Species 0.000 description 1
- 241000944832 Sodalis phage SO1 Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000972185 Spiromyces aspiralis Species 0.000 description 1
- 241001561382 Spizellomyces punctatus Species 0.000 description 1
- 241000751137 Staphylococcus epidermidis RP62A Species 0.000 description 1
- 241000543700 Staphylococcus virus Twort Species 0.000 description 1
- 241000546138 Stigeoclonium helveticum Species 0.000 description 1
- 241000315804 Streptomyces avermitilis MA-4680 = NBRC 14893 Species 0.000 description 1
- 241001170492 Sulfurovum sp. Species 0.000 description 1
- 101800001271 Surface protein Proteins 0.000 description 1
- 241001185310 Symbiotes <prokaryote> Species 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 241001137870 Thermoanaerobacterium Species 0.000 description 1
- 241000847591 Thermococcus barophilus MP Species 0.000 description 1
- 241001127160 Thermococcus marinus Species 0.000 description 1
- 241000522612 Thermococcus peptonophilus Species 0.000 description 1
- 241000482676 Thermococcus thioreducens Species 0.000 description 1
- 241000529868 Thermococcus zilligii Species 0.000 description 1
- 241000203783 Thermomonospora curvata Species 0.000 description 1
- 241000435340 Thermoplasma volcanium GSS1 Species 0.000 description 1
- 241001528280 Thioalkalivibrio Species 0.000 description 1
- 101150107801 Top2a gene Proteins 0.000 description 1
- 241000229115 Torulaspora globosa Species 0.000 description 1
- 241001495125 Torulaspora pretoriensis Species 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 102000004408 Transcription factor TFIIB Human genes 0.000 description 1
- 108090000941 Transcription factor TFIIB Proteins 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 102100026145 Transitional endoplasmic reticulum ATPase Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 101710159648 Uncharacterized protein Proteins 0.000 description 1
- 101710095001 Uncharacterized protein in nifU 5'region Proteins 0.000 description 1
- 241001465202 Uncinocarpus reesii Species 0.000 description 1
- 241000004327 Uroleucon rudbeckiae Species 0.000 description 1
- 101100439693 Ustilago maydis (strain 521 / FGSC 9021) CHS4 gene Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 108010027273 Valosin Containing Protein Proteins 0.000 description 1
- 241001135138 Vibrio pelagius Species 0.000 description 1
- 241000971502 Wiseana iridescent virus Species 0.000 description 1
- 241000235029 Zygosaccharomyces bailii Species 0.000 description 1
- 241000235034 Zygosaccharomyces bisporus Species 0.000 description 1
- 241000235033 Zygosaccharomyces rouxii Species 0.000 description 1
- OIBDVHSTOUGZTJ-PEBLQZBPSA-N [(2r,3r,4s,5s,6s)-3,4,6-triacetyloxy-5-(trifluoromethylsulfonyloxy)oxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@H]1O[C@@H](OC(C)=O)[C@@H](OS(=O)(=O)C(F)(F)F)[C@@H](OC(C)=O)[C@@H]1OC(C)=O OIBDVHSTOUGZTJ-PEBLQZBPSA-N 0.000 description 1
- 241000114035 [Bacillus] selenitireducens MLS10 Species 0.000 description 1
- 241000222126 [Candida] glabrata Species 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229940011158 alteromonas macleodii Drugs 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000010516 arginylation Effects 0.000 description 1
- 229940011019 arthrospira platensis Drugs 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 208000032343 candida glabrata infection Diseases 0.000 description 1
- 229940055022 candida parapsilosis Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 102000021178 chitin binding proteins Human genes 0.000 description 1
- 108091011157 chitin binding proteins Proteins 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 239000012501 chromatography medium Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 241000050254 delta proteobacterium MLMS-1 Species 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000001336 diazotrophic effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 241001492478 dsDNA viruses, no RNA stage Species 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 230000006251 gamma-carboxylation Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 235000009424 haa Nutrition 0.000 description 1
- 150000003278 haem Chemical group 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000000696 methanogenic effect Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000013823 prenylation Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000019525 primary metabolic process Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 230000016434 protein splicing Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940035024 thioglycerol Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000013024 troubleshooting Methods 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 241000813441 uncultured archaeon GZfos9C4 Species 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1252—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/545—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/10—Peptides being immobilised on, or in, an organic carrier the carrier being a carbohydrate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
- C07K2319/92—Fusion polypeptide containing a motif for post-translational modification containing an intein ("protein splicing")domain
Definitions
- the present invention relates to protein purification, primarily in the chromatographic field. More closely, the invention relates to affinity chromatography using a split intein system with an improved C-intein tag and N-intein ligand, wherein the target protein may be purified as a tag-less end product with a native N-terminus.
- Inteins are protein elements expressed as in-frame insertions that interrupt enzyme sequences and catalyze their own excision and ligation of two flanking polypeptides, generating an active protein.
- Genetically, inteins are encoded in two distinct ways: as intact inteins, interrupting two flanking extein sequences, or as split inteins, wherein each extein and part of the intein are encoded by two different genes. While they hold great promise as bioengineering and protein purification tools, split inteins with rapid kinetic properties found in nature are dependent on specific amino acids at the intein-extein junction, severely limiting the proteins that can be fused to inteins for affinity purification and recovery of native protein sequences.
- the prototypical split intein DNAE from Nostoc punctiforme exhibits kinetic properties suitable for protein purification applications.
- its activity is dependent on phenylalanine at the +2 position in the C-extein. This dependency severely narrows and impairs its general applicability.
- Inteins have been engineered to accomplish several important functions in biotechnology, including applications as self-cleaving proteins for recombinant protein purification.
- Split inteins are particularly promising in this regard, as they can simultaneously provide affinity ligand and self-cleavage properties.
- a target protein that is the subject of purification may be substituted for either extein.
- the DNAE family of split inteins has shown the most promise with C-terminal cleavage protein purification approaches.
- W02014/004336 describes proteins fused to split intein N-fragments and split intein C-fragments which could be attached to a support.
- the solid support could be a particle, bead, resin, or a slide.
- WO2014/110393 describes proteins of interest fused to a split intein C-fragment which is contacted with a split intein N-fragment and a purification tag.
- the N-fragment may be attached to a solid phase via the purification tag and methods for affinity purification are discussed.
- US 10 066027 describes a protein purification system and methods of using the system.
- a split intein comprising an N-terminal intein segment, which can be immobilized, and a C-terminal intein segment, which has the property of being self-cleaving, and which can be attached to a protein of interest
- the N-terminal intein segment is provided with a sensitivity enhancing motif which renders it more sensitive to extrinsic conditions.
- US 10 308 679 describes fusion proteins comprising an N-intein polypeptide and N- intein solubilization partner, and affinity matrices comprising such fusion proteins.
- WO 2018/091424 describes a method for production of an affinity chromatography resin comprising an amino-terminal, (N-terminal), split intein fragment as an affinity ligand, comprising the following steps: a) expression of an N-terminal split intein fragment protein as insoluble protein in inclusion bodies in bacterial cells, preferably E.coli, b) harvesting said inclusion bodies; c) solubilizing said inclusion bodies and releasing expressed protein; d) binding said protein on a solid support; e) refolding said protein; f) releasing said protein from the solid support; and g) immobilizing said protein as ligands on a chromatography resin to form an affinity chromatography resin.
- This procedure enables immobilization a ligand density of 2-10 mg/ml resin.
- split inteins have been used for protein purification using a combined affinity tag and tag cleavage mechanism.
- the utility of such systems is limited by several factors.
- the protein releasing cleavage has to be sufficiently fast and provide an acceptable yield.
- the present invention overcomes the disadvantages within prior art and enables generic purification of tag-less/native proteins in just one rapid affinity chromatography step using a split intein system.
- the present invention provides N-intein protein variant sequences of native split inteins or consensus sequences derived from native inteins and split inteins wherein, the N-intein variant is modified as compared to the native sequence or consensus sequence to eliminate all asparagine (N) amino acid residues present in the sequence.
- N asparagine
- Preferably all such N-intein variant sequences are further modified to substitute cysteine (C) at position 1 with any other amino acid that is not cysteine.
- the present invention provides N-intein protein variants of native split inteins or consensus sequences derived from inteins/split inteins wherein the N-intein protein variant does not include an asparagine (N) at position 36 of the variant sequence. This position is calculated according to conventional clustal alignment with native split inteins starting from the initial catalytical cysteine which is number 1.
- This position is conserved to N in prior art and native N-intein sequences but the present inventors have found that this position may be mutated to other amino acids that are less senstivie to deamidation such as histidine (H or His) or glutamine (Q or Gin), and to thereby achieve increased alkaline stability, which is important as it gives tolerance to increased pH values during for example chromatographic procedures.
- H or His histidine
- Q or Gin glutamine
- At least the N at position 36 has to be mutated, but it is also contemplated that more N may be mutated, preferably to H or Q, in the N-intein sequence.
- the present invention also provides N- and C-inteins which overcome the absolute requirement of phenylalanine in the +2 position of the target protein of interest (POI).
- the N- and C-inteins of the invention can be used for production of any recombinant protein.
- tag cleavage will occur at the exact junction of the tag intein and the POI, which means that the POI will be expressed in its native form with no extraneous amino acids encoded by the affinity tag.
- the intein sequences of the invention the POI is produced in high yield and with fast cleavage kinetics.
- the N-intein is coupled to solid phase which can be regenerated under alkali conditions.
- the present invention provides an N-intein, a C-intein, a split intein system and methods of using the same as defined in the appended claims. Brief description of the drawings
- Fig 1 is a graph showing the relative binding capacity for N-intein ligands according to the invention (A40, A41 and A48) coupled to an SPR biosensor chip.
- Fig 2 is a staple diagram showing the relative binding capacity for N-intein ligands according to the invention (B72, B22, A48) and a comparative ligand (A53) coupled to an SPR sensor chip.
- Fig 3 shows static binding capacity of the N-intein ligands of the invention.
- Amino acid analysis is done by conventional method.
- A48 prototypes are coupled by epoxy chemistry to porous agarose particles.
- Fig 4A is a chromatogram of the purification results of Experiment 6.
- Fig. 4B shows the SDS PAGE results from Experiment 6.
- Fig 5 is a graph showing the relative binding capacity for N-intein ligands according to the invention (A40 and A48) coupled to an SPR biosensor chip.
- Ranges can be expressed herein as from “about” one particular value, and/or to “about” another particular value. When such a range is expressed, a further aspect includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will be understood that the particular value forms a further aspect. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as “about” that particular value in addition to the value itself. For example, if the value “10” is disclosed, then “about 10” is also disclosed. It is also understood that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.
- a weight percent (wt. %) of a component is based on the total weight of the formulation or composition in which the component is included.
- the terms “optional” or “optionally” means that the subsequently described event or circumstance can or can not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.
- contacting refers to bringing two biological entities together in such a manner that the compound can affect the activity of the target, either directly; i.e., by interacting with the target itself, or indirectly; i.e., by interacting with another molecule, co-factor, factor, or protein on which the activity of the target is dependent. “Contacting” can also mean facilitating the interaction of two biological entities, such as peptides, to bond covalently or otherwise.
- kit means a collection of at least two components constituting the kit. Together, the components constitute a functional unit for a given purpose. Individual member components may be physically packaged together or separately. For example, a kit comprising an instruction for using the kit may or may not physically include the instruction with other individual member components. Instead, the instruction can be supplied as a separate member component, either in a paper form or an electronic form which may be supplied on computer readable memory device or downloaded from an internet website, or as recorded presentation.
- instruction(s) means documents describing relevant materials or methodologies pertaining to a kit. These materials may include any combination of the following: background information, list of components and their availability information (purchase information, etc.), brief or detailed protocols for using the kit, trouble-shooting, references, technical support, and any other related documents. Instructions can be supplied with the kit or as a separate member component, either as a paper form or an electronic form which may be supplied on computer readable memory device or downloaded from an internet website, or as recorded presentation. Instructions can comprise one or multiple documents, and are meant to include future updates.
- peptide refers to proteins and fragments thereof.
- Polypeptides are disclosed herein as amino acid residue sequences. Those sequences are written left to right in the direction from the amino to the carboxy terminus.
- amino acid residue sequences are denominated by either a three letter or a single letter code as indicated as follows: Alanine (Ala, A), Arginine (Arg, R), Asparagine (Asn, N), Aspartic Acid (Asp, D), Cysteine (Cys, C), Glutamine (Gin, Q), Glutamic Acid (Glu, E), Glycine (Gly, G), Histidine (His, H), Isoleucine (lie, I), Leucine (Leu, L), Lysine (Lys, K), Methionine (Met, M), Phenylalanine (Phe, F), Proline (Pro, P), Serine (Ser, S), Threonine (Thr, T), Tryptophan (Trp, W), Tyrosine (Tyr, Y), and Valine (Val, V).
- Peptides include any oligopeptide, polypeptide, gene product, expression product, or protein.
- a peptide is
- peptide refers to amino acids joined to each other by peptide bonds or modified peptide bonds, e.g., peptide isosteres, etc. and may contain modified amino acids other than the 20 gene-encoded amino acids.
- the peptides can be modified by either natural processes, such as post-translational processing, or by chemical modification techniques which are well known in the art. Modifications can occur anywhere in the peptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. The same type of modification can be present in the same or varying degrees at several sites in a given polypeptide. Also, a given peptide can have many types of modifications.
- Modifications include, without limitation, linkage of distinct domains or motifs, acetylation, acylation, ADP-ribosylation, amidation, covalent cross-linking or cyclization, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of a phosphytidylinositol, disulfide bond formation, demethylation, formation of cysteine or pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristolyation, oxidation, pergylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, and transfer-RNA mediated addition of amino acids to protein such as arginylation.
- variant refers to a molecule that retains a biological activity that is the same or substantially similar to that of the original sequence.
- the variant may be from the same or different species or be a synthetic sequence based on a natural or prior molecule.
- variant refers to a molecule having a structure attained from the structure of a parent molecule (e.g., a protein or peptide disclosed herein) and whose structure or sequence is sufficiently similar to those disclosed herein that based upon that similarity, would be expected by one skilled in the art to exhibit the same or similar activities and utilities compared to the parent molecule.
- substitution in a variant protein is indicated as: [original amino acid/position in sequence/substituted amino acid]
- N36H an asparagine at position 36 of an amino acid sequence that has been mutated to a histidine (H) is indicated interchangeably as “N36H” or “N36 to H”.
- protein of interest includes any synthetic or naturally occurring protein or peptide.
- the term therefore encompasses those compounds traditionally regarded as drugs, vaccines, and biopharmaceuticals including molecules such as proteins, peptides, and the like.
- therapeutic agents are described in well-known literature references such as the Merck Index (14th edition), the Physicians' Desk Reference (64th edition), and The Pharmacological Basis of Therapeutics (1st edition), and they include, without limitation, medicaments; substances used for the treatment, prevention, diagnosis, cure or mitigation of a disease or illness; substances that affect the structure or function of the body, or pro-drugs, which become biologically active or more active after they have been placed in a physiological environment.
- isolated peptide or “purified peptide” is meant to mean a peptide (or a fragment thereof) that is substantially free from the materials with which the peptide is normally associated in nature, or from the materials with which the peptide is associated in an artificial expression or production system, including but not limited to an expression host cell lysate, growth medium components, buffer components, cell culture supernatant, or components of a synthetic in vitro translation system.
- the peptides disclosed herein, or fragments thereof can be obtained, for example, by extraction from a natural source (for example, a mammalian cell), by expression of a recombinant nucleic acid encoding the peptide (for example, in a cell or in a cell-free translation system), or by chemically synthesizing the peptide.
- a natural source for example, a mammalian cell
- a recombinant nucleic acid encoding the peptide for example, in a cell or in a cell-free translation system
- chemically synthesizing the peptide for example, in a cell or in a cell-free translation system
- peptide fragments may be obtained by any of these methods, or by cleaving full length proteins and/or peptides.
- nucleic acid refers to a naturally occurring or synthetic oligonucleotide or polynucleotide, whether DNA or RNA or DNA-RNA hybrid, single- stranded or double-stranded, sense or antisense, which is capable of hybridization to a complementary nucleic acid by Watson-Crick base-pairing.
- Nucleic acids of the invention can also include nucleotide analogs (e.g., BrdU), and non-phosphodiester intemucleoside linkages (e.g., peptide nucleic acid (PNA) or thiodiester linkages).
- nucleic acids can include, without limitation, DNA, RNA, cDNA, gDNA, ssDNA, dsDNA or any combination thereof.
- isolated nucleic acid or “purified nucleic acid” is meant to mean DNA that is free of the genes that, in the naturally-occurring genome of the organism from which the DNA of the invention is derived, flank the gene.
- the term therefore includes, for example, a recombinant DNA which is incorporated into a vector, such as an autonomously replicating plasmid or virus; or incorporated into the genomic DNA of a prokaryote or eukaryote (e.g., a transgene); or which exists as a separate molecule (for example, a cDNA or a genomic or cDNA fragment produced by PCR, restriction endonuclease digestion, or chemical or in vitro synthesis).
- isolated nucleic acid also refers to RNA, e.g., an mRNA molecule that is encoded by an isolated DNA molecule, or that is chemically synthesized, or that is separated or substantially free from at least some cellular components, for example, other types of RNA molecules or peptide molecules.
- exein refers to the portion of an intein-modified protein that is not part of the intein and which can be spliced or cleaved upon excision of the intein.
- “Intein” refers to an in-frame intervening sequence in a protein.
- An intein can catalyze its own excision from the protein through a post-translational protein splicing process to yield the free intein and a mature protein.
- An intein can also catalyze the cleavage of the intein- extein bond at either the intein N-terminus, or the intein C-terminus, or both of the intein- extein termini.
- “intein” encompasses mini-inteins, modified or mutated inteins, and split inteins.
- split intein refers to any intein in which one or more peptide bond breaks exists between the N-terminal intein segment and the C-terminal intein segment such that the N-terminal and C-terminal intein segments become separate molecules that can non-covalently reassociate, or reconstitute, into an intein that is functional for splicing or cleaving reactions.
- Any catalytically active intein, or fragment thereof, may be used to derive a split intein for use in the systems and methods disclosed herein.
- the split intein may be derived from a eukaryotic intein.
- the split intein may be derived from a bacterial intein. In another aspect, the split intein may be derived from an archaeal intein. Preferably, the split intein so-derived will possess only the amino acid sequences essential for catalyzing splicing reactions.
- N-terminal intein segment or “N-intein” refers to any intein sequence that comprises an N-terminal amino acid sequence that is functional for splicing and/or cleaving reactions when combined with a corresponding C-terminal intein segment.
- An N-terminal intein segment thus also comprises a sequence that is spliced out when splicing occurs.
- An N-terminal intein segment can comprise a sequence that is a modification of the N-terminal portion of a naturally occurring (native) intein sequence.
- Non-intein residues can also be genetically fused to intein segments to provide additional functionality, such as the ability to be affinity purified or to be covalently immobilized.
- C-terminal intein segment refers to any intein sequence that comprises a C-terminal amino acid sequence that is functional for splicing or cleaving reactions when combined with a corresponding N-terminal intein segment.
- the C-terminal intein segment comprises a sequence that is spliced out when splicing occurs.
- the C-terminal intein segment is cleaved from a peptide sequence fused to its C-terminus. The sequence which is cleaved from the C-terminal intein's C- terminus is referred to herein as a “protein of interest POP is discussed in more detail below.
- a C-terminal intein segment can comprise a sequence that is a modification of the C-terminal portion of a naturally occurring (native) intein sequence.
- a C terminal intein segment can comprise additional amino acid residues and/or mutated residues so long as the inclusion of such additional and/or mutated residues does not render the C-terminal intein segment non-functional for splicing or cleaving.
- a consensus sequence is a sequence of DNA, RNA, or protein that represents aligned, related sequences.
- the consensus sequence of the related sequences can be defined in different ways, but is normally defined by the most common nucleotide(s) or amino acid residue(s) at each position.
- An example of a consensus sequence of the invention is the N- intein consensus sequence of SEQ ID NO: 6.
- splice or “splices” means to excise a central portion of a polypeptide to form two or more smaller polypeptide molecules. In some cases, splicing also includes the step of fusing together two or more of the smaller polypeptides to form a new polypeptide. Splicing can also refer to the joining of two polypeptides encoded on two separate gene products through the action of a split intein.
- cleave or “cleaves” means to divide a single polypeptide to form two or more smaller polypeptide molecules.
- cleavage is mediated by the addition of an extrinsic endopeptidase, which is often referred to as “proteolytic cleavage”.
- cleaving can be mediated by the intrinsic activity of one or both of the cleaved peptide sequences, which is often referred to as “self-cleavage”.
- Cleavage can also refer to the self-cleavage of two polypeptides that is induced by the addition of a non-proteolytic third peptide, as in the action of split intein system described herein.
- fused covalently bonded to.
- a first peptide is fused to a second peptide when the two peptides are covalently bonded to each other (e.g., via a peptide bond).
- an “isolated” or “substantially pure” substance is one that has been separated from components which naturally accompany it.
- a polypeptide is substantially pure when it is at least 50% (e.g., 60%, 70%, 80%, 90%, 95%, and 99%) by weight free from the other proteins and naturally-occurring organic molecules with which it is naturally associated.
- bind or “binds” means that one molecule recognizes and adheres to another molecule in a sample, but does not substantially recognize or adhere to other molecules in the sample.
- One molecule “specifically binds” another molecule if it has a binding affinity greater than about 10 5 to 10 6 liters/mole for the other molecule.
- Nucleic acids, nucleotide sequences, proteins or amino acid sequences referred to herein can be isolated, purified, synthesized chemically, or produced through recombinant DNA technology. All of these methods are well known in the art.
- modified or “mutated,” as in “modified intein” or “mutated intein,” refer to one or more modifications in either the nucleic acid or amino acid sequence being referred to, such as an intein, when compared to the native, or naturally occurring structure. Such modification can be a substitution, addition, or deletion. The modification can occur in one or more amino acid residues or one or more nucleotides of the structure being referred to, such as an intein.
- modified peptide As used herein, the term “modified peptide”, “modified protein” or “modified protein of interest” or “modified target protein” refers to a protein which has been modified.
- operably linked refers to the association of two or more biomolecules in a configuration relative to one another such that the normal function of the biomolecules can be performed.
- “operably linked” refers to the association of two or more nucleic acid sequences, by means of enzymatic ligation or otherwise, in a configuration relative to one another such that the normal function of the sequences can be performed.
- the nucleotide sequence encoding a pre-sequence or secretory leader is operably linked to a nucleotide sequence for a polypeptide if it is expressed as a pre-protein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the coding sequence; and a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation of the sequence.
- Sequence homology can refer to the situation where nucleic acid or protein sequences are similar because they have a common evolutionary origin. “Sequence homology” can indicate that sequences are very similar. Sequence similarity is observable; homology can be based on the observation. “Very similar” can mean at least 70% identity, homology or similarity; at least 75% identity, homology or similarity; at least 80% identity, homology or similarity; at least 85% identity, homology or similarity; at least 90% identity, homology or similarity; such as at least 93% or at least 95% or even at least 97% identity, homology or similarity.
- the nucleotide sequence similarity or homology or identity can be determined using the “Align” program of Myers et al.
- amino acid sequence similarity or identity or homology can be determined using the BlastP program (Altschul et al. Nucl. Acids Res. 25:3389-3402), and available at NCBI.
- BlastP program Altschul et al. Nucl. Acids Res. 25:3389-3402
- similarity or identity or homology are intended to indicate a quantitative measure of homology between two sequences.
- similarity refers to the number of positions with identical nucleotides divided by the number of nucleotides in the shorter of the two sequences wherein alignment of the two sequences can be determined in accordance with the Wilbur and Lipman algorithm. (1983) Proc. Natl. Acad. Sci. USA 80:726. For example, using a window size of 20 nucleotides, a word length of 4 nucleotides, and a gap penalty of 4, and computer-assisted analysis and interpretation of the sequence data including alignment can be conveniently performed using commercially available programs (e.g., IntelligeneticsTM Suite, Intelligenetics Inc. CA).
- RNA sequences are said to be similar, or have a degree of sequence identity with DNA sequences, thymidine (T) in the DNA sequence is considered equal to uracil (U) in the RNA sequence.
- T thymidine
- U uracil
- the following references also provide algorithms for comparing the relative identity or homology or similarity of amino acid residues of two proteins, and additionally or alternatively with respect to the foregoing, the references can be used for determining percent homology or identity or similarity. Needleman et al. (1970) J. Mol. Biol. 48:444-453; Smith et al. (1983) Advances App. Math. 2:482-489; Smith et al. (1981) Nuc. Acids Res. 11:2205-2220; Feng et al. (1987) J.
- Plasmid and “vector” and “cassette” refer to an extrachromosomal element often carrying genes which are not part of the central metabolism of the cell and usually in the form of circular double-stranded DNA molecules.
- Such elements may be autonomously replicating sequences, genome integrating sequences, phage or nucleotide sequences, linear or circular, of a single- or double-stranded DNA or RNA, derived from any source, in which a number of nucleotide sequences have been joined or recombined into a unique construction which is capable of introducing a promoter fragment and DNA sequence for a selected gene product along with appropriate 3' untranslated sequence into a cell.
- a “vector” is a modified plasmid that contains additional multiple insertion sites for cloning and an “expression cassette” that contains a DNA sequence for a selected gene product (i.e., a transgene) for expression in the host cell.
- This “expression cassette” typically includes a 5' promoter region, the transgene ORF, and a 3' terminator region, with all necessary regulatory sequences required for transcription and translation of the ORF.
- integration of the expression cassette into the host permits expression of the transgene ORF in the cassette.
- buffer or “buffered solution” refers to solutions which resist changes in pH by the action of its conjugate acid-base range.
- loading buffer or “equilibrium buffer” refers to the buffer containing the salt or salts which is mixed with the protein preparation for loading the protein preparation onto a column. This buffer is also used to equilibrate the column before loading, and to wash to column after loading the protein.
- wash buffer is used herein to refer to the buffer that is passed over a column (for example) following loading of a protein of interest (such as one coupled to a C- terminal intein fragment, for example) and prior to elution of the protein of interest.
- the wash buffer may serve to remove one or more contaminants without substantial elution of the desired protein.
- wash buffer refers to the buffer used to elute the desired protein from the column.
- solution refers to either a buffered or a non-buffered solution, including water.
- washing means passing an appropriate buffer through or over a solid support, such as a chromatographic resin.
- eluting a molecule (e.g. a desired protein or contaminant) from a solid support means removing the molecule from such material.
- contaminant refers to any foreign or objectionable molecule, particularly a biological macromolecule such as a DNA, an RNA, or a protein, other than the protein being purified, that is present in a sample of a protein being purified.
- Contaminants include, for example, other proteins from cells that express and/or secrete the protein being purified.
- separate or “isolate” as used in connection with protein purification refers to the separation of a desired protein from a second protein or other contaminant or mixture of impurities in a mixture comprising both the desired protein and a second protein or other contaminant or impurity mixture, such that at least the majority of the molecules of the desired protein are removed from that portion of the mixture that comprises at least the majority of the molecules of the second protein or other contaminant or mixture of impurities.
- purify or “purifying” a desired protein from a composition or solution comprising the desired protein and one or more contaminants means increasing the degree of purity of the desired protein in the composition or solution by removing (completely or partially) at least one contaminant from the composition or solution.
- the invention relates to affinity chromatography and affinity tag cleavage mechanisms in a single step using a split intein system according to the invention which cleaves with broad amino acid tolerance to generate a tag less protein of interest (POI) as end product.
- the two halves of the intein are the affinity ligand (N-intein) and the affinity tag (C-intein) and they associate rapidly. Immobilizing one half (N-intein) on a chromatography resin enables the capture of the other half (C-intein) coupled to the POI from solution. In the presence of Zn 2+ ions, the cleavage reaction is inhibited, enabling a stable complex to form while impurities are washed away.
- a chelator or reducing agent is added, and the cleavage reaction proceeds, enabling collection of the POI, while the intein tag remains bound non-covalently to the cognate intein linked to the chromatography resin.
- the invention provides N-intein protein variant sequences of native split inteins or consensus sequences derived from native inteins and split inteins wherein, the N- intein variant is modified as compared to the native sequence or consensus sequence to eliminate all asparagine (N) amino acid residues present in the sequence.
- N asparagine
- all such sequences do not include a Cysteine (C) at position 1 of the N-intein variant sequence.
- the invention provides N-intein protein variant sequences that do not include an asparagine (N) at position 36 of the variant sequence.
- N asparagine
- This position is calculated according to conventional clustal alignment with native split inteins starting from the initial catalytical cysteine which is number 1.
- This position is conserved to N in prior art and native N-intein sequences but the present inventors have found that this position can be mutated to an amino acid that provides increased alkaline stability as compared to the native N-intein protein sequence which is important as it gives tolerance to increased pH values during for example chromatographic procedures.
- an amino acid that provides increased alkaline stability is histidine (H or His) or glutamine (Q or Gin).
- inteins Native intein are known in the art. A list of inteins is found in Table 1 below. All inteins have the potential to be made into split inteins while some inteins naturally exist in split form. All of the inteins found in the table either exist as split inteins or have the potential to be made into split inteins modified in accordance with the invention at position 36 such that the conserved N is replaced with another amino acid that imparts alkaline stability such as H or Q.
- APMV Pol isolate “Rowbotham- Mimivirus
- Ade-ER3 PRP8 Ajellomyces dermatitidis ER-3 Human fungal pathogen taxon: 559297
- JEL197 isolate “AFTOL-ID 21”, taxon: 109871
- Chlorella virus NY2A infects dsDNA eucaryotic
- Chlorella NC64A which infects virus, taxon: 46021, Family Paramecium bursaria Phycodnaviridae
- CV-NY2A RIR1 Chlorella virus NY2A infects dsDNA eucaryotic Chlorella NC64A, which infects virus, taxon: 46021, Family Paramecium bursaria Phycodnaviridae Costelytra zealandica iridescent
- Cne-A PRP8 (Fne-A Filobasidiella neoformans Yeast, human pathogen ⁇ Cryptococcus neoformans) PRP8) Serotype A, PHLS 8104
- Cne-AD PRP8 Fne- Cryptococcus neoformans Yeast, human pathogen, AD PRP8 ⁇ Filobasidiella neoformans ), ATCC32045, taxon: 5207 Serotype AD, CBS132).
- CroV RIR1 cafeteria roenbergensis virus BV- taxon: 693272, Giant virus PW1 infecting marine heterotrophic nanoflagellate
- CroV RPB2 cafeteria roenbergensis virus BV- taxon: 693272, Giant virus PW1 infecting marine heterotrophic nanoflagellate
- CroV Top2 cafeteria roenbergensis virus BV- taxon: 693272, Giant virus PW1 infecting marine heterotrophic nanoflagellate
- Ddi RPC2 Dictyostelium discoideum strain Mycetozoa (a social amoeba)
- Eni-FGSCA4 PRP8 Emericella nidulans (anamorph: Filamentous fungus, Aspergillus nidulans) FGSC A4 taxon: 162425
- Fte RPB2 (RpoB) Floydiella terrestris , strain UTEX Green alga, chloroplast gene, 1709 taxon: 51328
- Hca PRP8 Fungi human pathogen (anamorph:
- Ptr PRP8 Pyrenophora tritici-repentis Pt-lC- Ascomycete BF fungus, taxon: 426418
- Torulaspora pretoriensis strain Tpr VMA Yeast, taxon: 35629
- Eubacteria AP-APSE1 dpol Acyrthosiphon pisum secondary Bacteriophage, taxon: 67571 endosymbiot phage 1
- Bacteriophage Aaphi23 Actinobacillus Haemophilus phage Aaphi23 actinomycetemcomitans Bacteriophage, taxon: 230158
- BsuP-M1918 RIR1 B. subtil is Ml 918 (prophage) Prophage in B. subtilis M1918. taxon: 157928
- EP-Min27 Primase Enterobacteria phage Min27 bacteriphage of host “ Escherichia coli
- Mex TrbC Methylobacterium extorquens AMI Alphaproteob acteri a Mfa RecA Mycobacterium fallax CITP8139, taxon: 1793 Mfl GyrA Mycobacterium flavescens FlaO taxon: 1776, reference #930991
- FlaO strain FlaO, taxon: 1776, ref. #930991
- Mgi-PYR-GCK DnaB Mycobacterium gilvum PYR-GCK taxon: 350054
- Mgi-PYR-GCK GyrA Mycobacterium gilvum PYR-GCK taxon: 350054
- Mle-TN RecA Mycobacterium leprae strain TN Human pathogen, taxon: 1769 Mle-TN SufB (Mle Mycobacterium leprae Human pathogen, taxon: 1769 Ppsl)
- Mtu SufB Mycobacterium tuberculosis strains Human pathogen, taxon: 83332
- Nsp-JS614 DnaB Nocardioides species JS614 taxon: 196162
- Nsp-JS614 TOPRIM Nocardioides species JS614 taxon: 196162
- Nsp-PCC7120 DnaE- Nostoc species PCC7120, Cyanobacterium , Nitrogen c ( Anabaena sp. PCC7120) fixing, taxon: 103690
- Nsp-PCC7120 DnaE- Nostoc species PCC7120, Cyanobacterium , Nitrogen n (. Anabaena sp. PCC7120) fixing, taxon: 103690
- SoP-SOl dpol Sodalis phage SO-1 a Sodalis glossinidius strain GA-SG, secondary symbiont of Glossina austeni (Newstead)”
- Trichodesmium erythraeum Ter Sn£2 Cyanobacterium , taxon: 203124 IMS101 Trichodesmium erythraeum
- thermophilus HB27 thermophile taxon: 262724 Tth-HB27 DnaE-2 Thermus thermophilus HB27 thermophile, taxon: 262724 Tth-HB27 RIRl-1 Thermus thermophilus HB27 thermophile, taxon: 262724 Tth-HB27 RIR1-2 Thermus thermophilus HB27 thermophile, taxon: 262724 Tth-HB8 DnaE-1 Thermus thermophilus HB8 thermophile, taxon: 300852 Tth-HB8 DnaE-2 Thermus thermophilus HB8 thermophile, taxon: 300852 Tth-HB8 RIRl-1 Thermus thermophilus HB8 thermophile, taxon: 300852 Tth-HB8 RIR1-2 Thermus thermophilus HB8 thermophile, taxon: 300852 Tvu DnaE-c Thermosynechococcus vulcanus Cyanobacterium
- Fac-Ferl RIR1 Ferroplasma acidarmanus , strain Ferl, eats iron taxon: 97393 and taxon 261390
- Fac-Ferl SufB Fe Ferroplasma acidarmanus strain ferl, eats Ppsl iron, taxon: 97393
- Fac-Typel RIR1 Ferroplasma acidarmanus type I, Eats iron, taxon 261390 Fac-typel SufB (Fac Ferroplasma acidarmanus Eats iron, taxon: 261390 Ppsl)
- Pab RtcB Pyrococcus abyssi Thermophile, strain Orsay, taxon: 29292
- Tko Pol-1 Pyrococcus/Thermococcus Thermophile, taxon: 69014 kodakaraensis KOD1
- Tko Pol-2 Pyrococcus/Thermococcus Thermophile, taxon: 69014 kodakaraensis KOD1 Thermococcus kodakaraensis
- Tli Pol-1 Thermococcus litoralis Thermophile, taxon: 2265 Tli Pol-2 Thermococcus litoralis Thermophile, taxon: 2265 Tma Pol Thermococcus marinus taxon: 187879 Ton-NAl LHR Thermococcus onnurineus NA1 Taxon: 523850 Ton-NAl Pol Thermococcus onnurineus NA1 taxon: 342948 Tpe Pol Thermococcus peptonophilus strain taxon: 32644 SM2
- the split inteins of the disclosed compositions or that can be used in the disclosed methods can be modified, or mutated, inteins.
- a modified intein can comprise modifications to the N-terminal intein segment, the C-terminal intein segment, or both.
- the modifications can include additional amino acids at the N-terminus the C-terminus of either portion of the split intein, or can be within the either portion of the split intein.
- Table 2 shows a list of amino acids, their abbreviations, polarity, and charge.
- the invention provides an N-intein protein variant of the native N-intein domain of Nostoc punctiforme (Npu) wherein the native N-intein domain has the following sequence:
- the invention provides an N-intein protein variant of SEQ ID NO: 1 wherein the protein variant comprises an amino acid substitution of the cysteine (C) at position 1 of SEQ ID NO: 1 to any other amino acid that is not cysteine in addition to an amino acid substitution of the asparagine (N) at position 36 of SEQ ID NO: 1 with an amino acid that increases alkaline stability of the N-intein protein variant as compared to alkaline stability of the native N-intein of SEQ ID NO: 1.
- the protein variant comprises an amino acid substitution of the cysteine (C) at position 1 of SEQ ID NO: 1 to any other amino acid that is not cysteine in addition to an amino acid substitution of the asparagine (N) at position 36 of SEQ ID NO: 1 with an amino acid that increases alkaline stability of the N-intein protein variant as compared to alkaline stability of the native N-intein of SEQ ID NO: 1.
- the invention also provides an N-intein protein variant of a reference protein wherein the reference protein has at least about 50%, 60%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 1 and preferably wherein the reference protein has at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 1, and wherein the N-intein protein variant of the invention comprises an amino acid substitution of the asparagine (N) at position 36 of the reference protein with an amino acid that increases alkaline stability of the N-intein protein variant as compared to alkaline stability of the native N-intein of SEQ ID NO: 1.
- N asparagine
- the N-intein comprises the amino acid sequence of SEQ ID NO: 2 which is a N-intein consensus derived sequence.
- An N-intein variant sequences based on SEQ ID NO: 2 also comprise an amino acid at position 36 other than N that increases alkaline stability of the N-intein protein variant as compared to alkaline stability of the native N-intein of SEQ ID NO: 1.
- the amino acid that increases stability alkaline stability is an amino acid that are less sensitive to deamidation as compared to aparagine (N).
- the amino acid sequence of SEQ I D NO: 2 is as follows:
- X in positions 20, 35, 70, 73, and 95 are each independently selected from K, R or A;
- X in position 28 is C, A or S;
- X in position 36 is N, H or Q; X in position 25 is N or R;
- X is position 59 is D or C
- X in position 80 is E or Q; and X in position 90 is Q, R or K.
- N-inteins in accordance with the invention are selected from the group of N-intein variants referred to herein as A48, B22, B72 and A41 wherein: A48 has the sequence of of SEQ ID NO: 2 wherein:
- X in position 28 is A
- X in position 36 is H
- X in position 25 is N;
- X in position 59 is D
- X in position 80 is E; and X in position 90 is Q;
- B22 has the sequence of SEQ ID NO: 2, wherein:
- X in position 28 is A
- X in position 36 is H
- X in position 25 is N;
- X in position 59 is D
- X in position 80 is E; and X in position 90 is Q;
- B72 has the sequence of SEQ ID NO: 2, wherein:
- X in position 28 is C
- X in position 36 is H
- X in position 25 is N;
- X in position 59 is D
- X in position 80 is E; and X in position 90 is Q
- A40 has the sequence of SEQ ID NO: 2, wherein:
- X in position 28 is A; X in position 36 is N;
- X in position 25 is N;
- X in position 59 is D
- A41 has the sequence of SEQ ID NO: 2, wherein:
- X in position 28 is A
- X in position 36 is N;
- X in position 25 is N;
- X in position 59 is D
- Comparative ligand A53 has the sequence of SEQ ID NO: 2 wherein:
- X in position 28 is C
- X in position 36 is N;
- X in position 25 is N;
- X in position 59 is D
- the N-intein of the invention may be coupled to solid phase, such as a membrane, fiber, particle, bead or chip.
- the solid phase may be a chromatography resin of natural or synthetic origin, such as a natural or synthetic resin, preferably a polysaccharide such as agarose.
- the solid phase, such as a chromatography resin may be provided with embedded magnetic particles.
- the solid phase is a non-diffusion limited resin/fibrous material.
- the solid phase may be formed from one or more polymeric nanofibre substrates, such as electrospun polymer nanofibres.
- Polymer nanofibres for use in the present invention typically have mean diameters from 10 nm to 1000 nm.
- the length of polymer nanofibres is not particularly limited.
- the polymer nanofibres can suitably be monofilament nanofibres and may e.g. have a circular, ellipsoidal or essentially circular/ellipsoidal cross section.
- the one or more polymer nanofibres are provided in the form of one or more non-woven sheets, each comprising one or more polymer nanofibers.
- a non-woven sheet comprising one or more polymer nanofibres is a mat of said one or more polymer nanofibres with each nanofibre oriented essentially randomly, i.e. it has not been fabricated so that the nanofibre or nanofibres adopts a particular pattern.
- Non-woven sheets typically have area densities from 1 to 40 g/m2.
- Non-woven sheets typically have a thickness from 5 to 120 pm.
- the polymer should be a polymer suitable for use as a chromatography medium, i.e. an adsorbent, in a chromatography method.
- Suitable polymers include polyamides such as nylon, polyacrylic acid, polymethacrylic acid, polyacrylonitrile, polystyrene, polysulfones e.g. polyethersulfone (PES), polycaprolactone, collagen, chitosan, polyethylene oxide, agarose, agarose acetate, cellulose, cellulose acetate, and combinations thereof.
- polyamides such as nylon, polyacrylic acid, polymethacrylic acid, polyacrylonitrile, polystyrene, polysulfones e.g. polyethersulfone (PES), polycaprolactone, collagen, chitosan, polyethylene oxide, agarose, agarose acetate, cellulose, cellulose acetate, and combinations thereof.
- the N-intein according to the invention may be immobilized on a solid support in a very high degree, 0.2 -2 pmole/ml N-intein is coupled per ml resin (swollen gel).
- the N-intein according to the invention may be coupled to the solid phase via a Lys- tail, comprising one or more Lys, such as at least two, on the C-terminal.
- the N-intein is coupled to the solid phase via a Cys-tail on the C-terminal.
- the invention also provides a C-intein comprising the following sequence SEQ ID NO 3 as follows:
- VKIVSRKSLGVQNVYDIGVEKDHNFLLANGLIASN (SEQ ID NO: 3) or sequences having at least 50%, 60%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity therewith and preferably sequences having at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity therewith.
- selection of the N-intein and C-intein can be from the same wild type split intein (e.g., both from Npu, or a variant of either the N- or C-intein, or alternatively can be selected from different wild type split inteins or the consensus split intein sequences, as it has been discovered that the affinity of a N-fragment for a different C- fragment (e.g., Npu N-fragment or variant thereof with Ssp C-fragment or variant thereof) still maintains sufficient binding affinity for use in the disclosed methods.
- the invention in a third aspect, relates to a vector comprising the above C-intein of SEQ ID NO: 3 and a gene encoding a protein of interest (POI). Also disclosed herein are vectors comprising nucleic acids encoding the C-terminal intein segment, as well as cell lines comprising said vectors.
- plasmid or viral vectors are agents that transport the disclosed nucleic acids, such as those encoding a C-terminal intein segment and a peptide of interest, into a cell without degradation and include a promoter yielding expression of the gene in the cells into which they can be delivered.
- a C-terminal intein segment and peptide of interest are derived from either a virus or a retrovirus.
- Retroviral vectors are able to carry a larger genetic payload, i.e., a transgene or marker gene, than other viral vectors and for this reason are a commonly used vector. However, they are not as useful in non-proliferating cells.
- Adenovirus vectors are relatively stable and easy to work with, have high titers, and can be delivered in aerosol formulation, and can transfect non-dividing cells.
- Pox viral vectors are large and have several sites for inserting genes; they are thermostable and can be stored at room temperature.
- the invention provides a split intein system for affinity purification of a protein of interest (POI), comprising a N-intein and C-intein as described above.
- POI protein of interest
- the N-intein comprises a N36H mutation for increased alkaline stability.
- the N-intein is attached to a solid phase and the C-intein is co-expressed with the POI and used as a tag for affinity purification of the POI.
- the C-intein is co-expressed with the POI and used as a tag for affinity purification of the POI.
- the C-intein is co-expressed with the POI and used as a tag for affinity purification of the POI.
- the C-intein is attached to a solid phase and using the N-intein as a tag, but the former is preferred.
- the alkaline stability of the N-intein ligand in the split intein system according to the invention enables be re-generation after cleavage of the POI from the solid phase, under alkaline conditions, such as 0.05-0.5 M NaOH.
- the solid phase may be regenerated up to 100 times.
- the C-intein and an additional tag is co-expressed with the POI.
- the additional tag may be any conventional chromatography tag, such as an IEX tag or an affinity tag.
- the invention in a fifth aspect relates to a method for purification of a protein of interest (POI), using the split intein system according to the invention, comprising association of the C-intein and N-intein at neutral pH, such as 6-8, and in the presence of divalent cations (which impairs spontaneous cleavage); washing said solid phase in the presence of divalent cations; addition of a chelator to allow spontaneous cleavage between C-intein and POI; collection of tagless POI; and re-generating said solid phase under alkaline conditions, such as 0.5M NaOH.
- POI protein of interest
- This protocol is suitable for protein non-sensitive for Zn.
- the advantages are long contact times are allowed with the resin and addition of large sample volume.
- Sample loading could be made for long times, such as up to 1.5 hours.
- more than 30% yield, preferably 50%, most preferably more than 80% of POI is achieved in less than 4 hours cleavage.
- the invention enables a high ligand density when the N-intein is immobilized to a solid phase.
- the N-intein is attached to a chromatography resin, such as agarose or any other suitable resin for protein purification.
- a static binding capacity of 0.2 -2 pmole/ml C-intein bound POI per settled ml resin.
- the invention also relates to a method for purification of a protein of interest (POI), comprising the following steps: co-expressing a POI with a C-intein according to the invention and an additional tag; binding said additional tag to its binding partner on a solid phase; cleaving off the POI and the C-intein; binding said C-intein to an N-intein attached to a solid phase at neutral pH and cleaving off said bound C-intein and N-intein from said POI; and re-generating said solid phase under alkaline conditions, such as 0.5M NaOH.
- the purpose of this twin tag increased purity (enables dual affinity purification), solubility, detectability.
- Affinity tags can be peptide or protein sequences cloned in frame with protein coding sequences that change the protein's behavior. Affinity tags can be appended to the N- or C- terminus of proteins which can be used in methods of purifying a protein from cells.
- Cells expressing a peptide comprising an affinity tag can be expressed with a signal sequence in the supematant/cell culture medium.
- Cells expressing a peptide comprising an affinity tag can also be pelleted, lysed, and the cell lysate applied to a column, resin or other solid support that displays a ligand to the affinity tags.
- the affinity tag and any fused peptides are bound to the solid support, which can also be washed several times with buffer to eliminate unbound (contaminant) proteins.
- a protein of interest if attached to an affinity tag, can be eluted from the solid support via a buffer that causes the affinity tag to dissociate from the ligand resulting in a purified protein, or can be cleaved from the bound affinity tag using a soluble protease.
- the affinity tag is cleaved through the self-cleaving mechanism of the C-intein segment in the active intein complex.
- affinity examples include, but are not limited to, maltose binding protein, which can bind to immobilized maltose to facilitate purification of the fused target protein; Chitin binding protein, which can bind to immobilized chitin; Glutathione S transferase, which can bind to immobilized glutathione; poly-histidine, which can bind to immobilized chelated metals; FLAG octapeptide, which can bind to immobilized anti-FLAG antibodies.
- Affinity tags can also be used to facilitate the purification of a protein of interest using the disclosed modified peptides through a variety of methods, including, but not limited to, selective precipitation, ion exchange chromatography, binding to precipitation-capable ligands, dialysis (by changing the size and/or charge of the target protein) and other highly selective separation methods.
- affinity tags can be used that do not actually bind to a ligand, but instead either selectively precipitate or act as ligands for immobilized corresponding binding domains.
- the tags are more generally referred to as purification tags.
- the ELP tag selectively precipitates under specific salt and temperature conditions, allowing fused peptides to be purified by centrifugation.
- Another example is the antibody Fc domain, which serves as a ligand for immobilized protein A or Protein G-binding domains.
- Target proteins for all protocols are: any recombinant proteins, especially proteins requiring native or near native N-terminal sequences, for example therapeutic protein candidates, biologies, antibody fragments, antibody mimetics, protein scaffolds, enzymes, recombinant proteins or peptides, such as growth factors, cytokines, chemokines, hormones, antigen (viral, bacterial, yeast, mammalian) production, vaccine production, cell surface receptors, fusion proteins.
- the N-intein ligands A40, A41 and A48 according to the invention were immobilized on BiacoreTM CM5 sensor chips (Cytiva, Sweden) in an amount sufficient to give an immobilized level of about 450 Response Units (RU) or higher.
- RU Response Unit
- 20 pg/ml C-intein (SEQ ID NO: 3) tagged Green Fluorescent Protein (GFP) was flowed over the chip for 1 minute and the signal strength was noted.
- the surface was then cleaned-in-place (CIP), i.e. flushed with 100 mM NaOH, 4 M Guanidine-HCl for 10 minutes at room temperature 22 ⁇ 3°C.
- CIP cleaned-in-place
- Fig 5 shows the results for A40 and A48 during 20 cycles. Relative remaining binding capacity (%)
- EXPERIMENT 2 Alkali stability of N-intein ligands of the invention
- the purified N-intein ligands A53, B72, B22 and A48 were immobilized on BiacoreTM CM5 sensor chips (Cytiva, Sweden) in an amount sufficient to give an immobilized level of about 450 Response Units (RU) or higher.
- RU Response Unit
- 20 pg/ml uncleavable C-intein (SEQ ID NO 3) tagged IL-lb was flowed over the chip for 1 minute and the signal strength was noted.
- the surface was then cleaned-in-place (CIP), i.e. flushed with 100 mM NaOH, 4 M Guanidine-HCl for 10 minutes at room temperature 22 ⁇ 3°C. This was repeated for 50 cycles and the immobilized ligand alkaline stability was followed as the relative loss of uncleavable C-intein tagged IL-lb binding capacity (signal strength) after each cycle.
- CIP cleaned-in-place
- the gel was transferred into the three-neck round bottom flask (RBF) and 5 millilitres of Tris buffer (pH 8.6) with 375 microlitres thioglycerol was added.
- the reaction mixture was at the shaking table at 45 °C for 2 hours.
- the slurry was transferred to glass filter.
- the gel was washed with 5 millilitres of basic wash buffer 3 times and then 5 millilitres of acidic wash buffer 3 times. Repeated this base/acid wash another 2 times, in total 18 washes in this step.
- the gel resin was washed with 5 millilitres of distilled water 10 times. The washed and drained gel was kept in 20% ethanol in fridge before analysis.
- the dry weight of gel resin was determined by measuring the weight of 1 millilitre of gel. In the sample preparation, 2 gram of drained gel resin mixed well with 2 gram of water to give about 50% resin slurry and then the slurry was added into the 1 mL Teflon cube. Then vacuum was applied to drain the gel in the cube and thus 1 mL of gel was obtained. Transfer the gel onto the dry weight balance. The weight was determined after 35 minutes with drying temperature set at 105°C.
- Amino acid analysis was measured after the dry weight determination. With the corresponding dry weights and information of the size and primary amino sequence of the protein the ligand density could be derived in mg/mL gel resin.
- Results for the coupled agarose resin was a dry-weight of 90.6 mg/ml and with a ligand content of 18.4 mg/ml which corresponds to 1.38 umole/ml.
- EXPERIMENT 4 Static binding capacity in relation to ligand density
- the proposed capacity method presented herein can measure binding capacity of the resin in test tubes.
- prototype resin with immobilized A48 ligand with various ligand densities and dual tagged test-protein A43 were separately diluted in assay buffer (2x PBS) to 2.5% resin slurry and 0.4mg/mL, respectively. 50pL of the 2.5% resin slurry was added to an ILLUSTRATM microspin column followed by addition of 150pL diluted A43 (SEQ ID NO: 5). The reactions were allowed to incubate with 1450rpm shaking at 22°C for a 2 hour fixed timepoint before centrifuged at 3000rcf for lmin.
- SDS-PAGE Centrifuged samples (containing cleaved protein and unbound non-cleaved protein) were mixed 1 : 1 with 2x SDS-PAGE reducing sample buffer, boiled for 5 minutes at 95 °C and subjected to SDS-PAGE (18pL loaded).
- a C-intein tagged test-protein, A43 (SEQ ID NO: 5) standard was added (usually a five-point standard between 18.75-300pg/mL) in order to be able to calculate concentrations from the densitometric volumes.
- Gels were coomassie stained for 60min ( ⁇ 100mL/gel) followed by destaining for 120-180min at room temperature with gentle agitation (until background is completely clear). Densitometric quantification of the uncleaved/unbound and cleaved test-protein was performed with the IQ TL software. The densitometric raw data was then exported to Microsoft Excel.
- Fig 3 shows static binding capacity of the N-intein ligands of the invention.
- Amino acid analysis (AAA) done by conventional method.
- the A48 prototypes were coupled by epoxy chemistry to porous agarose particles.
- Elongation factor G (Ef-G) from Thermoanaerobacter tengcongensis was purified in this example using a resin prototype with immobilized ligand A48.
- the purification was repeated using a protocol including Zn-ions to the equilibration buffer and the clarified sample.
- the final Zn-concentration was 1.6 mM.
- the flowrate was reduced to 0.5 ml/min during sample application and then increased to 1 ml/imn during wash and elution. Wash and elution was done with a 50 mM Tris-HCl, 20 mM imidazole buffer pH 7.5. Only one elution peak was collected in this purification and that was after 4 hours of incubation after column washing.
- a 1 ml HiTrapTM column containing immobilized A48 ligand was used for purification of the C-intein tagged target protein IL-Ib (SEQ ID NO: 5) expressed intracellularly in E.coli BL21 (DE3) and lysed by sonication. Soluble protein were harvested by centrifugation and loaded onto a lmL HiTrapTM column immobilized with the A48 ligand.
- the Zn-free protocol (as in Experiment 4) was used on an Af TATM Avant system at 4 ml/min (600cm/h linear flow rate) during sample loading and washing.
- Fig 4A A chromatogram from the purification is shown in Fig 4A.
- the start material, flow through, wash fractions, 4h and 16h elution fractions were subjected to SDS-PAGE and Coomassie staining and subsequent analysis using IQTL software (Fig 4B).
- cleaved IL-Ib 9.4 mg cleaved IL-Ib was eluted after 4 hours incubation on the HiTrapTM column followed by an additional l.lmg after 16h. The purity was 99.5 (4 hours) and 99.8% (16 hours) according to SDS-PAGE analysis. The total protein amount was calculated from the theoretical UV absorption coefficient of the cleaved protein at 280 nm.
- the receptor binding domain (RBD) of SARS-COV-2 NCBI tagged with C-intein was expressed in ExpiHEK cells and secreted into the cell culture medium.
- Sample application and wash was performed at 4mL/min (load time -52.5 min (600cm/h linear flow rate)) followed by 6 column volumes of wash followed by a pause/hold step for 4h.
- the elution phase was performed at lmL/min.
- the column was left for additional 68h followed by a second elution.
- a single 40mM phosphate buffer pH 7.4 buffer supplemented with 300mM NaCl was used for all chromatography steps.
- the CCT-RBD protein has the following sequence:
- RBD domain is double underlined. His Tag- dashed underline
- E.coli BL21(DE3) was transformed with the A43 expression plasmid TwinStrepTM and C-intein (SEQ ID NO 3) tagged IL-lb and plated on an agar plate containing 50 pg/ml Kanamycin. The next day, a single colony was picked and grown in 5 ml of Luria-Bertani (LB) broth to OD6000.6. The culture was transferred to 200 ml LB broth containing the same antibiotics and grown at 37°C until OD600 was 0.6.
- LB Luria-Bertani
- IPTG Isopropyl b-D-l-thiogalactopyranoside
- the cell pellets were resuspended in Buffer A1 (100 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, pH 8.0) at 10 ml per gram wet-weight and disrupted by ultra- sonication (Sonics Vibracell, microtip, 30% amplitude, 2 sec on, 4 sec off, 3 min in total).
- Buffer A1 100 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, pH 8.0
- the supernatant containing the soluble fraction was collected after centrifugation at 40,000 x g for 20 minutes at 4°C and passed through a 5 ml HiTrapTM column, StreptactinTM XT (GE Healthcare, Sweden). The column was washed with the same Buffer A1 until the UV-absorbance at 280 nm was below 20 mAU. Bound C-intein tagged IL-lb was eluted in Buffer B1 (100 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 50 mM Biotin, pH 8.0) and collected.
- Buffer B1 100 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 50 mM Biotin, pH 8.0
- Purified protein was immediately applied to a 1 ml HiTrapTM column packed with a resin containing immobilized N-intein ligand A48 without adding the inhibitor ZnCF.
- the cleaved, tag-free IL-lb was collected in the flow-through.
- N-intein variant comprising at least one amino acid substitution of a native split intein wherein the N-intein protein variant sequence does not include an asparagine (N) in at least position 36 as measured from the initial catalytic cysteine and wherein the substituted amino acid provides increased alkaline stability as compared to the native N-intein protein sequence or a consensus N-intein sequence.
- N asparagine
- N-intein variant of claim 1 wherein the substituted amino acid that provide increased alkaline stability is H or Q.
- Npu N-intein protein variant of the wildtype N-intein domain of Nostoc punctiforme (Npu) wherein the wildtype Npu N-intein domain comprises the following sequence:
- N-intein protein variant of claim 3 wherein the amino acid substitution that increases alkaline stability is histidine (H) or glutamine (Q).
- N-intein protein variant according to claim 4 wherein the amino acid substitution that increases alkaline stability is histidine (H).
- N-intein variant sequence comprising:
- X in positions 20, 35, 70, 73, and 95 are each independently selected from K, R or A;
- X in position 28 is C, A or S;
- X in position 36 is N, H or Q;
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention relates to protein purification, primarily in the chromatographic field. More closely, the invention relates to affinity chromatography using a split intein system with an improved C-intein tag and N-intein ligand, wherein the target protein may be purified as a tag-less end product with a native N-terminus.
Description
PROTEIN PURIFICATION USING A SPLIT INTEIN SYSTEM
FIELD OF THE INVENTION
The present invention relates to protein purification, primarily in the chromatographic field. More closely, the invention relates to affinity chromatography using a split intein system with an improved C-intein tag and N-intein ligand, wherein the target protein may be purified as a tag-less end product with a native N-terminus.
BACKGROUND OF THE INVENTION
Inteins are protein elements expressed as in-frame insertions that interrupt enzyme sequences and catalyze their own excision and ligation of two flanking polypeptides, generating an active protein. Genetically, inteins are encoded in two distinct ways: as intact inteins, interrupting two flanking extein sequences, or as split inteins, wherein each extein and part of the intein are encoded by two different genes. While they hold great promise as bioengineering and protein purification tools, split inteins with rapid kinetic properties found in nature are dependent on specific amino acids at the intein-extein junction, severely limiting the proteins that can be fused to inteins for affinity purification and recovery of native protein sequences. In particular, the prototypical split intein DNAE from Nostoc punctiforme exhibits kinetic properties suitable for protein purification applications. However, its activity is dependent on phenylalanine at the +2 position in the C-extein. This dependency severely narrows and impairs its general applicability.
Inteins have been engineered to accomplish several important functions in biotechnology, including applications as self-cleaving proteins for recombinant protein purification. Split inteins are particularly promising in this regard, as they can simultaneously provide affinity ligand and self-cleavage properties. In protein purification, a target protein that is the subject of purification may be substituted for either extein. To date, the DNAE family of split inteins has shown the most promise with C-terminal cleavage protein purification approaches.
W02014/004336 describes proteins fused to split intein N-fragments and split intein C-fragments which could be attached to a support. The solid support could be a particle, bead, resin, or a slide.
WO2014/110393 describes proteins of interest fused to a split intein C-fragment which is contacted with a split intein N-fragment and a purification tag. The N-fragment may be
attached to a solid phase via the purification tag and methods for affinity purification are discussed.
US 10 066027 describes a protein purification system and methods of using the system. Disclosed is a split intein comprising an N-terminal intein segment, which can be immobilized, and a C-terminal intein segment, which has the property of being self-cleaving, and which can be attached to a protein of interest The N-terminal intein segment is provided with a sensitivity enhancing motif which renders it more sensitive to extrinsic conditions.
US 10 308 679 describes fusion proteins comprising an N-intein polypeptide and N- intein solubilization partner, and affinity matrices comprising such fusion proteins.
WO 2018/091424 describes a method for production of an affinity chromatography resin comprising an amino-terminal, (N-terminal), split intein fragment as an affinity ligand, comprising the following steps: a) expression of an N-terminal split intein fragment protein as insoluble protein in inclusion bodies in bacterial cells, preferably E.coli, b) harvesting said inclusion bodies; c) solubilizing said inclusion bodies and releasing expressed protein; d) binding said protein on a solid support; e) refolding said protein; f) releasing said protein from the solid support; and g) immobilizing said protein as ligands on a chromatography resin to form an affinity chromatography resin. This procedure enables immobilization a ligand density of 2-10 mg/ml resin.
As described above, split inteins have been used for protein purification using a combined affinity tag and tag cleavage mechanism. However, the utility of such systems, is limited by several factors. First, there is the amino acid requirements at the splice junction of the intended product, i.e. the requirement of Phe in the +2 position of the C-extein, to effect cleavage and attain purification of tag-less proteins. Recombinant protein production without extraneous amino acid on the N-terminus is highly desirable. Second, the protein releasing cleavage has to be sufficiently fast and provide an acceptable yield. Third, there is a solubility requirement of the split intein N- or C-fragment for attachment thereof to a solid support. Fourth, hitherto there are no available split intein systems suitable for large scale purification of tag-less proteins.
SUMMARY OF THE INVENTION
The present invention overcomes the disadvantages within prior art and enables generic purification of tag-less/native proteins in just one rapid affinity chromatography step using a split intein system.
The present invention provides N-intein protein variant sequences of native split inteins or consensus sequences derived from native inteins and split inteins wherein, the N-intein variant is modified as compared to the native sequence or consensus sequence to eliminate all asparagine (N) amino acid residues present in the sequence. Preferably all such N-intein variant sequences are further modified to substitute cysteine (C) at position 1 with any other amino acid that is not cysteine.
The present invention provides N-intein protein variants of native split inteins or consensus sequences derived from inteins/split inteins wherein the N-intein protein variant does not include an asparagine (N) at position 36 of the variant sequence. This position is calculated according to conventional clustal alignment with native split inteins starting from the initial catalytical cysteine which is number 1. This position is conserved to N in prior art and native N-intein sequences but the present inventors have found that this position may be mutated to other amino acids that are less senstivie to deamidation such as histidine (H or His) or glutamine (Q or Gin), and to thereby achieve increased alkaline stability, which is important as it gives tolerance to increased pH values during for example chromatographic procedures. At least the N at position 36 has to be mutated, but it is also contemplated that more N may be mutated, preferably to H or Q, in the N-intein sequence.
The present invention also provides N- and C-inteins which overcome the absolute requirement of phenylalanine in the +2 position of the target protein of interest (POI). The N- and C-inteins of the invention can be used for production of any recombinant protein. By using the N- and C-inteins of the invention tag cleavage will occur at the exact junction of the tag intein and the POI, which means that the POI will be expressed in its native form with no extraneous amino acids encoded by the affinity tag. Furthermore, with the intein sequences of the invention, the POI is produced in high yield and with fast cleavage kinetics. The N-intein is coupled to solid phase which can be regenerated under alkali conditions.
The present invention provides an N-intein, a C-intein, a split intein system and methods of using the same as defined in the appended claims.
Brief description of the drawings
Fig 1 is a graph showing the relative binding capacity for N-intein ligands according to the invention (A40, A41 and A48) coupled to an SPR biosensor chip.
Fig 2 is a staple diagram showing the relative binding capacity for N-intein ligands according to the invention (B72, B22, A48) and a comparative ligand (A53) coupled to an SPR sensor chip.
Fig 3 shows static binding capacity of the N-intein ligands of the invention. Amino acid analysis (AAA) is done by conventional method. A48 prototypes are coupled by epoxy chemistry to porous agarose particles.
Fig 4A is a chromatogram of the purification results of Experiment 6.
Fig. 4B shows the SDS PAGE results from Experiment 6.
Fig 5 is a graph showing the relative binding capacity for N-intein ligands according to the invention (A40 and A48) coupled to an SPR biosensor chip.
Detailed description of the invention
Definitions
As used in the specification and the appended claims, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a functional group,” “an alkyl,” or “a residue” includes mixtures of two or more such functional groups, alkyls, or residues, and the like.
Ranges can be expressed herein as from “about” one particular value, and/or to “about” another particular value. When such a range is expressed, a further aspect includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will be understood that the particular value forms a further aspect. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as “about” that particular value in addition to the value itself. For example, if the value “10” is disclosed, then “about 10” is also disclosed. It is also understood that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.
A weight percent (wt. %) of a component, unless specifically stated to the contrary, is based on the total weight of the formulation or composition in which the component is included.
As used herein, the terms “optional” or “optionally” means that the subsequently described event or circumstance can or can not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.
The term “contacting” as used herein refers to bringing two biological entities together in such a manner that the compound can affect the activity of the target, either directly; i.e., by interacting with the target itself, or indirectly; i.e., by interacting with another molecule, co-factor, factor, or protein on which the activity of the target is dependent. “Contacting” can also mean facilitating the interaction of two biological entities, such as peptides, to bond covalently or otherwise.
As used herein, “kit” means a collection of at least two components constituting the kit. Together, the components constitute a functional unit for a given purpose. Individual member components may be physically packaged together or separately. For example, a kit comprising an instruction for using the kit may or may not physically include the instruction with other individual member components. Instead, the instruction can be supplied as a separate member component, either in a paper form or an electronic form which may be supplied on computer readable memory device or downloaded from an internet website, or as recorded presentation.
As used herein, “instruction(s)” means documents describing relevant materials or methodologies pertaining to a kit. These materials may include any combination of the following: background information, list of components and their availability information (purchase information, etc.), brief or detailed protocols for using the kit, trouble-shooting, references, technical support, and any other related documents. Instructions can be supplied with the kit or as a separate member component, either as a paper form or an electronic form which may be supplied on computer readable memory device or downloaded from an internet website, or as recorded presentation. Instructions can comprise one or multiple documents, and are meant to include future updates.
The term “peptide”, “polypeptides” and “protein” are used interchangeably herein and include proteins and fragments thereof. Polypeptides are disclosed herein as amino acid residue sequences. Those sequences are written left to right in the direction from the amino to the carboxy terminus. In accordance with standard nomenclature, amino acid residue sequences are denominated by either a three letter or a single letter code as indicated as follows: Alanine (Ala, A), Arginine (Arg, R), Asparagine (Asn, N), Aspartic Acid (Asp, D), Cysteine (Cys, C), Glutamine (Gin, Q), Glutamic Acid (Glu, E), Glycine (Gly, G), Histidine (His, H), Isoleucine (lie, I), Leucine (Leu, L), Lysine (Lys, K), Methionine (Met, M),
Phenylalanine (Phe, F), Proline (Pro, P), Serine (Ser, S), Threonine (Thr, T), Tryptophan (Trp, W), Tyrosine (Tyr, Y), and Valine (Val, V). Peptides include any oligopeptide, polypeptide, gene product, expression product, or protein. A peptide is comprised of consecutive amino acids and encompasses naturally occurring or synthetic molecules.
In addition, as used herein, the term “peptide” refers to amino acids joined to each other by peptide bonds or modified peptide bonds, e.g., peptide isosteres, etc. and may contain modified amino acids other than the 20 gene-encoded amino acids. The peptides can be modified by either natural processes, such as post-translational processing, or by chemical modification techniques which are well known in the art. Modifications can occur anywhere in the peptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. The same type of modification can be present in the same or varying degrees at several sites in a given polypeptide. Also, a given peptide can have many types of modifications. Modifications include, without limitation, linkage of distinct domains or motifs, acetylation, acylation, ADP-ribosylation, amidation, covalent cross-linking or cyclization, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of a phosphytidylinositol, disulfide bond formation, demethylation, formation of cysteine or pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristolyation, oxidation, pergylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, and transfer-RNA mediated addition of amino acids to protein such as arginylation. (See Proteins — Structure and Molecular Properties 2nd Ed., T. E. Creighton, W.H. Freeman and Company, New York (1993); Posttranslational Covalent Modification of Proteins, B. C. Johnson, Ed., Academic Press, New York, pp. 1-12 (1983)).
As used herein, “variant” refers to a molecule that retains a biological activity that is the same or substantially similar to that of the original sequence. The variant may be from the same or different species or be a synthetic sequence based on a natural or prior molecule. Moreover, as used herein, “variant” refers to a molecule having a structure attained from the structure of a parent molecule (e.g., a protein or peptide disclosed herein) and whose structure or sequence is sufficiently similar to those disclosed herein that based upon that similarity, would be expected by one skilled in the art to exhibit the same or similar activities and utilities compared to the parent molecule. For example, substituting specific amino acids in a given peptide can yield a variant peptide with similar activity to the parent.
In the context of the present invention, a substitution in a variant protein is indicated as: [original amino acid/position in sequence/substituted amino acid] For example, an asparagine (N) at position 36 of an amino acid sequence that has been mutated to a histidine (H) is indicated interchangeably as “N36H” or “N36 to H”.
As used herein, the term “protein of interest (POI)” includes any synthetic or naturally occurring protein or peptide. The term therefore encompasses those compounds traditionally regarded as drugs, vaccines, and biopharmaceuticals including molecules such as proteins, peptides, and the like. Examples of therapeutic agents are described in well-known literature references such as the Merck Index (14th edition), the Physicians' Desk Reference (64th edition), and The Pharmacological Basis of Therapeutics (1st edition), and they include, without limitation, medicaments; substances used for the treatment, prevention, diagnosis, cure or mitigation of a disease or illness; substances that affect the structure or function of the body, or pro-drugs, which become biologically active or more active after they have been placed in a physiological environment.
As used herein, “isolated peptide” or “purified peptide” is meant to mean a peptide (or a fragment thereof) that is substantially free from the materials with which the peptide is normally associated in nature, or from the materials with which the peptide is associated in an artificial expression or production system, including but not limited to an expression host cell lysate, growth medium components, buffer components, cell culture supernatant, or components of a synthetic in vitro translation system. The peptides disclosed herein, or fragments thereof, can be obtained, for example, by extraction from a natural source (for example, a mammalian cell), by expression of a recombinant nucleic acid encoding the peptide (for example, in a cell or in a cell-free translation system), or by chemically synthesizing the peptide. In addition, peptide fragments may be obtained by any of these methods, or by cleaving full length proteins and/or peptides.
The word “or” as used herein means any one member of a particular list and also includes any combination of members of that list.
The phrase “nucleic acid” as used herein refers to a naturally occurring or synthetic oligonucleotide or polynucleotide, whether DNA or RNA or DNA-RNA hybrid, single- stranded or double-stranded, sense or antisense, which is capable of hybridization to a complementary nucleic acid by Watson-Crick base-pairing. Nucleic acids of the invention can also include nucleotide analogs (e.g., BrdU), and non-phosphodiester intemucleoside linkages (e.g., peptide nucleic acid (PNA) or thiodiester linkages). In particular, nucleic acids
can include, without limitation, DNA, RNA, cDNA, gDNA, ssDNA, dsDNA or any combination thereof.
As used herein, “isolated nucleic acid” or “purified nucleic acid” is meant to mean DNA that is free of the genes that, in the naturally-occurring genome of the organism from which the DNA of the invention is derived, flank the gene. The term therefore includes, for example, a recombinant DNA which is incorporated into a vector, such as an autonomously replicating plasmid or virus; or incorporated into the genomic DNA of a prokaryote or eukaryote (e.g., a transgene); or which exists as a separate molecule (for example, a cDNA or a genomic or cDNA fragment produced by PCR, restriction endonuclease digestion, or chemical or in vitro synthesis). It also includes a recombinant DNA which is part of a hybrid gene encoding additional polypeptide sequences. The term “isolated nucleic acid” also refers to RNA, e.g., an mRNA molecule that is encoded by an isolated DNA molecule, or that is chemically synthesized, or that is separated or substantially free from at least some cellular components, for example, other types of RNA molecules or peptide molecules.
As used herein, “extein” refers to the portion of an intein-modified protein that is not part of the intein and which can be spliced or cleaved upon excision of the intein.
“Intein” refers to an in-frame intervening sequence in a protein. An intein can catalyze its own excision from the protein through a post-translational protein splicing process to yield the free intein and a mature protein. An intein can also catalyze the cleavage of the intein- extein bond at either the intein N-terminus, or the intein C-terminus, or both of the intein- extein termini. As used herein, “intein” encompasses mini-inteins, modified or mutated inteins, and split inteins.
As used herein, the term “split intein” refers to any intein in which one or more peptide bond breaks exists between the N-terminal intein segment and the C-terminal intein segment such that the N-terminal and C-terminal intein segments become separate molecules that can non-covalently reassociate, or reconstitute, into an intein that is functional for splicing or cleaving reactions. Any catalytically active intein, or fragment thereof, may be used to derive a split intein for use in the systems and methods disclosed herein. For example, in one aspect the split intein may be derived from a eukaryotic intein. In another aspect, the split intein may be derived from a bacterial intein. In another aspect, the split intein may be derived from an archaeal intein. Preferably, the split intein so-derived will possess only the amino acid sequences essential for catalyzing splicing reactions.
As used herein, the “N-terminal intein segment” or “N-intein” refers to any intein sequence that comprises an N-terminal amino acid sequence that is functional for splicing
and/or cleaving reactions when combined with a corresponding C-terminal intein segment.
An N-terminal intein segment thus also comprises a sequence that is spliced out when splicing occurs. An N-terminal intein segment can comprise a sequence that is a modification of the N-terminal portion of a naturally occurring (native) intein sequence. Non-intein residues can also be genetically fused to intein segments to provide additional functionality, such as the ability to be affinity purified or to be covalently immobilized.
As used herein, the “C-terminal intein segment” or “C-intein” refers to any intein sequence that comprises a C-terminal amino acid sequence that is functional for splicing or cleaving reactions when combined with a corresponding N-terminal intein segment. In one aspect, the C-terminal intein segment comprises a sequence that is spliced out when splicing occurs. In another aspect, the C-terminal intein segment is cleaved from a peptide sequence fused to its C-terminus. The sequence which is cleaved from the C-terminal intein's C- terminus is referred to herein as a “protein of interest POP is discussed in more detail below. A C-terminal intein segment can comprise a sequence that is a modification of the C-terminal portion of a naturally occurring (native) intein sequence. For example, a C terminal intein segment can comprise additional amino acid residues and/or mutated residues so long as the inclusion of such additional and/or mutated residues does not render the C-terminal intein segment non-functional for splicing or cleaving.
A consensus sequence is a sequence of DNA, RNA, or protein that represents aligned, related sequences. The consensus sequence of the related sequences can be defined in different ways, but is normally defined by the most common nucleotide(s) or amino acid residue(s) at each position. An example of a consensus sequence of the invention is the N- intein consensus sequence of SEQ ID NO: 6.
As used herein, the term “splice” or “splices” means to excise a central portion of a polypeptide to form two or more smaller polypeptide molecules. In some cases, splicing also includes the step of fusing together two or more of the smaller polypeptides to form a new polypeptide. Splicing can also refer to the joining of two polypeptides encoded on two separate gene products through the action of a split intein.
As used herein, the term “cleave” or “cleaves” means to divide a single polypeptide to form two or more smaller polypeptide molecules. In some cases, cleavage is mediated by the addition of an extrinsic endopeptidase, which is often referred to as “proteolytic cleavage”. In other cases, cleaving can be mediated by the intrinsic activity of one or both of the cleaved peptide sequences, which is often referred to as “self-cleavage”. Cleavage can also refer to
the self-cleavage of two polypeptides that is induced by the addition of a non-proteolytic third peptide, as in the action of split intein system described herein.
By the term “fused” is meant covalently bonded to. For example, a first peptide is fused to a second peptide when the two peptides are covalently bonded to each other (e.g., via a peptide bond).
As used herein an “isolated” or “substantially pure” substance is one that has been separated from components which naturally accompany it. Typically, a polypeptide is substantially pure when it is at least 50% (e.g., 60%, 70%, 80%, 90%, 95%, and 99%) by weight free from the other proteins and naturally-occurring organic molecules with which it is naturally associated.
Herein, “bind” or “binds” means that one molecule recognizes and adheres to another molecule in a sample, but does not substantially recognize or adhere to other molecules in the sample. One molecule “specifically binds” another molecule if it has a binding affinity greater than about 105 to 106 liters/mole for the other molecule.
Nucleic acids, nucleotide sequences, proteins or amino acid sequences referred to herein can be isolated, purified, synthesized chemically, or produced through recombinant DNA technology. All of these methods are well known in the art.
As used herein, the terms “modified” or “mutated,” as in “modified intein” or “mutated intein,” refer to one or more modifications in either the nucleic acid or amino acid sequence being referred to, such as an intein, when compared to the native, or naturally occurring structure. Such modification can be a substitution, addition, or deletion. The modification can occur in one or more amino acid residues or one or more nucleotides of the structure being referred to, such as an intein.
As used herein, the term “modified peptide”, “modified protein” or “modified protein of interest” or “modified target protein” refers to a protein which has been modified.
As used herein, “operably linked” refers to the association of two or more biomolecules in a configuration relative to one another such that the normal function of the biomolecules can be performed. In relation to nucleotide sequences, “operably linked” refers to the association of two or more nucleic acid sequences, by means of enzymatic ligation or otherwise, in a configuration relative to one another such that the normal function of the sequences can be performed. For example, the nucleotide sequence encoding a pre-sequence or secretory leader is operably linked to a nucleotide sequence for a polypeptide if it is expressed as a pre-protein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the coding
sequence; and a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation of the sequence.
“Sequence homology” can refer to the situation where nucleic acid or protein sequences are similar because they have a common evolutionary origin. “Sequence homology” can indicate that sequences are very similar. Sequence similarity is observable; homology can be based on the observation. “Very similar” can mean at least 70% identity, homology or similarity; at least 75% identity, homology or similarity; at least 80% identity, homology or similarity; at least 85% identity, homology or similarity; at least 90% identity, homology or similarity; such as at least 93% or at least 95% or even at least 97% identity, homology or similarity. The nucleotide sequence similarity or homology or identity can be determined using the “Align” program of Myers et al. (1988) CABIOS 4:11-17 and available at NCBI. Additionally or alternatively, amino acid sequence similarity or identity or homology can be determined using the BlastP program (Altschul et al. Nucl. Acids Res. 25:3389-3402), and available at NCBI. Alternatively or additionally, the terms “similarity” or “identity” or “homology,” for instance, with respect to a nucleotide sequence, are intended to indicate a quantitative measure of homology between two sequences.
Alternatively or additionally, “similarity” with respect to sequences refers to the number of positions with identical nucleotides divided by the number of nucleotides in the shorter of the two sequences wherein alignment of the two sequences can be determined in accordance with the Wilbur and Lipman algorithm. (1983) Proc. Natl. Acad. Sci. USA 80:726. For example, using a window size of 20 nucleotides, a word length of 4 nucleotides, and a gap penalty of 4, and computer-assisted analysis and interpretation of the sequence data including alignment can be conveniently performed using commercially available programs (e.g., Intelligenetics™ Suite, Intelligenetics Inc. CA). When RNA sequences are said to be similar, or have a degree of sequence identity with DNA sequences, thymidine (T) in the DNA sequence is considered equal to uracil (U) in the RNA sequence. The following references also provide algorithms for comparing the relative identity or homology or similarity of amino acid residues of two proteins, and additionally or alternatively with respect to the foregoing, the references can be used for determining percent homology or identity or similarity. Needleman et al. (1970) J. Mol. Biol. 48:444-453; Smith et al. (1983) Advances App. Math. 2:482-489; Smith et al. (1981) Nuc. Acids Res. 11:2205-2220; Feng et al. (1987) J. Molec. Evol. 25:351-360; Higgins et al. (1989) CABIOS 5:151-153; Thompson et al. (1994) Nuc. Acids Res. 22:4673-480; and Devereux et al. (1984) 12:387-395.
“Stringent hybridization conditions” is a term which is well known in the art; see, for
example, Sambrook, “Molecular Cloning, A Laboratory Manual” second ed., CSH Press,
Cold Spring Harbor, 1989; “Nucleic Acid Hybridization, A Practical Approach”, Hames and Higgins eds., IRL Press, Oxford, 1985; see also FIG. 2 and description thereof herein wherein there is a sequence comparison.
The terms “plasmid” and “vector” and “cassette” refer to an extrachromosomal element often carrying genes which are not part of the central metabolism of the cell and usually in the form of circular double-stranded DNA molecules. Such elements may be autonomously replicating sequences, genome integrating sequences, phage or nucleotide sequences, linear or circular, of a single- or double-stranded DNA or RNA, derived from any source, in which a number of nucleotide sequences have been joined or recombined into a unique construction which is capable of introducing a promoter fragment and DNA sequence for a selected gene product along with appropriate 3' untranslated sequence into a cell. Typically, a “vector” is a modified plasmid that contains additional multiple insertion sites for cloning and an “expression cassette” that contains a DNA sequence for a selected gene product (i.e., a transgene) for expression in the host cell. This “expression cassette” typically includes a 5' promoter region, the transgene ORF, and a 3' terminator region, with all necessary regulatory sequences required for transcription and translation of the ORF. Thus, integration of the expression cassette into the host permits expression of the transgene ORF in the cassette.
The term “buffer” or “buffered solution” refers to solutions which resist changes in pH by the action of its conjugate acid-base range.
The term “loading buffer” or “equilibrium buffer” refers to the buffer containing the salt or salts which is mixed with the protein preparation for loading the protein preparation onto a column. This buffer is also used to equilibrate the column before loading, and to wash to column after loading the protein.
The term “wash buffer” is used herein to refer to the buffer that is passed over a column (for example) following loading of a protein of interest (such as one coupled to a C- terminal intein fragment, for example) and prior to elution of the protein of interest. The wash buffer may serve to remove one or more contaminants without substantial elution of the desired protein.
The term “elution buffer” refers to the buffer used to elute the desired protein from the column. As used herein, the term “solution” refers to either a buffered or a non-buffered solution, including water.
The term “washing” means passing an appropriate buffer through or over a solid support, such as a chromatographic resin.
The term “eluting” a molecule (e.g. a desired protein or contaminant) from a solid support means removing the molecule from such material.
The term “contaminant” or “impurity” refers to any foreign or objectionable molecule, particularly a biological macromolecule such as a DNA, an RNA, or a protein, other than the protein being purified, that is present in a sample of a protein being purified. Contaminants include, for example, other proteins from cells that express and/or secrete the protein being purified.
The term “separate” or “isolate” as used in connection with protein purification refers to the separation of a desired protein from a second protein or other contaminant or mixture of impurities in a mixture comprising both the desired protein and a second protein or other contaminant or impurity mixture, such that at least the majority of the molecules of the desired protein are removed from that portion of the mixture that comprises at least the majority of the molecules of the second protein or other contaminant or mixture of impurities.
The term “purify” or “purifying” a desired protein from a composition or solution comprising the desired protein and one or more contaminants means increasing the degree of purity of the desired protein in the composition or solution by removing (completely or partially) at least one contaminant from the composition or solution.
N-intein Protein Variants
The invention relates to affinity chromatography and affinity tag cleavage mechanisms in a single step using a split intein system according to the invention which cleaves with broad amino acid tolerance to generate a tag less protein of interest (POI) as end product. The two halves of the intein are the affinity ligand (N-intein) and the affinity tag (C-intein) and they associate rapidly. Immobilizing one half (N-intein) on a chromatography resin enables the capture of the other half (C-intein) coupled to the POI from solution. In the presence of Zn2+ ions, the cleavage reaction is inhibited, enabling a stable complex to form while impurities are washed away. After impurities are eliminated, a chelator or reducing agent is added, and the cleavage reaction proceeds, enabling collection of the POI, while the intein tag remains bound non-covalently to the cognate intein linked to the chromatography resin.
Preferably the invention provides N-intein protein variant sequences of native split inteins or consensus sequences derived from native inteins and split inteins wherein, the N- intein variant is modified as compared to the native sequence or consensus sequence to
eliminate all asparagine (N) amino acid residues present in the sequence. Preferably all such sequences do not include a Cysteine (C) at position 1 of the N-intein variant sequence.
Preferably, the invention provides N-intein protein variant sequences that do not include an asparagine (N) at position 36 of the variant sequence. This position is calculated according to conventional clustal alignment with native split inteins starting from the initial catalytical cysteine which is number 1. This position is conserved to N in prior art and native N-intein sequences but the present inventors have found that this position can be mutated to an amino acid that provides increased alkaline stability as compared to the native N-intein protein sequence which is important as it gives tolerance to increased pH values during for example chromatographic procedures. Preferably an amino acid that provides increased alkaline stability is histidine (H or His) or glutamine (Q or Gin).
Native intein are known in the art. A list of inteins is found in Table 1 below. All inteins have the potential to be made into split inteins while some inteins naturally exist in split form. All of the inteins found in the table either exist as split inteins or have the potential to be made into split inteins modified in accordance with the invention at position 36 such that the conserved N is replaced with another amino acid that imparts alkaline stability such as H or Q.
Table 1 -Naturally occurring Inteins
Intein Name Organism Name Organism Description Eucarya
Acanthomoeba polyphaga
APMV Pol isolate = “Rowbotham- Mimivirus
Bradford”, Virus, infects Amoebae, taxon: 212035
Abr PRP8 Aspergillus brevipes FRR2439 Fungi, ATCC 16899, taxon: 75551
Aca-Gl 86AR PRP8 Ajellomyces capsulatus G186AR Taxon: 447093, strain G186AR
Aca-H143 PRP8 Ajellomyces capsulatus HI 43 Taxon: 544712 Aca-JER2004 PRP8 Ajellomyces capsulatus (anamorph: strain = JER2004, taxon: 5037, Histoplasma capsulatum ) Fungi strain = “NAml”, taxon:
Aca-NAml PRP8 Ajellomyces capsulatus NAml 339724
Ade-ER3 PRP8 Ajellomyces dermatitidis ER-3 Human fungal pathogen taxon: 559297
Ade-SLH14081 PRP8 Ajelkmyces denmtitidis Human fungal pathogen
J>LH140o 1,
Afu-Af293 PRP8 Aspergillus fumigatus var. Human pathogenic fungus, ellipticus , strain Af293 taxon: 330879
Afu-FRR0163 PRP8 Aspergillus fumigatus strain Human pathogenic fungus,
FRR0163 taxon: 5085
Afu-NRRL5109 Aspergillus fumigatus var.
Human pathogenic fungus,
PRP8 ellipticus , strain NRRL 5109 taxon: 41121
Agi-NRRL6136 PRP8 Aspergillus giganteus Strain NRRL Fungus, taxon: 5060
6136
Ani-FGSCA4 PRP8 Aspergillus nidulans FGSC A Filamentous fungus, taxon: 227321
Avi PRP8 Aspergillus viridinutans strain Fungi, ATCC 16902,
FRR0577 taxon: 75553
Bci PRP8 Botrytis cinerea (teleomorph of Plant fungal pathogen
Botryotinia fuckeliana BO 5.10) Bde-JEL197 RPB2 Batrachochytrium dendrobatidis Chytrid fungus,
JEL197 isolate = “AFTOL-ID 21”, taxon: 109871
Bde-JEL423 PRP8-1 Batrachochytrium dendrobatidis Chytrid fungus, isolate
JEL423 JEL423, taxon 403673
Bde-JEL423 PRP8-2 Batrachochytrium dendrobatidis Chytrid fungus, isolate
JEL423 JEL423, taxon 403673
Bde-JEL423 RPC2 Batrachochytrium dendrobatidis Chytrid fungus, isolate
JEL423 JEL423, taxon 403673
Bde-JEL423 eIF-5B Batrachochytrium dendrobatidis Chytrid fungus, isolate
JEL423 JEL423, taxon 403673
Bfu-B05 PRP8 Botryotinia fuckeliana B05.10 Taxon: 332648
CIV RIR1 Chilo iridescent virus dsDNA eucaryotic virus, taxon: 10488
CV-NY2A
Chlorella virus NY2A infects dsDNA eucaryotic
ORF212392
Chlorella NC64A, which infects virus, taxon: 46021, Family Paramecium bursaria Phycodnaviridae
CV-NY2A RIR1 Chlorella virus NY2A infects dsDNA eucaryotic Chlorella NC64A, which infects virus, taxon: 46021, Family Paramecium bursaria Phycodnaviridae Costelytra zealandica iridescent
CZIV RIR1 dsDNA eucaryotic virus, virus
Taxon: 68348
Cba-WM02.98 PRP8 Cryptococcus bacillisporus strain Yeast, human pathogen,
WM02.98 (aka Cryptococcus taxon: 37769
neoformans gattii)
Cba-WM728 PRP8 Cryptococcus bacillisporus strain Yeast, human pathogen, WM728 taxon: 37769
Ceu ClpP Chlamydomonas eugametos Green alga, taxon: 3053 (chloroplast)
Cga PRP8 Cryptococcus gattii (aka Yeast, human pathogen Cryptococcus bacillisporus)
Cgl VMA Candida glabrata Yeast, taxon: 5478 Cla PRP8 Cryptococcus laurentii strain Fungi, Basidiomycete yeast, CBS139 taxon: 5418
Cmo ClpP Chlamydomonas moewusii , strain Green alga, chloroplast gene, UTEX 97 taxon: 3054
Cmo RPB2 (RpoBb) Chlamydomonas moewusii , strain Green alga, chloroplast gene,
UTEX 97 taxon: 3054
Cne-A PRP8 (Fne-A Filobasidiella neoformans Yeast, human pathogen {Cryptococcus neoformans) PRP8) Serotype A, PHLS 8104
Cne-AD PRP8 (Fne- Cryptococcus neoformans Yeast, human pathogen, AD PRP8) {Filobasidiella neoformans ), ATCC32045, taxon: 5207 Serotype AD, CBS132).
Cne-JEC21 PRP8 Cryptococcus neoformans var. Yeast, human pathogen, neoformans JEC21 serotype = “D” taxon: 214684 Candida parapsilosis , strain
Cpa ThrRS Yeast, Fungus, taxon: 5480
CLIB214
Cre RPB2 Chlamydomonas reinhardtii Green algae, taxon: 3055 (nucleus)
CroV Pol Cafeteria roenbergensis virus BV- taxon: 693272, Giant virus PW1 infecting marine heterotrophic nanoflagellate
CroV RIR1 Cafeteria roenbergensis virus BV- taxon: 693272, Giant virus PW1 infecting marine heterotrophic nanoflagellate
CroV RPB2 Cafeteria roenbergensis virus BV- taxon: 693272, Giant virus PW1 infecting marine heterotrophic nanoflagellate
CroV Top2 Cafeteria roenbergensis virus BV- taxon: 693272, Giant virus PW1 infecting marine heterotrophic nanoflagellate
Cst RPB2 Coelomomyces stegomyiae Chytrid fungus, isolate = “AFTOL-ID 18”,
taxon: 143960
Ctr ThrRS Candida tropicalis ATCC750 Yeast
Ctr VMA Candida tropicalis (nucleus) Yeast
Ctr-MYA3404 VMA Candida tropicalis MYA-3404 Taxon: 294747
Ddi RPC2 Dictyostelium discoideum strain Mycetozoa (a social amoeba)
AX4 (nucleus)
Dhan GLT1 Debaryomyces hansenii CBS767 Fungi, Anamorph: Candida famata , taxon: 4959
Dhan VMA Debaryomyces hansenii CBS767 Fungi, taxon: 284592 Emericella nidulans R20 Eni PRP8 taxon: 162425 (anamorph:
Aspergillus nidulans)
Eni-FGSCA4 PRP8 Emericella nidulans (anamorph: Filamentous fungus, Aspergillus nidulans) FGSC A4 taxon: 162425
Fte RPB2 (RpoB) Floydiella terrestris , strain UTEX Green alga, chloroplast gene, 1709 taxon: 51328
Gth DnaB Guillardia theta (plastid) Cryptophyte Algae HaVOl Pol Heterosigma akashiwo virus 01 Algal virus, taxon: 97195, strain HaVOl
Histoplasma capsulatum
Hca PRP8 Fungi, human pathogen (anamorph:
Ajellomyces capsulatus)
IIV6 RIRl Invertebrate iridescent virus 6 dsDNA eucaryotic virus, taxon: 176652
Kex-CBS379 VMA Kazachstania exigua, formerly Yeast, taxon: 34358 Saccharomyces exiguus, strain CBS379
Kluyveromyces lactis , strain
Kla-CBS683 VMA Yeast, taxon: 28985 CBS683
Kla-IF01267 VMA Kluyveromyces lactis IF01267 Fungi, taxon: 28985
Kluyveromyces lactis NRRL Y-
Kla-NRRLY 1140 Fungi, taxon: 284590 1140
VMA Lei VMA Lodderomyces elongisporus Yeast Mca-CBSl 13480 Microsporum canis CBS 113480 Taxon: 554155 PRP8
Nau PRP8 Neosartorya aurata NRRL 4378 Fungus, taxon: 41051
Nfe-NRRL5534 PRP8 Neosartorya fennelliae NRRL 5534 Fungus, taxon: 41048
Nfi PRP8 Neosartorya fischeri Fungi
Ngl-FR2163 PRP8 Neosartorya glabra FRR2163 Fungi, ATCC 16909, taxon: 41049
Ngl-FRR1833 PRP8 Neosartorya glabra FRR1833 Fungi, taxon: 41049,
(preliminary identification)
Nqu PRP8 Neosartorya quadricincta , strain taxon: 41053 NRRL 4175
Nspi PRP8 Neosartorya spinosa FRR4595 Fungi, taxon: 36631 Pabr-PbOl PRP8 Paracoccidioides brasiliensis PbOl Taxon: 502779 Pabr-Pb03 PRP8 Paracoccidioides brasiliensis Pb03 Taxon: 482561 Pan CHS2 Podospora anserina Fungi, Taxon 5145 Pan GLT1 Podospora anserina Fungi, Taxon 5145 Pbl PRP8-a Phycomyces blakesleeanus Zygomycete fungus, strain NRRL155
Pbl PRP8-b Phycomyces blakesleeanus Zygomycete fungus, strain NRRL155
Pbr-Pbl8 PRP8 Paracoccidioides brasiliensis Pb 18 Fungi, taxon: 121759 Pch PRP8 Penicillium chrysogenum Fungus, taxon: 5076 Pex PRP8 Penicillium expansum Fungus, taxon27334 Pgu GLT1 Pichia ( Candida ) guilliermondii Fungi, Taxon 294746 Pgu-alt GLT1 Pichia ( Candida ) guilliermondii Fungi Pno GLT1 Phaeosphaeria nodorum SN 15 Fungi, taxon: 321614 Pno RPA2 Phaeosphaeria nodorum SN 15 Fungi, taxon: 321614 Ppu DnaB Porphyra purpurea (chloroplast) Red Alga Pst VMA Pichia stipitis CBS 6054, Yeast taxon: 322104
Ptr PRP8 Pyrenophora tritici-repentis Pt-lC- Ascomycete BF fungus, taxon: 426418
Pvu PRP8 Penicillium vulpinum (formerly Fungus P. claviforme) Pye DnaB Porphyra yezoensis chloroplast, Red alga, organelle = “plastid: cultivar U-51 chloroplast”,
“taxon: 2788
Sas RPB2 Spiromyces aspiralis NRRL 22631 Zygomycete fungus, isolate = “AFTOL-ID 185”, taxon: 68401
Sca-CBS4309 VMA Saccharomyces castellii , strain Yeast, taxon: 27288 CBS4309 Sca-IF01992 VMA Saccharomyces castellii , strain Yeast, taxon: 27288
IF01992
Scar VMA Saccharomyces car iocanus, Yeast, taxon: 114526 strain = “UFRJ 50791 See VMA Saccharomyces cerevisiae (nucleus) Yeast, also in See strains
OUT7163, OUT7045,
OUT7163, IFO 1992
Sce-DH1-1A VMA Saccharomyces cerevisiae strain Yeast, taxon: 173900, also in
DH1-1A See strains
OUT7900, OUT7903,
OUT7112
Sce-JAY291 VMA Saccharomyces cerevisiae JAY291 Taxon: 574961 Saccharomyces cerevisiae Sce-OUT7091 VMA Yeast, taxon: 4932, also in See
OUT7091 strains OUT7043, OUT7064
Saccharomyces cerevisiae
Sce-OUT7112 VMA Yeast, taxon: 4932, also in See OUT7112 strains OUT7900, OUT7903
Sce-YJM789 VMA Saccharomyces cerevisiae strain Yeast, taxon: 307796 YJM789
Sda VMA Saccharomyces dairenensis , strain Yeast, taxon: 27289, Also in CBS 421 Sda strain IFO0211
Sex-IFOl 128 VMA Saccharomyces exiguus, Yeast, taxon: 34358 strain = “IFO 1128”
She RPB2 (RpoB) Stigeoclonium helveticum , strain Green alga, chloroplast gene, UTEX 441 taxon: 55999
Sja VMA Schizosaccharomyces japonicus Ascomycete fungus, yFS275 taxon: 402676
Spa VMA Saccharomyces pastorianus Yeast, taxon: 27292 IFO 11023
Spu PRP8 Spizellomyces punctatus Chytrid fungus, Sun VMA Saccharomyces unisporus , strain Yeast, taxon: 27294 CBS 398
Torulaspora globosa, strain CBS
Tgl VMA Yeast, taxon: 48254 764
Torulaspora pretoriensis , strain Tpr VMA Yeast, taxon: 35629
CBS
5080
Ure-1704 PRP8 Uncinocarpus reesii Filamentous fungus Vpo VMA Vanderwaltozyma polyspora, Yeast, taxon: 36033 formerly Kluyveromyces polysporus, strain CBS 2163
WIV RIR1 Wiseana iridescent virus dsDNA eucaryotic virus, taxon: 68347
Zba VMA Zygosaccharomyces bailii, strain Yeast, taxon: 4954
CBS 685
Zbi VMA Zygosaccharomyces bisporus , strain Yeast, taxon: 4957
CBS 702
Zro VMA Zygosaccharomyces rouxii, strain Yeast, taxon: 4956 CBS 688
Eubacteria AP-APSE1 dpol Acyrthosiphon pisum secondary Bacteriophage, taxon: 67571 endosymbiot phage 1
Bacteriophage APSE-2, isolate =
AP-APSE2 dpol Bacteriophage of Candidatus T5A
Hamiltonella defensa , endosymbiot of Acyrthosiphon pisum , taxon: 340054
AP-APSE4 dpol Bacteriophage of Candidatus Bacteriophage, taxon: 568990 Hamiltonella defensa strain 5ATac, endosymbiot of Acyrthosiphon pisum
AP-APSE5 dpol Bacteriophage APSE-5 Bacteriophage of Candidatus Hamiltonella defensa , endosymbiot of Uroleucon rudbeckiae , taxon: 568991
AP-Aaphi23 MupF Bacteriophage Aaphi23, Actinobacillus Haemophilus phage Aaphi23 actinomycetemcomitans Bacteriophage, taxon: 230158
Aae RIR2 Aquifex aeolicus strain VF5 Thermophilic chemolithoautotroph, taxon: 63363
Aave-AACOOl Acidovorax avenae subsp. citrulli taxon: 397945
Aavel721 AACOO-1
Aave-AACOOl RIR1 Acidovorax avenae subsp. citrulli taxon: 397945 AACOO-1
Aave-ATCC 19860 Acidovorax avenae subsp. avenae Taxon: 643561 RIR1 ATCC 19860
Aba Hyp-02185 Acinetobacter baumannii ACICU taxon: 405416 Ace RIR1 Acidothermus cellulolyticus 1 IB taxon: 351607 Aeh DnaB-1 Alkalilimnicola ehrlichei MLHE-1 taxon: 187272 Aeh DnaB-2 Alkalilimnicola ehrlichei MLHE-1 taxon: 187272 Aeh RIR1 Alkalilimnicola ehrlichei MLHE-1 taxon: 187272 AgP-S1249 MupF Aggregatibacter phage SI 249 Taxon: 683735 Aha DnaE-c Aphanothece halophytica Cyanobacterium , taxon: 72020 Aha DnaE-n Aphanothece halophytica Cyanobacterium , taxon: 72020 Alvi-DSM180 GyrA Allochromatium vinosum DSM 180 Taxon: 572477
Ama MADE823 phage uncharacterized protein Probably prophage gene, [Alteromonas macleodii ‘Deep taxon: 314275 ecotype’]
Amax-CS328 DnaX Arthrospira maxima CS-328 Taxon: 513049 Aov DnaE-c Aphanizomenon ovalisporum Cyanobacterium , taxon: 75695 Aov DnaE-n Aphanizomenon ovalisporum Cyanobacterium , taxon: 75695 Apl-Cl DnaX Arthrospira platensis Taxon: 118562, strain Cl Arsp-FB24 DnaB Arthrobacter species FB24 taxon: 290399 Anabaena species PCC7120,
Asp DnaE-c Cyanobacterium , Nitrogen
( Nostoc sp. PCC7120) fixing, taxon: 103690
Anabaena species PCC7120,
Asp DnaE-n Cyanobacterium , Nitrogen
(. Nostoc sp. PCC7120) fixing, taxon: 103690
Ava DnaE-c Anabaena variabilis ATCC29413 Cyanobacterium , taxon: 240292 Ava DnaE-n Anabaena variabilis ATCC29413 Cyanobacterium , taxon: 240292 Avin RIR1 BIL Azotobacter vinelandii taxon: 354 Bce-MC03 DnaB Burkholderia cenocepacia MCO-3 taxon: 406425 Bce-PC 184 DnaB Burkholderia cenocepacia PC 184 taxon: 350702 Bse-MLSIO TerA Bacillus selenitireducens MLS 10 Probably prophage gene,
Taxon: 439292
BsuP-M1918 RIR1 B. subtil is Ml 918 (prophage) Prophage in B. subtilis M1918. taxon: 157928
BsuP-SPBc2 RIR1 B. subtilis strain 168 Sp beta c2 B. subtilis taxon 1423. SPbeta prophage c2 phage, taxon: 66797 Bvi IcmO Burkholderia vietnamiensis G4 plasmid = “pBVIE03”. taxon: 269482
CP-P1201 Thyl Corynebacterium phage PI 201 lytic bacteriophage PI 201 from Corynebacterium glutamicum NCEtU 87078. Viruses; dsDNA viruses, taxon: 384848
Cag RIR1 Chlorochromatium aggregatum Motile, phototrophic consortia Cau SpoVR Chloroflexus aurantiacus J-10-fl Anoxy genic phototroph, taxon: 324602
Phage, specific host =
CbP-C-St RNR Clostridium botulinum phage C-St
“ Clostridium botulinum type C strain C-Stockholm, taxon: 12336
CbP-D1873 RNR Clostridium botulinum phage D Ssp. phage from Clostridium botulinum type D strain, 1873, taxon: 29342
Coxiella burnetii Dugway 5 J 108-
Cbu-Dugway DnaB Proteobacteria; Legionellales; 111 taxon: 434922
Cbu-Goat DnaB Coxiella burnetii ‘MSU Goat Q177 Proteobacteria; Legionellales; taxon: 360116 Cbu-RSA334 DnaB Coxiella burnetii RSA 334 Proteobacteria; Legionellales; taxon: 360117 Cbu-RSA493 DnaB Coxiella burnetii RSA 493 Proteobacteria; Legionellales; taxon: 227377 Cce Hypl-Csp-2 Cyanothece sp. ATCC 51142 Marine unicellular diazotrophic cyanobacterium , taxon: 43989
Cch RIR1 Chlorobium chlorochromatii CaD3 taxon: 340177 Ccy Hypl-Csp-1 Cyanothece sp. CCY0110 Cyanobacterium , taxon: 391612
Ccy Hypl-Csp-2 Cyanothece sp. CCY0110 Cyanobacterium , taxon: 391612
Cellulomonas flavigena DSM
CA-DSM20109 DnaB Taxon: 446466 20109 Chy RIR1 Carboxydothermus Therm ophile, taxon = 246194 hydrogenoformans Z-2901
Ckl PTerm Clostridium kluyveri DSM 555 plasmid = “pCKL555A”, taxon: 431943
Cylindrospermopsis raciborskii CS-
Cra-CS505 DnaE-c Taxon: 533240 505
Cylindrospermopsis raciborskii CS- Cra-CS505 DnaE-n Taxon: 533240 505
Cylindrospermopsis raciborskii CS-
Cra-CS505 GyrB Taxon: 533240 505
Csp-CCYOl 10 DnaE-
Cyanothece sp. CCY0110 Taxon: 391612 c
Csp-CCYOl 10 DnaE-
Cyanothece sp. CCY0110 Taxon: 391612 n
Csp-PCC7424 DnaE-
Cyanothece sp. PCC 7424 Cyanobacterium , taxon: 65393 c
Csp-PCC7424 DnaE-
Cyanothece sp. PCC7424 Cyanobacterium , taxon: 65393 n
Csp-PCC7425 DnaB Cyanothece sp. PCC 7425 Taxon: 395961
Csp-PCC7822 DnaE- Cyanothece sp. PCC 7822 Taxon: 497965 n
Csp-PCC8801 DnaE-
Cyanothece sp. PCC 8801 Taxon: 41431 c
Csp-PCC8801 DnaE-
Cyanothece sp. PCC 8801 Taxon: 41431 n
Cth ATPase BIL Clostridium thermocellum ATCC27405, taxon: 203119
Cth-ATCC27405 Clostridium thermocellum Probable prophage, Ter A ATCC27405 ATCC27405, taxon: 203119
Cth-DSM2360 TerA Clostridium thermocellum DSM Probably prophage 2360 gene, Taxon: 572545
Cwa DnaB Crocosphaera watsonii WH 8501 taxon: 165597 ( Synechocystis sp. WH 8501) Cwa DnaE-c Crocosphaera watsonii WH 8501 Cyanobacterium , (, Synechocystis sp. WH 8501) taxon: 165597 Cwa DnaE-n Crocosphaera watsonii WH 8501 Cyanobacterium , (, Synechocystis sp. WH 8501) taxon: 165597 Cwa PEP Crocosphaera watsonii WH 8501 taxon: 165597 (, Synechocystis sp. WH 8501) Cwa RIR1 Crocosphaera watsonii WH 8501 taxon: 165597 (, Synechocystis sp. WH 8501) Candidatus Desulforudis
Daud RIR1 taxon: 477974 audaxviator MP104C
Dge DnaB Deinococcus geothermalis Thermophilic, radiation DSM11300 resistant
Desulfitobacterium hafniense DCB
Dha-DCB2 RIR1 Anaerobic dehalogenating 2 bacteria, taxon: 49338
Dha-Y51 RIR1 Desulfitobacterium hafniense Y51 Anaerobic dehalogenating bacteria, taxon: 138119
Dpr-MLMSl RIR1 delta proteobacterium MLMS-1 Taxon: 262489 Deinococcus radiodurans Rl, Dra RIR1 Radiation resistant, TIGR strain taxon: 1299
Deinococcus radiodurans Rl,
Dra Snf2-c Radiation and DNA damage TIGR strain resi stent, taxon: 1299
Deinococcus radiodurans Rl,
Dra Snf2-n Radiation and DNA damage TIGR strain resi stent, taxon: 1299
Dra-ATCC13939
Deinococcus radiodurans Rl, Radiation and DNA damage
Sn£2
ATCC13939/Brooks & Murray resi stent, taxon: 1299 strain
Dth UDP GD Dictyoglomus thermophilum H-6 12 strain = “H-6-12; ATCC 35947,
taxon: 309799
Dvul ParB Desulfovibrio vulgaris subsp. taxon: 391774 vulgaris DP4
EP-Min27 Primase Enterobacteria phage Min27 bacteriphage of host = “ Escherichia coli
0157: H7 str. Min27”
Fal DnaB Frankia alni ACN14a Plant symbiot, taxon: 326424 Fsp-CcB RIR1 Frankia species CcI3 taxon: 106370 Gob DnaE Gemmata obscuriglobus UQM2246 Taxon 114, TIGR genome strain, budding bacteria
Gob Hyp Gemmata obscuriglobus UQM2246 Taxon 114, TIGR genome strain, budding bacteria
Gvi DnaB Gloeobacter violaceus , PCC 7421 taxon: 33072
Gvi RIRl-1 Gloeobacter violaceus , PCC 7421 taxon: 33072
Gvi RIR1-2 Gloeobacter violaceus , PCC 7421 taxon: 33072
Hhal DnaB Halorhodospira halophila SL1 taxon: 349124
KH-DSM17836 DnaB Kribbella flavida DSM 17836 Taxon: 479435 Kra DnaB Kineococcus radiotolerans Radiation resistant
SRS30216
LLP-KS Y 1 Pol A Lactococcus phage KS Y 1 Bacteriophage, taxon: 388452
LP-phiHSIC Helicase Listonella pelagia phage phiHSIC taxon: 310539, a pseudotemperate marine phage of Listonella pelagia
Lsp-PCC8106 GyrB Lyngbya sp. PCC 8106 Taxon: 313612 MP-Be DnaB Mycobacteriophage Bethlehem Bacteriophage, taxon: 260121 MP-Be gp51 Mycobacteriophage Bethlehem Bacteriophage, taxon: 260121 MP-Catera gp206 Mycobacteriophage Catera My cob acteri ophage, taxon: 373404
MP-KBG gp53 Mycobacterium phage KBG Taxon: 540066 MP-Mcjwl DnaB My cobacteriophage CJW 1 Bacteriophage, taxon: 205869 MP-Omega DnaB Mycobacteriophage Omega Bacteriophage, taxon: 205879 MP-U2 gp50 Mycobacteriophage U2 Bacteriophage, taxon: 260120
Maer-NIES843 DnaB Microcystis aeruginosa NIES-843 Bloom-forming toxic cyanobacterium , taxon: 449447
Maer-NIES843 DnaE-
Microcystis aeruginosa NIES-843 Bloom-forming toxic c cyanobacterium , taxon: 449447
Maer-NIES843 DnaE-
Microcystis aeruginosa NIES-843 Bloom-forming toxic n cyanobacterium , taxon: 449447
Mau-ATCC27029 Micromonospora aurantiaca ATCC Taxon: 644283
GyrA 27029
Mav-104 DnaB Mycobacterium avium 104 taxon: 243243
Mav-ATCC25291 Mycobacterium avium subsp. avium Taxon: 553481
DnaB ATCC 25291
Mav-ATCC35712 Mycobacterium avium ATCC35712, taxon 1764
DnaB
Mav-PT DnaB Mycobacterium avium subsp. taxon: 262316 paratuberculosis str. klO Mbo Ppsl Mycobacterium bovis subsp. bovis strain = “AF2122/97”, AF2122/97 taxon: 233413 Mbo RecA Mycobacterium bovis subsp. bovis taxon: 233413 AF2122/97
Mbo SufB (Mbo
Mycobacterium bovis subsp. bovis taxon: 233413 Ppsl) AF2122/97
Mbo-1173P DnaB Mycobacterium bovis BCG Pasteur strain = BCG Pasteur 1173P 1173P2,, taxon: 410289
Mbo-AF2122 DnaB Mycobacterium bovis subsp. bovis strain = “AF2122/97”, AF2122/97 taxon: 233413
Mca MupF Methylococcus capsulatus Bath, prophage MuMc02, prophage MuMc02 taxon: 243233
Mca RIR1 Methylococcus capsulatus Bath taxon: 243233 Mch RecA Mycobacterium chitae IP14116003, taxon: 1792
Mcht-PCC7420
Microcoleus chthonoplastes Cyanobacterium ,
DnaE-1
PCC7420 taxon: 118168
Mcht-PCC7420
Microcoleus chthonoplastes Cyanobacterium ,
DnaE-2c PCC7420 taxon: 118168
Mcht-PCC7420
Microcoleus chthonoplastes Cyanobacterium ,
DnaE-2n PCC7420 taxon: 118168
Mcht-PCC7420 GyrB Microcoleus chthonoplastes PCC Taxon: 118168
7420
Mcht-PCC7420
Microcoleus chthonoplastes PCC Taxon: 118168
RIRl-1
7420
Mcht-PCC7420
Microcoleus chthonoplastes PCC Taxon: 118168
RIR1-2
7420
Mex Helicase Methylobacterium extorquens AMI Alphaproteob acteri a
Mex TrbC Methylobacterium extorquens AMI Alphaproteob acteri a
Mfa RecA Mycobacterium fallax CITP8139, taxon: 1793 Mfl GyrA Mycobacterium flavescens FlaO taxon: 1776, reference #930991
Mfl RecA Mycobacterium flavescens FlaO strain = FlaO, taxon: 1776, ref. #930991
Mfl-ATCC 14474 strain = ATCC 14474, taxon:
Mycobacterium flavescens , RecA 1776,
ATCC 14474 ref #930991
Mfl-PYR-GCK DnaB Mycobacterium flavescens PYR- taxon: 350054
GCK
Mga GyrA Mycobacterium gastri HP4389, taxon: 1777 Mga RecA Mycobacterium gastri HP4389, taxon: Mil
Mga SufB (Mga
Mycobacterium gastri HP4389, taxon: Mil Ppsl)
Mgi-PYR-GCK DnaB Mycobacterium gilvum PYR-GCK taxon: 350054 Mgi-PYR-GCK GyrA Mycobacterium gilvum PYR-GCK taxon: 350054
Mgo GyrA Mycobacterium gordonae taxon: 1778, reference number 930835
Min- 1442 DnaB Mycobacterium intr acellular e strain 1442, taxon: 1767 Mycobacterium intr acellular e Min-ATCC 13950 Taxon: 487521 ATCC GyrA 13950
Mkas GyrA Mycobacterium kansasii taxon: 1768 Mkas-ATCC 12478 Mycobacterium kansasii ATCC Taxon: 557599 GyrA 12478
Mle-Br4923 GyrA Mycobacterium leprae Br4923 Taxon: 561304 Mle-TN DnaB Mycobacterium leprae , strain TN Human pathogen, taxon: 1769 Mle-TN GyrA Mycobacterium leprae TN Human pathogen,
STRAIN = TN, taxon: 1769
Mle-TN RecA Mycobacterium leprae , strain TN Human pathogen, taxon: 1769 Mle-TN SufB (Mle Mycobacterium leprae Human pathogen, taxon: 1769 Ppsl)
Mma GyrA Mycobacterium malmoense taxon: 1780
Mmag Magn8951
Magnetospirillum magnetotacticum Gram negative, taxon: 272627 BIL
MS-1
Msh RecA Mycobacterium shimodei ATCC27962, taxon: 29313 Mycobacterium smegmatis MC2
Msm DnaB-1 MC2 155, taxon: 246196 155
Mycobacterium smegmatis MC2
Msm DnaB -2 MC2 155, taxon: 246196 155 Msp-KMS DnaB Mycobacterium species KMS taxon: 189918
Msp-KMS GyrA Mycobacterium species KMS taxon: 189918 Msp-MCS DnaB Mycobacterium species MCS taxon: 164756 Msp-MCS GyrA Mycobacterium species MCS taxon: 164756 Mthe RecA Mycobacterium thermoresistibile ATCC 19527, taxon: 1797
Mtu SufB (Mtu Ppsl) Mycobacterium tuberculosis strains Human pathogen, taxon: 83332
H37Rv & CDC1551
Mtu-C RecA Mycobacterium tuberculosis C Taxon: 348776 Mtu-CDC1551 DnaB Mycobacterium tuberculosis , Human pathogen, taxon: 83332 CDC1551
Mtu-CPHL RecA Mycobacterium tuberculosis Taxon: 611303 CPHL A
Mtu-Canetti RecA Mycobacterium tuberculosis / Taxon: 1773 strain = “ Canetti ”
Mycobacterium tuberculosis
Mtu-EAS054 RecA Taxon: 520140 EAS054 Mtu-F 11 DnaB Mycobacterium tuberculosis , strain taxon: 336982 FI 1
Mtu-H37Ra DnaB Mycobacterium tuberculosis H37Ra ATCC 25177, taxon: 419947 Mtu-H37Rv DnaB Mycobacterium tuberculosis H37Rv Human pathogen, taxon: 83332 Mtu-H37Rv RecA Mycobacterium tuberculosis Human pathogen, taxon: 83332
H37Rv, Also CDC1551
Mtu-Haarlem DnaB Mycobacterium tuberculosis str. Taxon: 395095 Haarlem
Mtu-K85 RecA Mycobacterium tuberculosis K85 Taxon: 611304 Mtu-R604 RecA-n Mycobacterium tuberculosis ‘98- Taxon: 555461 R604 INH-RIF-EM’
Mtu-So93 RecA Mycobacterium tuberculosis Human pathogen, taxon: 1773 So93/sub_species = “ Canetti ”
Mtu-T17 RecA-c Mycobacterium tuberculosis T17 Taxon: 537210 Mtu-T17 RecA-n Mycobacterium tuberculosis T17 Taxon: 537210 Mtu-T46 RecA Mycobacterium tuberculosis T46 Taxon: 611302 Mtu-T85 RecA Mycobacterium tuberculosis T85 Taxon: 520141 Mtu-T92 RecA Mycobacterium tuberculosis T92 Taxon: 515617 Mvan DnaB Mycobacterium vanbaalenii PYR-1 taxon: 350058 Mvan GyrA Mycobacterium vanbaalenii PYR-1 taxon: 350058 Mxa RAD25 Myxococcus xanthus DK1622 Deltaproteob acteri a Mxe GyrA Mycobacterium xenopi strain taxon: 1789 IMM5024
Naz-0708 RIRl-1 Nostoc azollae 0708 Taxon: 551115 Naz-0708 RIR1-2 Nostoc azollae 0708 Taxon: 551115 Nfa DnaB Nocar dia farcinica IFM 10152 taxon: 247156
Nfa Nfal5250 Nocar dia farcinica IFM 10152 taxon: 247156 Nfa RIR1 Nocar dia farcinica IFM 10152 taxon: 247156
Nosp-CCY9414
Nodularia spumigena CCY9414 Taxon: 313624
DnaE-n
Npu DnaB Nostoc punctiforme Cyanobacterium , taxon: 63737 Npu GyrB Nostoc punctiforme Cyanobacterium , taxon: 63737 Npu-PCC73102
Nostoc punctiforme PCC73102 Cyanobacterium , taxon: 63737, DnaE-c
ATCC29133
Npu-PCC73102
Nostoc punctiforme PCC73102 Cyanobacterium , taxon: 63737,
DnaE-n
ATCC29133
Nsp-JS614 DnaB Nocardioides species JS614 taxon: 196162 Nsp-JS614 TOPRIM Nocardioides species JS614 taxon: 196162
Nostoc species PCC7120,
Nsp-PCC7120 DnaB Cyanobacterium , Nitrogen
( Anabaena sp. PCC7120) fixing, taxon: 103690
Nsp-PCC7120 DnaE- Nostoc species PCC7120, Cyanobacterium , Nitrogen c ( Anabaena sp. PCC7120) fixing, taxon: 103690
Nsp-PCC7120 DnaE- Nostoc species PCC7120, Cyanobacterium , Nitrogen n (. Anabaena sp. PCC7120) fixing, taxon: 103690
Nostoc species PCC7120,
Nsp-PCC7120 RIRl Cyanobacterium , Nitrogen
(. Anabaena sp. PCC7120) fixing, taxon: 103690
Oscillatoria limnetica str. ‘ Solar
Oli DnaE-c Cyanobacterium , taxon: 262926 Lake’
Oscillatoria limnetica str. ‘ Solar
Oli DnaE-n Cyanobacterium , taxon: 262926 Lake’ PP -PhiEL Helicase Pseudomonas aeruginosa phage Phage infects Pseudomonas phiEL aeruginosa , taxon: 273133
PP-PhiEL ORF11 Pseudomonas aeruginosa phage phage infects Pseudomonas phiEL aeruginosa , taxon: 273133
PP-PhiEL ORF39 Pseudomonas aeruginosa phage Phage infects Pseudomonas phiEL aeruginosa , taxon: 273133
PP-PhiEL ORF40 Pseudomonas aeruginosa phage phage infects Pseudomonas phiEL aeruginosa , taxon: 273133
Pfl Fha BIL Pseudomonas fluorescens Pf-5 Plant commensal organism, taxon: 220664
Plut RIRl Pelodictyon luteolum DSM 273 Green sulfur bacteria, Taxon 319225
Pma-EXHl GyrA Persephonella marina EX-HI Taxon: 123214
Pma-ExHl DnaE Persephonella marina EX-HI Taxon: 123214 Polaromonas naphthalenivorans
Pna RIR1 taxon: 365044 CJ2 Pnuc DnaB Polynucleobacter sp. QLW- taxon: 312153 PlDMWA-1
Posp-JS666 DnaB Polaromonas species JS666 taxon: 296591 Posp-JS666 RIR1 Polaromonas species JS666 taxon: 296591 Pssp-Al-1 Fha Pseudomonas species Al-1 Psy Fha Pseudomonas syringae pv. tomato Plant (tomato) pathogen, str. DC3000 taxon: 223283
Rbr-D9 GyrB Raphidiopsis brookii D9 Taxon: 533247
Rce RIR1 Rhodospirillum centenum SW taxon: 414684, ATCC 51521
Rer- SK121 DnaB Rhodococcus erythropolis SK 121 Taxon: 596309
Rma DnaB Rhodothermus marinus Thermophile, taxon: 29549
Rma-DSM4252 DnaB Rhodothermus marinus DSM 4252 Taxon: 518766 Rma-DSM4252 DnaE Rhodothermus marinus DSM 4252 Thermophile, taxon: 518766 Rsp RIR1 Roseovarius species 217 taxon: 314264
SaP-SETP12 dpol Salmonella phage SETP12 Phage, taxon: 424946
SaP-SETP3 Helicase Salmonella phage SETP3 Phage, taxon: 424944
SaP-SETP3 dpol Salmonella phage SETP3 Phage, taxon: 424944 SaP-SETP5 dpol Salmonella phage SETP5 Phage, taxon: 424945 Sare DnaB Salinispora arenicola CNS-205 taxon: 391037 Sav RecG Helicase Streptomyces avermitilis MA-4680 taxon: 227882, ATCC 31267 Synechococcus elongatus PCC
Sel-PC6301 RIR1 taxon: 269084 Berkely strain
6301
6301 -equivalent name: Ssp PCC 6301 -synonym: Anacystis nudulans
Sel-PC7942 DnaE-c Synechococcus elongatus PC7942 taxon: 1140 Sel-PC7942 DnaE-n Synechococcus elongatus PC7942 taxon: 1140 Sel-PC7942 RIR1 Synechococcus elongatus PC7942 taxon: 1140
Sel-PCC6301 DnaE-c Synechococcus elongatus PCC Cyanobacterium ,
6301 and PCC7942 taxon: 269084, “Berkely strain 6301 -equivalent name: Synechococcus sp. PCC 6301 -synonym: Anacystis nudulans"
Sel-PCC6301 DnaE-n Synechococcus elongatus PCC Cyanobacterium , taxon: 269084”Berkely strain 6301 -equivalent name:
Synechococcus sp. PCC 6301 -synonym: Anacystis nudulanC
Sep RIR1 Staphylococcus epidermidis RP62A taxon: 176279
ShP-Sfv-2a-2457T-n Shigella flexneri 2a str. 2457T Putative bacteriphage
Primase
ShP-Sfv-2a-301 -n Shigella flexneri 2a str. 301 Putative bacteriphage Primase
ShP-Sfv-5 Primase Shigella flexneri 5 str. 8401 Bacteriphage, isolation source— epidemic, taxon: 373384
Phage/isolation source =
SoP-SOl dpol Sodalis phage SO-1 a Sodalis glossinidius strain GA-SG, secondary symbiont of Glossina austeni (Newstead)”
Spl DnaX Spirulina platensis , strain Cl (yanobacterium, taxon : 1156 Sru DnaB Salinibacter ruber DSM 13855 taxon: 309807, strain = “DSM 13855; M31”
Sru PolBc Salinibacter ruber DSM 13855 taxon: 309807, strain = “DSM 13855; M31”
Sru RIR1 Salinibacter ruber DSM 13855 taxon: 309807, strain = “DSM 13855; M31”
Ssp DnaB Synechocystis species, strain Cyanobacterium, taxon: 1148 PCC6803
Ssp DnaE-c Synechocystis species, strain Cyanobacterium, taxon: 1148 PCC6803
Ssp DnaE-n Synechocystis species, strain Cyanobacterium, taxon: 1148 PCC6803
Ssp DnaX Synechocystis species, strain Cyanobacterium, taxon: 1148 PCC6803
Ssp GyrB Synechocystis species, strain Cyanobacterium, taxon: 1148 PCC6803
Synechococcus species JA-2- Cyanobacterium, Taxon:
Ssp-JA2 DnaB 3B'a(2-13) 321332
Synechococcus species JA-2- Cyanobacterium, Taxon: Ssp-JA2 RIR1 3B'a(2-13) 321332
Cyanobacterium, Taxon: Ssp-JA3 DnaB Synechococcus species JA-3-3Ab 321327
Cyanobacterium, Taxon:
Ssp-JA3 RIR1 Synechococcus species JA-3-3Ab 321327
Ssp-PCC7002 DnaE-c Synechocystis species, strain PCC Cyanobacterium , taxon: 32049
7002
Ssp-PCC7002 DnaE-n Synechocystis species, strain PCC Cyanobacterium , taxon: 32049
7002
Ssp-PCC7335 RIR1 Synechococcus sp. PCC 7335 Taxon: 91464 StP-Twort ORF6 Staphylococcus phage Twort Phage, taxon 55510 Susp-NBC371 DnaB Sulfur ovum sp. NBC37-1 taxon: 387093 Intein
Taq-Y51MC23 DnaE Thermus aquaticus Y51MC23 Taxon: 498848 Taq-Y51MC23 RIR1 Thermus aquaticus Y51MC23 Taxon: 498848 Tcu-DSM43183
Thermomonospora curvata DSM Taxon: 471852 RecA
43183
Thermosynechococcus elongatus
Tel DnaE-c Cyanobacterium , taxon: 197221
BP-1
Thermosynechococcus elongatus Tel DnaE-n Cyanobacterium ,
BP-1
Trichodesmium erythraeum Ter DnaB-1 Cyanobacterium , taxon: 203124 IMS101
Trichodesmium erythraeum Ter DnaB-2 Cyanobacterium , taxon: 203124 IMS101
Trichodesmium erythraeum Ter DnaE-1 Cyanobacterium , taxon: 203124 IMS101
Trichodesmium erythraeum Ter DnaE-2 Cyanobacterium , taxon: 203124 IMS101
Trichodesmium erythraeum Ter DnaE-3c Cyanobacterium , taxon: 203124 IMS101
Trichodesmium erythraeum Ter DnaE-3n Cyanobacterium , taxon: 203124 IMS101
Trichodesmium erythraeum Ter GyrB Cyanobacterium , taxon: 203124 IMS101
Trichodesmium erythraeum Ter Ndse-1 Cyanobacterium , taxon: 203124 IMS101
Trichodesmium erythraeum Ter Ndse-2 Cyanobacterium , taxon: 203124 IMS101
Trichodesmium erythraeum Ter RIRl-1 Cyanobacterium , taxon: 203124 IMS101
Trichodesmium erythraeum Ter RIR1-2 Cyanobacterium , taxon: 203124 IMS101
Trichodesmium erythraeum Ter RIR1-3 Cyanobacterium , taxon: 203124 IMS101
Trichodesmium erythraeum Ter RIR1-4 Cyanobacterium , taxon: 203124 IMS101
Trichodesmium erythraeum Ter Sn£2 Cyanobacterium , taxon: 203124 IMS101
Trichodesmium erythraeum
Ter ThyX Cyanobacterium , taxon: 203124 IMS101
Tfus RecA-1 Thermobifida fusca YX Thermophile, taxon: 269800 Tfus RecA-2 Thermobifida fusca YX Thermophile, taxon: 269800 Tfus Tfu2914 Thermobifida fusca YX Thermophile, taxon: 269800 Thsp-K90 RIR1 Thioalkalivibrio sp. K90mix Taxon: 396595 Tth-DSM571 RIR1 Thermoanaerobacterium Taxon: 580327 thermosaccharolyticum DSM 571
Tth-HB27 DnaE-1 Thermus thermophilus HB27 thermophile, taxon: 262724 Tth-HB27 DnaE-2 Thermus thermophilus HB27 thermophile, taxon: 262724 Tth-HB27 RIRl-1 Thermus thermophilus HB27 thermophile, taxon: 262724 Tth-HB27 RIR1-2 Thermus thermophilus HB27 thermophile, taxon: 262724 Tth-HB8 DnaE-1 Thermus thermophilus HB8 thermophile, taxon: 300852 Tth-HB8 DnaE-2 Thermus thermophilus HB8 thermophile, taxon: 300852 Tth-HB8 RIRl-1 Thermus thermophilus HB8 thermophile, taxon: 300852 Tth-HB8 RIR1-2 Thermus thermophilus HB8 thermophile, taxon: 300852 Tvu DnaE-c Thermosynechococcus vulcanus Cyanobacterium , taxon: 32053 Tvu DnaE-n Thermosynechococcus vulcanus Cyanobacterium , taxon: 32053 Tye RNR-1 Thermodesulfovibrio yellow stonii taxon: 289376 DSM 11347
Tye RNR-2 Thermodesulfovibrio yellow stonii taxon: 289376 DSM 11347
Archaea Ape APE0745 Aeropyrum pernix K1 Thermophile, taxon: 56636 Cme-boo Pol-II Candidatus Methanoregula boonei taxon: 456442 6A8
Fac-Ferl RIR1 Ferroplasma acidarmanus , strain Ferl, eats iron taxon: 97393 and taxon 261390
Fac-Ferl SufB (Fac Ferroplasma acidarmanus strain ferl, eats Ppsl) iron, taxon: 97393
Fac-Typel RIR1 Ferroplasma acidarmanus type I, Eats iron, taxon 261390 Fac-typel SufB (Fac Ferroplasma acidarmanus Eats iron, taxon: 261390 Ppsl)
Hma CDC21 Haloarcula marismortui ATCC taxon: 272569, 43049 Hma Pol-II Haloarcula marismortui ATCC taxon: 272569, 43049 Hma PolB Haloarcula marismortui ATCC taxon: 272569, 43049
Hma Top A Haloarcula marismortui ATCC taxon: 272569 43049
Hmu-D SM 12286 Halomicrobium mukohataei DSM taxon: 485914 ( Halobacteria ) MCM 12286
Hmu-D SM 12286
Halomicrobium mukohataei DSM Taxon: 485914 PolB
12286
Hsa-Rl MCM Halobacterium salinarum R-l Halophile, taxon: 478009, strain = “Rl; DSM 671”
Hsp-NRCl CDC21 Halobacterium species NRC-1 Halophile, taxon: 64091 Hsp-NRCl Pol-II Halobacterium salinarum NRC-1 Halophile, taxon: 64091 Hut MCM-2 Halorhabdus utahensis DSM 12940 taxon: 519442
Hut-D SMI 2940
Halorhabdus utahensis DSM 12940 taxon: 519442 MCM-
1
Hvo PolB Haloferax volcanii DS70 taxon: 2246 Haloquadratum walsbyi DSM Hwa GyrB Halophile, taxon: 362976, 16790 strain: DSM 16790 = HBSQOOl
Haloquadratum walsbyi DSM
Hwa MCM-1 Halophile, taxon: 362976, 16790 strain: DSM 16790 = HBSQOOl
Haloquadratum walsbyi DSM
Hwa MCM-2 Halophile, taxon: 362976, 16790 strain: DSM 16790 = HBSQOOl
Haloquadratum walsbyi DSM
Hwa MCM-3 Halophile, taxon: 362976, 16790 strain: DSM 16790 = HBSQOOl
Haloquadratum walsbyi DSM
Hwa MCM-4 Halophile, taxon: 362976, 16790 strain: DSM 16790 = HBSQOOl
Haloquadratum walsbyi DSM
Hwa Pol-II- 1 Halophile, taxon: 362976, 16790 strain: DSM 16790 = HBSQOOl
Haloquadratum walsbyi DSM
Hwa Pol-II-2 Halophile, taxon: 362976, 16790 strain: DSM 16790 = HBSQOOl
Haloquadratum walsbyi DSM
Hwa PolB-1 Halophile, taxon: 362976, 16790 strain: DSM 16790 = HBSQOOl
Haloquadratum walsbyi DSM
Hwa PolB-2 Halophile, taxon: 362976, 16790 strain: DSM 16790 = HBSQOOl
Haloquadratum walsbyi DSM
Hwa PolB-3 Halophile, taxon: 362976, 16790 strain: DSM 16790 = HBSQOOl
Haloquadratum walsbyi DSM
Hwa RCF Halophile, taxon: 362976, 16790 strain: DSM 16790 = HBSQOOl
Haloquadratum walsbyi DSM
Hwa RIRl-1 Halophile, taxon: 362976, 16790 strain: DSM 16790 = HBSQOOl
Haloquadratum walsbyi DSM
Hwa RIR1-2 Halophile, taxon: 362976, 16790 strain: DSM 16790 = HBSQOOl
Haloquadratum walsbyi DSM
Hwa Top6B Halophile, taxon: 362976, 16790 strain: DSM 16790 = HBSQOOl
Haloquadratum walsbyi DSM
Hwa rPol A" Halophile, taxon: 362976, 16790 strain: DSM 16790 =
HBSQOOl
Maeo Pol-II Methanococcus aeolicus Nankai-3 taxon: 419665 Maeo RFC Methanococcus aeolicus Nankai-3 taxon: 419665 Maeo RNR Methanococcus aeolicus Nankai-3 taxon: 419665 Maeo-N3 Helicase Methanococcus aeolicus Nankai-3 taxon: 419665 Maeo-N3 RtcB Methanococcus aeolicus Nankai-3 taxon: 419665 Maeo-N3 UDP GD Methanococcus aeolicus Nankai-3 taxon: 419665 Mein-ME PEP Methanocaldococcus infernus ME thermophile, Taxon: 573063 Mein-ME RFC Methanocaldococcus infernus ME Taxon: 573063 Memar MCM2 Methanoculleus marisnigri JR1 taxon: 368407 Memar Pol-II Methanoculleus marisnigri JR1 taxon: 368407
Mesp-FS406 PolB-1 Methanocaldococcus sp. FS406-22 Taxon: 644281 Mesp-FS406 PolB-2 Methanocaldococcus sp. FS406-22 Taxon: 644281 Mesp-FS406 PolB-3 Methanocaldococcus sp. FS406-22 Taxon: 644281 Mesp-FS406-22 LHR Methanocaldococcus sp. FS406-22 Taxon: 644281
Mfe- Methanocaldococcus fervens AG86 Taxon: 573064 Mfe- Methanocaldococcus fervens AG86 Taxon: 573064 Mhu Methanospirillum hungateii JF-1 taxon 323259 Mja
Methanococcus jannaschii Thermophile, DSM 2661, {Methanocaldococcus jannaschii taxon: 2190 DSM 2661)
Mja Helicase Methanococcus jannaschii Thermophile, DSM 2661, {Methanocaldococcus jannaschii taxon: 2190 DSM 2661)
Mja Hyp-1 Methanococcus jannaschii Thermophile, DSM 2661, {Methanocaldococcus jannaschii taxon: 2190 DSM 2661)
Mja IF2 Methanococcus jannaschii Thermophile, DSM 2661, {Methanocaldococcus jannaschii taxon: 2190 DSM 2661)
Mja KlbA Methanococcus jannaschii Thermophile, DSM 2661, {Methanocaldococcus jannaschii taxon: 2190 DSM 2661)
Mja PEP Methanococcus jannaschii Thermophile, DSM 2661, {Methanocaldococcus jannaschii taxon: 2190 DSM 2661)
Mja Pol-1 Methanococcus jannaschii Thermophile, DSM 2661, {Methanocaldococcus jannaschii taxon: 2190 DSM 2661)
Mja Pol -2 Methanococcus jannaschii Thermophile, DSM 2661, {Methanocaldococcus jannaschii taxon: 2190 DSM 2661)
Mja RFC- 1 Methanococcus jannaschii Thermophile, DSM 2661, {Methanocaldococcus jannaschii taxon: 2190 DSM 2661)
Mja RFC-2 Methanococcus jannaschii Thermophile, DSM 2661, {Methanocaldococcus jannaschii taxon: 2190 DSM 2661)
Mja RFC-3 Methanococcus jannaschii Thermophile, DSM 2661, {Methanocaldococcus jannaschii taxon: 2190 DSM 2661)
Mja RNR-1 Methanococcus jannaschii Thermophile, DSM 2661,
( Methanocaldococcus jannaschii taxon: 2190 DSM 2661)
Mja RNR-2 Methanococcus jannaschii Thermophile, DSM 2661, {Methanocaldococcus jannaschii taxon: 2190 DSM 2661)
Mja RtcB (Mja Hyp-
Methanococcus jannaschii Thermophile, DSM 2661,
2)
{Methanocaldococcus jannaschii taxon: 2190 DSM 2661)
Mja TFIIB Methanococcus jannaschii Thermophile, DSM 2661, {Methanocaldococcus jannaschii taxon: 2190 DSM 2661)
Mja UDP GD Methanococcus jannaschii Thermophile, DSM 2661, {Methanocaldococcus jannaschii taxon: 2190 DSM 2661)
Mja r-Gyr Methanococcus jannaschii Thermophile, DSM 2661, {Methanocaldococcus jannaschii taxon: 2190 DSM 2661)
Mja rPol A' Methanococcus jannaschii Thermophile, DSM 2661, {Methanocaldococcus jannaschii taxon: 2190 DSM 2661)
Mja rPol A" Methanococcus jannaschii Thermophile, DSM 2661, {Methanocaldococcus jannaschii taxon: 2190 DSM 2661)
Mka CDC48 Methanopyrus kandleri AVI 9 Thermophile, taxon: 190192 Mka EF2 Methanopyrus kandleri AVI 9 Thermophile, taxon: 190192 Mka RFC Methanopyrus kandleri AVI 9 Thermophile, taxon: 190192 Mka RtcB Methanopyrus kandleri AVI 9 Thermophile, taxon: 190192 Mka VatB Methanopyrus kandleri AVI 9 Thermophile, taxon: 190192 Mth RIR1 Methanothermobacter Thermophile, delta H strain thermautotrophicus {Methanobacterium thermoautotrophicum )
Mvu-M7 Helicase Methanocaldococcus vulcanius M7 Taxon: 579137 Mvu-M7 Pol-1 Methanocaldococcus vulcanius M7 Taxon: 579137 Mvu-M7 Pol-2 Methanocaldococcus vulcanius M7 Taxon: 579137 Mvu-M7 Pol-3 Methanocaldococcus vulcanius M7 Taxon: 579137 Mvu-M7 UDP GD Methanocaldococcus vulcanius M7 Taxon: 579137 Neq Pol-c Nanoarchaeum equitans Kin4-M Thermophile, taxon: 228908 Neq Pol-n Nanoarchaeum equitans Kin4-M Thermophile, taxon: 228908 Nma-ATCC43099 Natrialba magadii ATCC 43099 Taxon: 547559
MCM
Nma-ATCC43099 Natrialba magadii ATCC 43099 Taxon: 547559
PolB-1
Nma-ATCC43099 Natrialba magadii ATCC 43099 Taxon: 547559
PolB-2
Natronomonas pharaonis DSM
Nph CDC21 taxon: 348780 2160
Natronomonas pharaonis DSM
Nph PolB-1 taxon: 348780 2160
Natronomonas pharaonis DSM
Nph PolB-2 taxon: 348780 2160
Natronomonas pharaonis DSM
Nph rPol A" taxon: 348780 2160
Pab CDC21-1 Pyrococcus abyssi Thermophile, strain Orsay, taxon: 29292
Pab CDC21-2 Pyrococcus abyssi Thermophile, strain Orsay, taxon: 29292
Pab IF 2 Pyrococcus abyssi Thermophile, strain Orsay, taxon: 29292
Pab KlbA Pyrococcus abyssi Thermophile, strain Orsay, taxon: 29292
Pab Lon Pyrococcus abyssi Thermophile, strain Orsay, taxon: 29292
Pab Moaa Pyrococcus abyssi Thermophile, strain Orsay, taxon: 29292
Pab Pol-II Pyrococcus abyssi Thermophile, strain Orsay, taxon: 29292
Pab RFC-1 Pyrococcus abyssi Thermophile, strain Orsay, taxon: 29292
Pab RFC-2 Pyrococcus abyssi Thermophile, strain Orsay, taxon: 29292
Pab RIRl-1 Pyrococcus abyssi Thermophile, strain Orsay, taxon: 29292
Pab RIR1-2 Pyrococcus abyssi Thermophile, strain Orsay, taxon: 29292
Pab RIR1-3 Pyrococcus abyssi Thermophile, strain Orsay, taxon: 29292
Pab RtcB (Pab Hyp-2) Pyrococcus abyssi Thermophile, strain Orsay, taxon: 29292
Pab VMA Pyrococcus abyssi Thermophile, strain Orsay, taxon: 29292
Par RIR1 Pyrobaculum arsenaticum DSM taxon: 340102
13514
Pfu CDC21 Pyrococcus fiiriosus Thermophile, taxon: 186497, DSM3638
Pfu IF 2 Pyrococcus fiiriosus Thermophile, taxon: 186497, DSM3638
Pfu KlbA Pyrococcus fiiriosus Thermophile, taxon: 186497, DSM3638
Pfu Lon Pyrococcus fiiriosus Thermophile, taxon: 186497, DSM3638
Pfu RFC Pyrococcus fiiriosus Thermophile, DSM3638, taxon: 186497
Pfu RIRl-1 Pyrococcus fiiriosus Thermophile, taxon: 186497, DSM3638
Pfu RIR1-2 Pyrococcus fiiriosus Thermophile, taxon: 186497, DSM3638
Pfu RtcB (Pfu Hyp-2) Pyrococcus fiiriosus Thermophile, taxon: 186497, DSM3638
Pfu Top A Pyrococcus fiiriosus Thermophile, taxon: 186497, DSM3638
Pfu VMA Pyrococcus fiiriosus Thermophile, taxon: 186497, DSM3638
Pho CDC21-1 Pyrococcus horikoshii OT3 Thermophile, taxon: 53953 Pho CDC21-2 Pyrococcus horikoshii OT3 Thermophile, taxon: 53953 Pho IF 2 Pyrococcus horikoshii OT3 Thermophile, taxon: 53953 Pho KlbA Pyrococcus horikoshii OT3 Thermophile, taxon: 53953 Pho LHR Pyrococcus horikoshii OT3 Thermophile, taxon: 53953 Pho Lon Pyrococcus horikoshii OT3 Thermophile, taxon: 53953 Pho Pol I Pyrococcus horikoshii OT3 Thermophile, taxon: 53953 Pho Pol-II Pyrococcus horikoshii OT3 Thermophile, taxon: 53953 Pho RFC Pyrococcus horikoshii OT3 Thermophile, taxon: 53953 Pho RIR1 Pyrococcus horikoshii OT3 Thermophile, taxon: 53953 Pho RadA Pyrococcus horikoshii OT3 Thermophile, taxon: 53953 Pho RtcB (Pho Hyp-
Pyrococcus horikoshii OT3 Thermophile, taxon: 53953 2)
Pho VMA Pyrococcus horikoshii OT3 Thermophile, taxon: 53953 Pho r-Gyr Pyrococcus horikoshii OT3 Thermophile, taxon: 53953 Psp-GBD Pol Pyrococcus species GB-D Thermophile Pto VMA Picrophilus torridus , DSM 9790 DSM 9790, taxon: 263820, Thermoacidophile
Smar 1471 Staphylothermus marinus F 1 taxon: 399550
Smar MCM2 Staphylothermus marinus F 1 taxon: 399550
Tac-ATCC25905
Thermoplasma acidophilum, ATCC Thermophile, taxon: 2303
VMA
25905
Tac-DSM1728 VMA Thermoplasma acidophilum, Thermophile, taxon: 2303
DSM1728
Tag
Thermococcus aggregans Thermophile, taxon: 110163 Pol-
Tag Thermococcus aggregans Thermophile, taxon: 110163 Pol-
Tag Thermococcus aggregans Thermophile, taxon: 110163 Pol-
Tba Thermococcus barophilus MP taxon: 391623 Tfu Thermococcus fumicolans Thermophilem, taxon: 46540 Tfu Thermococcus fumicolans Thermophile, taxon: 46540 Thy Thermococcus hydrothermalis Thermophile, taxon: 46539 Thy
Thermococcus hydrothermalis Thermophile, taxon: 46539 Thermococcus kodakaraensis
Tko CDC21-1 Thermophile, taxon: 69014 KOD1
Thermococcus kodakaraensis
Tko CDC21-2 Thermophile, taxon: 69014 KOD1
Thermococcus kodakaraensis
Tko Helicase Thermophile, taxon: 69014 KOD1
Thermococcus kodakaraensis
Tko IF 2 Thermophile, taxon: 69014 KOD1
Thermococcus kodakaraensis
Tko KlbA Thermophile, taxon: 69014 KOD1
Thermococcus kodakaraensis
Tko LHR Thermophile, taxon: 69014 KOD1
Tko Pol-1 (Pko Pol-1) Pyrococcus/Thermococcus Thermophile, taxon: 69014 kodakaraensis KOD1
Tko Pol-2 (Pko Pol-2) Pyrococcus/Thermococcus Thermophile, taxon: 69014 kodakaraensis KOD1 Thermococcus kodakaraensis
Tko Pol-II Thermophile, taxon: 69014 KOD1
Thermococcus kodakaraensis
Tko RFC Thermophile, taxon: 69014 KOD1
Thermococcus kodakaraensis
Tko RIRl-1 Thermophile, taxon: 69014 KOD1
Thermococcus kodakaraensis
Tko RIR1-2 Thermophile, taxon: 69014 KOD1
Thermococcus kodakaraensis
Tko RadA Thermophile, taxon: 69014 KOD1
Thermococcus kodakaraensis
Tko Top A Thermophile, taxon: 69014 KOD1
Thermococcus kodakaraensis
Tko r-Gyr Thermophile, taxon: 69014
KOD1
Tli Pol-1 Thermococcus litoralis Thermophile, taxon: 2265 Tli Pol-2 Thermococcus litoralis Thermophile, taxon: 2265 Tma Pol Thermococcus marinus taxon: 187879 Ton-NAl LHR Thermococcus onnurineus NA1 Taxon: 523850 Ton-NAl Pol Thermococcus onnurineus NA1 taxon: 342948 Tpe Pol Thermococcus peptonophilus strain taxon: 32644 SM2
Tsi-MM739 Lon Thermococcus sibiricus MM 739 Thermophile, Taxon: 604354 Tsi-MM739 Pol-1 Thermococcus sibiricus MM 739 Taxon: 604354 Tsi-MM739 Pol-2 Thermococcus sibiricus MM 739 Taxon: 604354 Tsi-MM739 RFC Thermococcus sibiricus MM 739 Taxon: 604354 Tsp AM4 RtcB Thermococcus sp. AM4 Taxon: 246969 Tsp-AM4 LHR Thermococcus sp. AM4 Taxon: 246969 Tsp-AM4 Lon Thermococcus sp. AM4 Taxon: 246969 Tsp-AM4 RIR1 Thermococcus sp. AM4 Taxon: 246969 Tsp-GE8 Pol-1 Thermococcus species GE8 Thermophile, taxon: 105583 Tsp-GE8 Pol-2 Thermococcus species GE8 Thermophile, taxon: 105583 Tsp-GT Pol-1 Thermococcus species GT taxon: 370106 Tsp-GT Pol-2 Thermococcus species GT taxon: 370106 Tsp-OGL-20P Pol Thermococcus sp. OGL-20P taxon: 277988 Tthi Pol Thermococcus thioreducens Hyperthermophile Tvo VMA Thermoplasma volcanium GSS1 Thermophile, taxon: 50339 Tzi Pol Thermococcus zilligii taxon: 54076
Unc-ERS PFL uncultured archaeon Gzfosl3El isolation source = “Eel River sediment”, clone = “GZfosl3El”, taxon: 285397
Unc-ERS RIR1 uncultured archaeon GZfos9C4 isolation source = “Eel River sediment”, taxon: 285366, clone = “GZfos9C4”
Unc-ERS RNR uncultured archaeon GZfoslOC7 isolation source = “Eel River sediment”, clone = “GZfoslOC7”, taxon: 285400 uncultured archaeon (Rice Cluster
Unc-MetRFS MCM2 Enriched methanogenic
I) consortium from rice field soil, taxon: 198240
The split inteins of the disclosed compositions or that can be used in the disclosed methods can be modified, or mutated, inteins. A modified intein can comprise modifications to the N-terminal intein segment, the C-terminal intein segment, or both. The modifications can include additional amino acids at the N-terminus the C-terminus of either portion of the split intein, or can be within the either portion of the split intein. Table 2 shows a list of amino acids, their abbreviations, polarity, and charge.
Table 2- List of Amino Acids
3 -Letter 1 -Letter
Amino Acid Code Code Polarity Charge
Alanine Ala A nonpolar neutral
Arginine Arg R Basic positive polar
Asparagine Asn N polar neutral
Aspartic acid Asp D acidic negative polar
Cysteine Cys C nonpolar neutral
Glutamic acid Glu E acidic negative polar
Glutamine Gin Q polar neutral
Glycine Gly G nonpolar neutral
Histidine His H Basic Positive (10%) polar Neutral (90%)
Isoleucine lie I nonpolar neutral
Leucine Leu L nonpolar neutral
Lysine Lys K Basic positive polar
Methionine Met M nonpolar neutral Phenylalanine Phe F nonpolar neutral
Proline Pro P nonpolar neutral
Serine Ser S polar neutral
Threonine Thr T polar neutral
Tryptophan Trp w nonpolar neutral
Tyrosine Tyr Y polar neutral
Valine Val V nonpolar neutral
Preferably, the invention provides an N-intein protein variant of the native N-intein domain of Nostoc punctiforme (Npu) wherein the native N-intein domain has the following
sequence:
CL S YETEILTVE Y GLLPIGKIVEKRIECT VY S VDNNGNI YT QP VAQWHDRGEQEVFE Y CLEDGSLIRATKDHKFMTVDGQMLPIDEIFERELDLMRV (SEQ ID NO: 1) wherein the protein variant comprises an amino acid substitution of the asparagine (N) at position 36 of SEQ ID NO: 1 with an amino acid that increases alkaline stability of the N- intein protein variant as compared to alkaline stability of the native N-intein of SEQ ID NO:l.
Preferably, the invention provides an N-intein protein variant of SEQ ID NO: 1 wherein the protein variant comprises an amino acid substitution of the cysteine (C) at position 1 of SEQ ID NO: 1 to any other amino acid that is not cysteine in addition to an amino acid substitution of the asparagine (N) at position 36 of SEQ ID NO: 1 with an amino acid that increases alkaline stability of the N-intein protein variant as compared to alkaline stability of the native N-intein of SEQ ID NO: 1.
The invention also provides an N-intein protein variant of a reference protein wherein the reference protein has at least about 50%, 60%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 1 and preferably wherein the reference protein has at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 1, and wherein the N-intein protein variant of the invention comprises an amino acid substitution of the asparagine (N) at position 36 of the reference protein with an amino acid that increases alkaline stability of the N-intein protein variant as compared to alkaline stability of the native N-intein of SEQ ID NO: 1.
In another embodiment the N-intein comprises the amino acid sequence of SEQ ID NO: 2 which is a N-intein consensus derived sequence. An N-intein variant sequences based on SEQ ID NO: 2 also comprise an amino acid at position 36 other than N that increases alkaline stability of the N-intein protein variant as compared to alkaline stability of the native N-intein of SEQ ID NO: 1. Preferably the amino acid that increases stability alkaline stability is an amino acid that are less sensitive to deamidation as compared to aparagine (N). The amino acid sequence of SEQ I D NO: 2 is as follows:
AL S YDTEILTVE Y GFLPIGXIVEEXIEXT VY S VDXXGF VYT QPIAQWHNRGEQ EVFEYXLEDGSIIRATXDHXFMTTDGXMLPIDEIFEXGLDLXQV (SEQ ID NO: 2) wherein
X in positions 20, 35, 70, 73, and 95 are each independently selected from K, R or A;
X in position 28 is C, A or S;
X in position 36 is N, H or Q;
X in position 25 is N or R;
X is position 59 is D or C;
X in position 80 is E or Q; and X in position 90 is Q, R or K.
Preferred embodiments of N-inteins in accordance with the invention are selected from the group of N-intein variants referred to herein as A48, B22, B72 and A41 wherein: A48 has the sequence of of SEQ ID NO: 2 wherein:
X in positions 20, 35, 70, 73, and 95 is R;
X in position 28 is A;
X in position 36 is H;
X in position 25 is N;
X in position 59 is D;
X in position 80 is E; and X in position 90 is Q;
B22 has the sequence of SEQ ID NO: 2, wherein:
X in positions 20, 35, 70, 73, and 95 is A;
X in position 28 is A;
X in position 36 is H;
X in position 25 is N;
X in position 59 is D;
X in position 80 is E; and X in position 90 is Q;
B72 has the sequence of SEQ ID NO: 2, wherein:
X in positions 20, 35, 70, 73, and 95 is K;
X in position 28 is C;
X in position 36 is H;
X in position 25 is N;
X in position 59 is D;
X in position 80 is E; and X in position 90 is Q
A40 has the sequence of SEQ ID NO: 2, wherein:
X in position 20, 35, 70, 73, and 95 is R;
X in position 28 is A;
X in position 36 is N;
X in position 25 is N;
X in position 59 is D;
X in position 80 is E; and
X in position 90 is Q.
A41 has the sequence of SEQ ID NO: 2, wherein:
X in positions 20, 35, 70, 73, and 95 is K;
X in position 28 is A;
X in position 36 is N;
X in position 25 is N;
X in position 59 is D;
X in position 80 is E; and
X in position 90 is Q;
Comparative ligand A53, has the sequence of SEQ ID NO: 2 wherein:
X in positions 20, 35, 70, 73, and 95 is K;
X in position 28 is C;
X in position 36 is N;
X in position 25 is N;
X in position 59 is D;
X in position 80 is E; and
X in position 90 is Q.
The N-intein of the invention may be coupled to solid phase, such as a membrane, fiber, particle, bead or chip. The solid phase may be a chromatography resin of natural or synthetic origin, such as a natural or synthetic resin, preferably a polysaccharide such as agarose. The solid phase, such as a chromatography resin, may be provided with embedded magnetic particles. In another embodiment the solid phase is a non-diffusion limited resin/fibrous material.
In this case the solid phase may be formed from one or more polymeric nanofibre substrates, such as electrospun polymer nanofibres. Polymer nanofibres for use in the present invention typically have mean diameters from 10 nm to 1000 nm. The length of polymer nanofibres is not particularly limited. The polymer nanofibres can suitably be monofilament nanofibres and may e.g. have a circular, ellipsoidal or essentially circular/ellipsoidal cross section. Typically, the one or more polymer nanofibres are provided in the form of one or more non-woven sheets, each comprising one or more polymer nanofibers. A non-woven
sheet comprising one or more polymer nanofibres is a mat of said one or more polymer nanofibres with each nanofibre oriented essentially randomly, i.e. it has not been fabricated so that the nanofibre or nanofibres adopts a particular pattern. Non-woven sheets typically have area densities from 1 to 40 g/m2. Non-woven sheets typically have a thickness from 5 to 120 pm. The polymer should be a polymer suitable for use as a chromatography medium, i.e. an adsorbent, in a chromatography method. Suitable polymers include polyamides such as nylon, polyacrylic acid, polymethacrylic acid, polyacrylonitrile, polystyrene, polysulfones e.g. polyethersulfone (PES), polycaprolactone, collagen, chitosan, polyethylene oxide, agarose, agarose acetate, cellulose, cellulose acetate, and combinations thereof.
The N-intein according to the invention may be immobilized on a solid support in a very high degree, 0.2 -2 pmole/ml N-intein is coupled per ml resin (swollen gel).
The N-intein according to the invention may be coupled to the solid phase via a Lys- tail, comprising one or more Lys, such as at least two, on the C-terminal. Alternatively, the N-intein is coupled to the solid phase via a Cys-tail on the C-terminal.
C-intein protein variants
Preferably the invention also provides a C-intein comprising the following sequence SEQ ID NO 3 as follows:
VKIVSRKSLGVQNVYDIGVEKDHNFLLANGLIASN (SEQ ID NO: 3) or sequences having at least 50%, 60%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity therewith and preferably sequences having at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity therewith..
It will be appreciated that selection of the N-intein and C-intein can be from the same wild type split intein (e.g., both from Npu, or a variant of either the N- or C-intein, or alternatively can be selected from different wild type split inteins or the consensus split intein sequences, as it has been discovered that the affinity of a N-fragment for a different C- fragment (e.g., Npu N-fragment or variant thereof with Ssp C-fragment or variant thereof) still maintains sufficient binding affinity for use in the disclosed methods.
Vectors Comprising Intein Variants of the Invention
In a third aspect, the invention relates to a vector comprising the above C-intein of SEQ ID NO: 3 and a gene encoding a protein of interest (POI). Also disclosed herein are vectors comprising nucleic acids encoding the C-terminal intein segment, as well as cell lines comprising said vectors. As used herein, plasmid or viral vectors are agents that transport the disclosed nucleic acids, such as those encoding a C-terminal intein segment and a peptide of interest, into a cell without degradation and include a promoter yielding expression of the
gene in the cells into which they can be delivered. In one example, a C-terminal intein segment and peptide of interest are derived from either a virus or a retrovirus. Retroviral vectors are able to carry a larger genetic payload, i.e., a transgene or marker gene, than other viral vectors and for this reason are a commonly used vector. However, they are not as useful in non-proliferating cells. Adenovirus vectors are relatively stable and easy to work with, have high titers, and can be delivered in aerosol formulation, and can transfect non-dividing cells. Pox viral vectors are large and have several sites for inserting genes; they are thermostable and can be stored at room temperature.
Split Intein Systems
Preferably, the invention provides a split intein system for affinity purification of a protein of interest (POI), comprising a N-intein and C-intein as described above.
Preferably the N-intein comprises a N36H mutation for increased alkaline stability.
Preferably the N-intein is attached to a solid phase and the C-intein is co-expressed with the POI and used as a tag for affinity purification of the POI. Vice versa is also possible, ie attaching the C-intein to a solid phase and using the N-intein as a tag, but the former is preferred.
The alkaline stability of the N-intein ligand in the split intein system according to the invention enables be re-generation after cleavage of the POI from the solid phase, under alkaline conditions, such as 0.05-0.5 M NaOH. The solid phase may be regenerated up to 100 times.
In one embodiment the C-intein and an additional tag is co-expressed with the POI. The additional tag may be any conventional chromatography tag, such as an IEX tag or an affinity tag.
Methods of Purifying a Protein of Interest (POI)
In a fifth aspect the invention relates to a method for purification of a protein of interest (POI), using the split intein system according to the invention, comprising association of the C-intein and N-intein at neutral pH, such as 6-8, and in the presence of divalent cations (which impairs spontaneous cleavage); washing said solid phase in the presence of divalent cations; addition of a chelator to allow spontaneous cleavage between C-intein and POI; collection of tagless POI; and re-generating said solid phase under alkaline conditions, such as 0.5M NaOH.
This protocol is suitable for protein non-sensitive for Zn. The advantages are long contact times are allowed with the resin and addition of large sample volume. Sample loading could be made for long times, such as up to 1.5 hours.
According to the invention more than 30% yield, preferably 50%, most preferably more than 80% of POI is achieved in less than 4 hours cleavage.
The invention enables a high ligand density when the N-intein is immobilized to a solid phase. Preferably the N-intein is attached to a chromatography resin, such as agarose or any other suitable resin for protein purification. According to the invention it is possible to achieve a static binding capacity of 0.2 -2 pmole/ml C-intein bound POI per settled ml resin.
Affinity Tags
The invention also relates to a method for purification of a protein of interest (POI), comprising the following steps: co-expressing a POI with a C-intein according to the invention and an additional tag; binding said additional tag to its binding partner on a solid phase; cleaving off the POI and the C-intein; binding said C-intein to an N-intein attached to a solid phase at neutral pH and cleaving off said bound C-intein and N-intein from said POI; and re-generating said solid phase under alkaline conditions, such as 0.5M NaOH. The purpose of this twin tag: increased purity (enables dual affinity purification), solubility, detectability.
Affinity tags can be peptide or protein sequences cloned in frame with protein coding sequences that change the protein's behavior. Affinity tags can be appended to the N- or C- terminus of proteins which can be used in methods of purifying a protein from cells. Cells expressing a peptide comprising an affinity tag can be expressed with a signal sequence in the supematant/cell culture medium. Cells expressing a peptide comprising an affinity tag can also be pelleted, lysed, and the cell lysate applied to a column, resin or other solid support that displays a ligand to the affinity tags. The affinity tag and any fused peptides are bound to the solid support, which can also be washed several times with buffer to eliminate unbound (contaminant) proteins. A protein of interest, if attached to an affinity tag, can be eluted from the solid support via a buffer that causes the affinity tag to dissociate from the ligand resulting in a purified protein, or can be cleaved from the bound affinity tag using a soluble protease. As disclosed herein, the affinity tag is cleaved through the self-cleaving mechanism of the C-intein segment in the active intein complex.
Examples of affinity include, but are not limited to, maltose binding protein, which can bind to immobilized maltose to facilitate purification of the fused target protein; Chitin binding protein, which can bind to immobilized chitin; Glutathione S transferase, which can bind to immobilized glutathione; poly-histidine, which can bind to immobilized chelated metals; FLAG octapeptide, which can bind to immobilized anti-FLAG antibodies.
Affinity tags can also be used to facilitate the purification of a protein of interest using the disclosed modified peptides through a variety of methods, including, but not limited to, selective precipitation, ion exchange chromatography, binding to precipitation-capable ligands, dialysis (by changing the size and/or charge of the target protein) and other highly selective separation methods.
In some aspects, affinity tags can be used that do not actually bind to a ligand, but instead either selectively precipitate or act as ligands for immobilized corresponding binding domains. In these instances, the tags are more generally referred to as purification tags. For example, the ELP tag selectively precipitates under specific salt and temperature conditions, allowing fused peptides to be purified by centrifugation. Another example is the antibody Fc domain, which serves as a ligand for immobilized protein A or Protein G-binding domains.
Proteins of Interest
Target proteins for all protocols are: any recombinant proteins, especially proteins requiring native or near native N-terminal sequences, for example therapeutic protein candidates, biologies, antibody fragments, antibody mimetics, protein scaffolds, enzymes, recombinant proteins or peptides, such as growth factors, cytokines, chemokines, hormones, antigen (viral, bacterial, yeast, mammalian) production, vaccine production, cell surface receptors, fusion proteins.
The invention will now be described more closely in association with some non limiting examples and the accompanying drawings.
EXAMPLES
EXPERIMENT 1: Alkali stability of N-intein ligands of the invention
The N-intein ligands A40, A41 and A48 according to the invention were immobilized on Biacore™ CM5 sensor chips (Cytiva, Sweden) in an amount sufficient to give an immobilized level of about 450 Response Units (RU) or higher. To follow the relative binding capacity of a C-intein tagged POI to the immobilized surface, 20 pg/ml C-intein (SEQ ID NO: 3) tagged Green Fluorescent Protein (GFP) was flowed over the chip for 1 minute and the signal strength was noted. The surface was then cleaned-in-place (CIP), i.e. flushed with 100 mM NaOH, 4 M Guanidine-HCl for 10 minutes at room temperature 22 ± 3°C. This was repeated for 50 cycles and the immobilized ligand alkaline stability was followed as the relative loss of relative C-intein tagged GFP binding capacity (signal strength) after each cycle.
The results are shown in Figure 1 and indicate that the ligand A48 (with the N36H mutation) has an improved alkaline stability compared to the ligands A41 and A40. The alkaline stability was further improved compared to native sequences. In addition, a N36H mutation significantly improved alkali stability as compared to wild type Npu N-intein sequence (A52 with a CIA mutation as compared to SEQ ID NO: 1).
The relative remaining binding capacity after 50 CIP cycles (%) was 55% for A40 and A41 while it was 69% for A48. Alkali stability using 0.5M NaOH is shown in figure 5.
Fig 5 shows the results for A40 and A48 during 20 cycles. Relative remaining binding capacity (%)
CIP: 2 min. 100 mM NaOH, 4 M Gdn-HCl, followed by 2 min. 0.5 M NaOH.
EXPERIMENT 2: Alkali stability of N-intein ligands of the invention
The purified N-intein ligands A53, B72, B22 and A48 were immobilized on Biacore™ CM5 sensor chips (Cytiva, Sweden) in an amount sufficient to give an immobilized level of about 450 Response Units (RU) or higher. To follow the relative binding capacity of an uncleavable C-intein tagged POI to the immobilized surface, 20 pg/ml uncleavable C-intein (SEQ ID NO 3) tagged IL-lb was flowed over the chip for 1 minute and the signal strength was noted. The surface was then cleaned-in-place (CIP), i.e. flushed with 100 mM NaOH, 4 M Guanidine-HCl for 10 minutes at room temperature 22 ± 3°C. This was repeated for 50 cycles and the immobilized ligand alkaline stability was followed as the relative loss of uncleavable C-intein tagged IL-lb binding capacity (signal strength) after each cycle.
The results are shown in Figure 2 and indicate that all three ligands with N36H mutations, (A48, B22 and B72) have improved alkaline stability compared to the ligand A53. The relative remaining binding capacity after 50 CIP cycles (%) for A53 was only 20% while it was 28% for B72, 30% for B22 and 35% for A48.
EXPERIMENT 3: Immobilization of N-intein ligand A48 to agarose gel resin
5 millilitres epoxy activated cross-linked activated gel resin was added into a polyproylene test-tube. 2.7 millilitres, corresponding to 135 milligram N-intein ligand A48 having a C-terminal Lys-tail in phosphate buffer was added into the tube followed by addition of 1.3 millilitres of phosphate buffer (pH 12.1) to adjust the agarose resin slurry to be about 50% and then 2 gram sodium sulfate was added. The pH of the resulting reaction
mixture was adjusted to 11.5. And the reaction mixture was heated up to 33 °C in a shaking table and kept shaking at 33 °C for 4 hours. Then the slurry was transferred to glass filter and washed with 10 millilitres of distilled water 3 times. After washing, the gel was transferred into the three-neck round bottom flask (RBF) and 5 millilitres of Tris buffer (pH 8.6) with 375 microlitres thioglycerol was added. The reaction mixture was at the shaking table at 45 °C for 2 hours. After the reaction, the slurry was transferred to glass filter. The gel was washed with 5 millilitres of basic wash buffer 3 times and then 5 millilitres of acidic wash buffer 3 times. Repeated this base/acid wash another 2 times, in total 18 washes in this step. Then the gel resin was washed with 5 millilitres of distilled water 10 times. The washed and drained gel was kept in 20% ethanol in fridge before analysis.
The dry weight of gel resin was determined by measuring the weight of 1 millilitre of gel. In the sample preparation, 2 gram of drained gel resin mixed well with 2 gram of water to give about 50% resin slurry and then the slurry was added into the 1 mL Teflon cube. Then vacuum was applied to drain the gel in the cube and thus 1 mL of gel was obtained. Transfer the gel onto the dry weight balance. The weight was determined after 35 minutes with drying temperature set at 105°C.
Amino acid analysis was measured after the dry weight determination. With the corresponding dry weights and information of the size and primary amino sequence of the protein the ligand density could be derived in mg/mL gel resin.
Results for the coupled agarose resin was a dry-weight of 90.6 mg/ml and with a ligand content of 18.4 mg/ml which corresponds to 1.38 umole/ml.
EXPERIMENT 4: Static binding capacity in relation to ligand density
The proposed capacity method presented herein can measure binding capacity of the resin in test tubes.
Reaction setup
Briefly, prototype resin with immobilized A48 ligand with various ligand densities and dual tagged test-protein A43 (SEQ ID NO: 5) were separately diluted in assay buffer (2x PBS) to 2.5% resin slurry and 0.4mg/mL, respectively. 50pL of the 2.5% resin slurry was added to an ILLUSTRA™ microspin column followed by addition of 150pL diluted A43 (SEQ ID NO: 5). The reactions were allowed to incubate with 1450rpm shaking at 22°C for a 2 hour fixed timepoint before centrifuged at 3000rcf for lmin.
SDS-PAGE
Centrifuged samples (containing cleaved protein and unbound non-cleaved protein) were mixed 1 : 1 with 2x SDS-PAGE reducing sample buffer, boiled for 5 minutes at 95 °C and subjected to SDS-PAGE (18pL loaded). A C-intein tagged test-protein, A43 (SEQ ID NO: 5) standard was added (usually a five-point standard between 18.75-300pg/mL) in order to be able to calculate concentrations from the densitometric volumes. Gels were coomassie stained for 60min (~100mL/gel) followed by destaining for 120-180min at room temperature with gentle agitation (until background is completely clear). Densitometric quantification of the uncleaved/unbound and cleaved test-protein was performed with the IQ TL software. The densitometric raw data was then exported to Microsoft Excel.
SBC Calculations
Since the test-protein input in the reactions are known we can indirectly calculate the static binding capacity (SBC) by the following equation: mg (input amount in pg — unbound amount in pg)
SBC mL resin volume (pL)
Fig 3 shows static binding capacity of the N-intein ligands of the invention. Amino acid analysis (AAA) done by conventional method. The A48 prototypes were coupled by epoxy chemistry to porous agarose particles.
EXPERIMENT 5: Purification of Elongation factor G without and with Zn protocol
Elongation factor G, (Ef-G) from Thermoanaerobacter tengcongensis was purified in this example using a resin prototype with immobilized ligand A48. C-intein (SEQ ID NO 3) tagged EfG was expressed intracellularly in E.coli strain BL21 (DE3).
Frozen cell-pellet after fermentation harvest was thawed and resuspended with extraction buffer, (20 mM Tris-HCl, pH 8.0) by magnetic stirring. DNAse I (bovine pancreas) and 1 mM MgS04 was added followed by addition of lysozyme (hen egg). After stirring for 30 minutes at room temperature the resuspended and lysozyme treated cell suspension was heated in a water-bath to 70-75°C and kept at this temperature for 5 minutes. After cooling the extract briefly on ice, the extract was clarified by centrifugation.
Purification using a Zn-free protocol was done on an AKTA™ Avant system at 2 ml/min during sample loading and washing and then at 1 ml/min. A 1 ml HiTrap™ column containing immobilized A48 ligand was used. Equilibration and binding of the C-intein
tagged target protein was done in a 20 mM MES buffer supplemented with 100 mM NaCl at pH 6.3 and the sample was adjusted to pH 6.3 using 2M Acetic acid. Column wash after sample application and subsequent elutions were done with a 20 mM Tris-HCl buffer supplemented with 400 mM NaCl at pH 8.0. After column washing the flow was stopped for 4 hours of incubation at room temperature and then cleaved EfG was eluted. A second stop in flow was added to allow a second elution, which was done after additional 16 hours of incubation.
17.8 mg pure, tag-free EfG was eluted after 4 hours incubation on the HiTrap™ column. The mass difference between eluted protein and CIPed protein was equal to the mass of the C-intein tag according to mass spectrometry analysis. The purity according to SDS- PAGE was high as well as in SEC-analysis on Superdex™ 200 Increase. The total protein amount was calculated from the theoretical UV absorption coefficent at 280 nm and the UV- signal on diluted elution and CIP fractions.
The purification was repeated using a protocol including Zn-ions to the equilibration buffer and the clarified sample. The final Zn-concentration was 1.6 mM. The flowrate was reduced to 0.5 ml/min during sample application and then increased to 1 ml/imn during wash and elution. Wash and elution was done with a 50 mM Tris-HCl, 20 mM imidazole buffer pH 7.5. Only one elution peak was collected in this purification and that was after 4 hours of incubation after column washing.
16.6 mg pure, tag-free EfG was eluted after 4 hours incubation on the HiTrap™ column. The purity according to a SEC-analysis on Superdex™ 200 Increase was 92%. The total protein amount was calculated from the theoretical UV absorption coefficent at 280 nm and the UV-signal on diluted elution fractions.
EXPERIMENT 6: Purification of IL-Ib
A 1 ml HiTrap™ column containing immobilized A48 ligand was used for purification of the C-intein tagged target protein IL-Ib (SEQ ID NO: 5) expressed intracellularly in E.coli BL21 (DE3) and lysed by sonication. Soluble protein were harvested by centrifugation and loaded onto a lmL HiTrap™ column immobilized with the A48 ligand. The Zn-free protocol (as in Experiment 4) was used on an Af TA™ Avant system at 4 ml/min (600cm/h linear flow rate) during sample loading and washing. The run was then paused for 4h before initiating flow again at lmL/min to elute the cleaved protein (4h cleavage fraction). The run was then paused again for an additional 12h before starting the flow at lmL/min to elute the protein that had not been cleaved after 4h. Equilibration and binding of the wash and elution was performed with
one single buffer. A chromatogram from the purification is shown in Fig 4A. The start material, flow through, wash fractions, 4h and 16h elution fractions were subjected to SDS-PAGE and Coomassie staining and subsequent analysis using IQTL software (Fig 4B).
9.4 mg cleaved IL-Ib was eluted after 4 hours incubation on the HiTrap™ column followed by an additional l.lmg after 16h. The purity was 99.5 (4 hours) and 99.8% (16 hours) according to SDS-PAGE analysis. The total protein amount was calculated from the theoretical UV absorption coefficient of the cleaved protein at 280 nm.
EXPERIMENT 7: Purification of receptor binding domain of SARS-COV-2
The receptor binding domain (RBD) of SARS-COV-2 NCBI tagged with C-intein was expressed in ExpiHEK cells and secreted into the cell culture medium. Approximately 210mL supernatant was loaded onto a lmL HiTrap column with immobilized A48 ligand and without any addition of salts or other additives to the cell culture supernatant using an ART A™ Avant FPLC system. Sample application and wash was performed at 4mL/min (load time -52.5 min (600cm/h linear flow rate)) followed by 6 column volumes of wash followed by a pause/hold step for 4h. The elution phase was performed at lmL/min. The column was left for additional 68h followed by a second elution. A single 40mM phosphate buffer pH 7.4 buffer supplemented with 300mM NaCl was used for all chromatography steps.
The theoretical absorbance 0.1% coefficient was used to determine protein concentration and yield within the Unicorn™ software (Cytiva Sweden AB). Purity was determined by densitometric SDS-PAGE analysis. For this experiment a total of 14.1mg cleaved protein was obtained with a purity above 96%. Theoretical molecular weight was ~25kDa while experimental SDS-PAGE analysis indicates a molecular weight of 33 kDa which is explained by two glycosylations and was also determined by mass spectrometry analysis.
The CCT-RBD protein has the following sequence:
METD TLLL W VLLL W VPGSTGVKI V SRK SLGY ON VYDIGVEKDHNFLL AN GLI ASNRVOPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSAS FSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVROIAPGOTGKIADYNYKLPDDFT GC VI AWN SNNLD SKY GGNYNYL YRLFRK SNLKPFERDI S TEI Y O AGS TPCN GVEGFN CYFPLO S Y GF OPTNGVGY OPYRVVVLSFELLHAP AT VCGPKKSTNLVKNKC VN I I II J HHHH (SEQ ID NO: 4)
Signal sequence- bold underline.
CCT-tag- dotted underline.
RBD domain is double underlined.
His Tag- dashed underline
The purity results from the cleaved protein are found in Table 3.
Table 3
EXPERIMENT 8: Tandem tagging and Affinity purification on two columns
E.coli BL21(DE3) was transformed with the A43 expression plasmid TwinStrep™ and C-intein (SEQ ID NO 3) tagged IL-lb and plated on an agar plate containing 50 pg/ml Kanamycin. The next day, a single colony was picked and grown in 5 ml of Luria-Bertani (LB) broth to OD6000.6. The culture was transferred to 200 ml LB broth containing the same antibiotics and grown at 37°C until OD600 was 0.6. Protein expression was induced at 22°C for 16 hours by the addition of Isopropyl b-D-l-thiogalactopyranoside (IPTG, 0.5 mM) After expression, the cells were harvested by centrifugation at 4,000 x g for 15 minutes and stored at -80°C until use.
For purification, the cell pellets were resuspended in Buffer A1 (100 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, pH 8.0) at 10 ml per gram wet-weight and disrupted by ultra- sonication (Sonics Vibracell, microtip, 30% amplitude, 2 sec on, 4 sec off, 3 min in total).
The supernatant containing the soluble fraction was collected after centrifugation at 40,000 x g for 20 minutes at 4°C and passed through a 5 ml HiTrap™ column, Streptactin™ XT (GE Healthcare, Sweden). The column was washed with the same Buffer A1 until the UV-absorbance at 280 nm was below 20 mAU. Bound C-intein tagged IL-lb was eluted in Buffer B1 (100 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 50 mM Biotin, pH 8.0) and collected.
Purified protein was immediately applied to a 1 ml HiTrap™ column packed with a resin containing immobilized N-intein ligand A48 without adding the inhibitor ZnCF. The cleaved, tag-free IL-lb was collected in the flow-through.
MSAWSHPOFEKGGGSGGGSGGSAWSHPOFEKGGGSGGGSVKIVSRKSLGVO
NVYDIGVEKDHNFLLANGLIASNAFVRSLNCTLRDSOOKSLVMSGPYELKALHLOG
ODMEOOVVFSMSFVOGEESNDKIPVALGLKEKNLYLSCVLKDDKPTLOLESVDPKN
YPKKKMEKRFVFNKIEINNKLEFESAOFPNWYISTSOAENMPVFLGGTKGGODITDF TMOFVSSAAA (SEQ ID NO: 5)
TwinStrep - dotted underlining CCT- bold underlining ILlb (test-protein)-underlined
The patent and scientific literature referred to herein establishes the knowledge that is available to those with skill in the art. All United States patents and published or unpublished United States patent applications cited herein are incorporated by reference. All published foreign patents and patent applications cited herein are hereby incorporated by reference. All other published references, documents, manuscripts and scientific literature cited herein are hereby incorporated by reference.
While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims. It should also be understood that the embodiments described herein are not mutually exclusive and that features from the various embodiments may be combined in whole or in part in accordance with the invention
What is claimed is:
1. An N-intein variant comprising at least one amino acid substitution of a native split intein wherein the N-intein protein variant sequence does not include an asparagine (N) in at least position 36 as measured from the initial catalytic cysteine and wherein the substituted amino acid provides increased alkaline stability as compared to the native N-intein protein sequence or a consensus N-intein sequence.
2. The N-intein variant of claim 1 wherein the substituted amino acid that provide increased alkaline stability is H or Q.
3. An N-intein protein variant of the wildtype N-intein domain of Nostoc punctiforme (Npu) wherein the wildtype Npu N-intein domain comprises the following sequence:
CL S YETEILTVE Y GLLPIGKIVEKRIECT VY S VDNNGNI YT QP VAQWHDRGEQEVFE Y CLEDGSLIRATKDHKFMTVDGQMLPIDEIFERELDLMRV (SEQ ID NO: 1), wherein the protein variant comprises an amino acid substitution of the asparagine (N) in at least position 36 of SEQ ID NO: 1 with an amino acid that increases alkaline stability of the N-intein protein variant as compared to alkaline stability of the wildtype N-intein domain and variants or the wildtype N-intein domain.
4. The N-intein protein variant of claim 3, wherein the amino acid substitution that increases alkaline stability is histidine (H) or glutamine (Q).
5. The N-intein protein variant according to claim 4, wherein the amino acid substitution that increases alkaline stability is histidine (H).
6. An N-intein variant sequence comprising:
ALSYDTEILTVEYGFLPIGXIVEEXIEXTVYSVDXXGFVYTQPIAQWHNRGEQEVFEY
XLEDGSIIRATXDHXFMTTDGXMLPIDEIFEXGLDLXQV (SEQ ID NO: 2) wherein,
X in positions 20, 35, 70, 73, and 95 are each independently selected from K, R or A;
X in position 28 is C, A or S;
X in position 36 is N, H or Q;
Claims
X in position 25 is N or R;
X is position 59 is D or C;
X in position 80 is E or Q; and X in position 90 is Q, R or K; and wherein the alkaline stability is increased as compared to SEQ ID NO: 1.
7. The N-intein variant sequence according to claim 6, wherein X in positions 20, 35, 70, 73, and 95 is R;
X in position 28 is A;
X in position 36 is H;
X in position 25 is N;
X in position 59 is D;
X in position 80 is E; and X in position 90 is Q;
8. The N-intein variant sequence according to claim 6, wherein X in positions 20, 35, 70, 73, and 95 is A;
X in position 28 is A;
X in position 36 is H;
X in position 25 is N;
X in position 59 is D;
X in position 80 is E; and X in position 90 is Q;
9. The N-intein variant sequence according to claim 6 wherein X in positions 20, 35, 70, 73, and 95 is K;
X in position 28 is C;
X in position 36 is H;
X in position 25 is N;
X in position 59 is D;
X in position 80 is E; and X in position 90 is Q
10. The N-intein variant sequence according to claim 6, wherein
X in position 20, 35, 70, 73, and 95 is R; X in position 28 is A;
X in position 36 is N;
X in position 25 is N;
X in position 59 is D;
X in position 80 is E; and X in position 90 is Q.
11. The N-intein variant sequence according to claim 6, wherein X in positions 20, 35, 70, 73, and 95 is K;
X in position 28 is A;
X in position 36 is N;
X in position 25 is N;
X in position 59 is D;
X in position 80 is E; and X in position 90 is Q;
12. The N-intein variant sequence according to one or more of the above claims, which is coupled to solid phase, such as a membrane, fiber, particle, bead or chip.
13. The N- intein variant sequence according to claim 12, wherein the solid phased is a chromatography resin of natural or synthetic origin.
14. The N-intein variant sequence according to claim 12 or 13, wherein the solid phase is a chromatography resin, such as a natural or synthetic resin, preferably a polysaccharide such as agarose.
15. The N-intein variant sequence according to claim 13, wherein the solid phase is provided with embedded magnetic particles.
16. The N-intein variant sequence according to claim 12, wherein the solid phase is a non-diffusion limited resin/fibrous material.
17. The N-intein variant sequence according to claim 12 or 13, wherein the N-intein is coupled to the solid phase via a Lys-tail, comprising one or more Lys, on the C-terminal.
18. The N-intein variant sequence according to claims 12 or 13, wherein the N-intein is coupled to the solid phase via a Cys-tail on the C-terminal.
19. The N-intein variant sequence according to one or more of the above claims 12-18, wherein 0.2 -2 pmole/ml N-intein is coupled per ml solid phase, preferably chromatography resin (ml swollen gel).
20. The N-intein sequence according to one or more of the above claims 1-19, wherein the N-intein is stabile under alkaline conditions corresponding to 0.05M- 0.5M, preferably 0.1-0.5M NaOH.
21. A C-intein variant sequence comprising the amino acid sequence: VKIVSRKSLGVQNVYDIGVEKDHNFLLANGLIASN (SEQ ID NO: 3) or sequences having at least 85% identity therewith.
22. A vector comprising the C-intein according to claim 21 and a gene encoding a protein of interest (POI).
23. A split intein system for affinity purification of a protein of interest (POI), comprising a N-intein variant sequence of a native N-intein and a C-intein, wherein the N-intein variant sequence has a N36H or N36Q mutation as compared to native N-intein.
24. A Split intein system according to claim 23 comprising a N-intein sequence variant of any one of claims 1-20 and a C intein variant sequence of SEQ ID NO: 3.
25. A split intein system according to claim 23 or 24, wherein the C-intein and an additional tag is co-expressed with the POI.
26. A split intein system according to claim 23, 24 or 25, wherein the N-intein is immobilized to a solid phase and the solid phase is re-generated after cleavage of the POI from the solid phase.
27. A split intein system according to claim 26, wherein the solid phase is re-generated under alkaline conditions, such as 0.05-0.5 M NaOH.
28. A split intein system according to claim 26 or 27, wherein the solid phase is regenerated up to 100 cycles, such as up to 50 cycles.
29. A chromatography column comprising a chromatography resin which comprises one or more N-intein variant sequence ligands, wherein the N-intein variant sequence is as defined in one or more of claims 1-20.
30. A method for purification of a C-intein tagged protein of interest (POI), using the split intein system according to one or more of claims 23-29, wherein the N-intein is immobilized to a solid phase; comprising contacting the C-intein and N-intein at neutral pH, such as 6-8, and in the presence of divalent cations; washing said solid phase in the presence of divalent cations; addition of a chelator to allow spontaneous cleavage between C-intein and POI; collection of tagless POI; and re-generating said solid phase under alkaline conditions, such as 0.05-0.5M NaOH.
31. The method for purification of a C-intein tagged protein of interest (POI), using the split intein system according to one or more of claims 23-29, wherein the N-intein is immobilized to a solid phase; comprising contacting the C-intein and N-intein at neutral pH, such as 6-8, preferably under high flow rate; washing said solid phase; collection of tagless POI after cleavage between C-intein and POI; and re-generating said solid phase under alkaline conditions, such as 0.05-0.5M NaOH.
32. The method for purification of a protein of interest (POI), comprising the following steps: co-expressing a POI with a C-intein according SEQ ID NO 3 and an additional tag; binding said additional tag to its binding partner on a first solid phase; cleaving off the POI and the C-intein; binding said C-intein to an N-intein attached to a second solid phase at
neutral pH and cleaving off said bound C-intein and N-intein from said POI; and re generating said second solid phase under alkaline conditions, such as 0.05-0.5M NaOH.
33. The method according to claim 32, wherein the additional tag is an affinity tag, ion exchange, hydrophobic interaction, solubility, multimodal.
34. The method according to any one of claims 30-33, wherein the alkaline conditions are combined with chaotrope agents, such as guanidine or urea, and the solid phase may be regenerated up to 100 times.
35. The method according to one or more of claims 30-34, wherein the POFs are: proteins requiring native or near native N-terminal sequences, for example therapeutic protein candidates, biologies, antibody fragments, antibody mimetics, enzymes, recombinant proteins or peptides, such as growth factors, cytokines, chemokines, hormones, antigen (viral, bacterial, yeast, mammalian) production, vaccine production, cell surface receptors, fusion proteins.
36. The method according to one or more of claims 30-35, wherein more than 30%, preferably more than 50%, most preferably more than 80% yield of POI is achieved in less than 4 hours cleavage.
37. The method according to any one or more of claims 30-36, wherein the N-intein is immobilized on a chromatography resin, and wherein the static binding capacity is 0.2 -2 pmole/ml C-intein bound POI per settled ml resin.
38. An N-intein variant according to one or more of claims 1-5, wherein all asparagine (N) amino acid residues are substituted with amino acid residue that provides increased alkaline stability as compared to the native N-intein protein sequence.
39. An N-intein variant according to one or more of claims 1-5, wherein all asparagine (N) amino acid residues are substituted with amino acid residue that provides increased alkaline stability and wherein the cysteine at the first residue is substituted with any other amino acid.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1917046.3A GB201917046D0 (en) | 2019-11-22 | 2019-11-22 | Improved protein production |
PCT/EP2020/082966 WO2021099607A1 (en) | 2019-11-22 | 2020-11-20 | Protein purification using a split intein system |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4061932A1 true EP4061932A1 (en) | 2022-09-28 |
Family
ID=69137378
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20820794.4A Pending EP4061932A1 (en) | 2019-11-22 | 2020-11-20 | Protein purification using a split intein system |
Country Status (8)
Country | Link |
---|---|
US (1) | US20240132538A1 (en) |
EP (1) | EP4061932A1 (en) |
JP (1) | JP2023502335A (en) |
KR (1) | KR20220105157A (en) |
CN (1) | CN114698379A (en) |
CA (1) | CA3155170A1 (en) |
GB (1) | GB201917046D0 (en) |
WO (1) | WO2021099607A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022238319A1 (en) | 2021-05-12 | 2022-11-17 | Cytiva Bioprocess R&D Ab | Improved protein purification |
CN114606252A (en) * | 2022-04-20 | 2022-06-10 | 广州市乾相生物科技有限公司 | Oligopeptide synthesis and purification method based on filtration method |
CN115028741A (en) * | 2022-06-21 | 2022-09-09 | 苏州工业园区唯可达生物科技有限公司 | Tumor antigen-antibody complex, preparation method and application thereof |
CN115925830B (en) * | 2022-08-15 | 2023-11-07 | 广州市乾相生物科技有限公司 | Intein variant and application thereof in preparation of snake venom peptide precursor by biological method |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2850411C (en) * | 2011-09-28 | 2023-08-15 | Era Biotech, S.A. | Split inteins and uses thereof |
EP2877490B1 (en) | 2012-06-27 | 2018-09-05 | The Trustees of Princeton University | Split inteins, conjugates and uses thereof |
CN104755502B (en) * | 2012-10-12 | 2018-05-18 | 清华大学 | The generation of polypeptide and purification process |
US10087213B2 (en) | 2013-01-11 | 2018-10-02 | The Texas A&M University System | Intein mediated purification of protein |
KR101891455B1 (en) | 2014-11-03 | 2018-08-27 | 메르크 파텐트 게엠베하 | Soluble intein fusion proteins and methods for purifying biomolecules |
US10066027B2 (en) | 2015-01-09 | 2018-09-04 | Ohio State Innovation Foundation | Protein production systems and methods thereof |
CN105316353A (en) * | 2015-02-13 | 2016-02-10 | 上海交通大学 | Fusion expression and purification method for recombinant proteins by aid of alkaline tags and intein |
CN108884154A (en) * | 2016-01-29 | 2018-11-23 | 普林斯顿大学理事会 | With the active fracture intein of unique splice |
CN105925596A (en) * | 2016-02-23 | 2016-09-07 | 上海交通大学 | Synthesis method of intein-based medicinal recombinant protein |
US11124539B2 (en) | 2016-11-16 | 2021-09-21 | Cytiva Bioprocess R&D Ab | Chromatography resin, production and use thereof |
-
2019
- 2019-11-22 GB GBGB1917046.3A patent/GB201917046D0/en not_active Ceased
-
2020
- 2020-11-20 WO PCT/EP2020/082966 patent/WO2021099607A1/en active Application Filing
- 2020-11-20 CN CN202080080416.2A patent/CN114698379A/en active Pending
- 2020-11-20 EP EP20820794.4A patent/EP4061932A1/en active Pending
- 2020-11-20 KR KR1020227016527A patent/KR20220105157A/en unknown
- 2020-11-20 JP JP2022526270A patent/JP2023502335A/en active Pending
- 2020-11-20 CA CA3155170A patent/CA3155170A1/en active Pending
- 2020-11-20 US US17/768,461 patent/US20240132538A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2021099607A1 (en) | 2021-05-27 |
JP2023502335A (en) | 2023-01-24 |
CN114698379A (en) | 2022-07-01 |
CA3155170A1 (en) | 2021-05-27 |
GB201917046D0 (en) | 2020-01-08 |
US20240132538A1 (en) | 2024-04-25 |
KR20220105157A (en) | 2022-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20240132538A1 (en) | Protein purification using a split intein system | |
US10669351B2 (en) | Split intein compositions | |
EP2307443B1 (en) | Affinity purification by cohesin-dockerin interaction | |
JP2016504417A (en) | Intein-mediated protein purification | |
WO2010150375A1 (en) | Modified biotin-conjugated protein | |
US10323235B2 (en) | Reversible regulation of intein activity through engineered new zinc binding domain | |
Zhou et al. | TrxA mediating fusion expression of antimicrobial peptide CM4 from multiple joined genes in Escherichia coli | |
CN111748544B (en) | Method for efficiently expressing lysostaphin | |
CN103242435B (en) | Affinity compatible streptavidin mutant and preparation method thereof | |
WO2022238319A1 (en) | Improved protein purification | |
CN111909916B (en) | Double-chain specific nuclease from euphausia superba and preparation method thereof | |
JP4491588B2 (en) | Purification method of killer protein | |
US20230174574A1 (en) | Methods and compositions for enhancing stability and solubility of split-inteins | |
KR20160093156A (en) | Method for producing antimicrobial peptide using intein | |
CN112391367A (en) | Preparation method of Cas9 protein for gene editing of human primary cells | |
JP5848501B2 (en) | Modified biotin-binding protein | |
Yuzbasheva et al. | Protein display on the Yarrowia lipolytica yeast cell surface using the cell wall protein YlPir1 | |
CN118221796A (en) | Method for purifying tissue factor and buffer composition for purification thereof | |
CA3233224A1 (en) | Chimeric protein and expression system | |
WO2019108660A1 (en) | Zinc finger moiety attached to a resin used to purify polynucleotide molecules | |
CN113321714A (en) | Recombinant N protein of SARS-CoV-2 and its preparation and purification method | |
CN111196842A (en) | Expression and purification method of non-transmembrane structural domain of outer membrane transport channel protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20220419 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230526 |